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Abstract 
 
 
ATP  and  ADP  mediate  gut  smooth  muscle  relaxation  through  two 
receptors,  P2Y1  and  P2Y11.  This  project  aims  to  investigate  the  interaction 
between these two receptors by  developing  a  recombinant  model  of  the  P2Y 
receptors  expressed  in  gut  smooth  muscle  cells  (SMCs)  by  transfecting  the 
human P2Y11 receptor cDNA into CHO-K1 cells, which  express an endogenous 
P2Y1  receptor.  Individual  clonal  cell  lines  expressing  different  densities  of 
hP2Y11  were  isolated  from  this  stably-transfected  CHO-K1:P2Y11  pool  and 
characterized.  A  clone  expressing  a  “high”  density  of  hP2Y11 (13) and a clone 
expressing  a  “low”  density  of  hP2Y11  (6)  were  selected  for  further  study. 
Control 1321N1 cell lines  expressing each receptor in isolation (1321N1-hP2Y1 
and 1321N1-hP2Y11) were used for  comparison  purposes.  The  potency  (EC50) 
of  eight  different  nucleotide  agonists  was  determined in calcium assays in the 
co-expressing cell lines. ADP and 2meSATP  responses were biphasic in clone 
13 but monophasic in clone 6. To investigate the nature  of the two sites of the 
biphasic curves in clone 13, the effect of MRS 2179, NF 340 and Reactive Red 
on agonist responses was determined. MRS 2179 antagonized the  high affinity 
site  of  the  biphasic  ADP  and  2meSATP  responses  in  clone  13  without 
affecting  the  low affinity  site.  NF  340  had  no  effect  on  agonist  responses  in 
clone 13. Reactive  Red  antagonized  both  sites  of  the  biphasic  curves  in  clone 
13.  These  data  suggest  that  the  high-affinity  site  of  the  biphasic  ADP  and 	 ﾠ ii	 ﾠ
2meSATP responses in clone 13 corresponds to P2Y1. The low-affinity site of 
the  2meSATP  curve  is  most  likely  P2Y11.  The  low-affinity  site  the  ADP 
response displays both P2Y1 and P2Y11-like. The  novel ADP site, therefore, is 
elicited by differences in the expression level of P2Y11 and  may correspond  to 
a  P2Y1:hP2Y11  receptor  heteromer  or  a  macromolecular  complex  containing 
both P2Y1 and P2Y11. 
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Chapter 1 
Introduction  
 
1.1 G protein-coupled receptors  
  Membrane  receptors  constitute  a  major  hub  of  information  relay  between  the 
extracellular  and  intracellular  milieus  and  are  key  players  in  cellular  communication 
across the plasma membrane. The G protein-coupled receptor (GPCR) superfamily of 
seven  transmembrane  proteins  represents  the  largest  family  of  integral  membrane 
receptors. Members of this superfamily are encoded by 4% of all genes and contribute to 
all  known  physiological  processes  in  mammals  (1-5).  The  GPCR  family  comprises 
around 800 human receptors (4), phylogenetically segregated into five main subfamilies, 
namely class A, class B, class C, frizzled and adhesion (2). Primary sequence analysis 
predicted a single receptor protein with seven transmembrane domains (see Figure 1-1). 
Given the remarkable diversity of their biological actions, GPCRs represent the most 
common target (up to 40%) of all known pharmaceutical drugs (6, 7). 
 
1.1.1 GPCR structure  
  GPCRs are activated by a plethora of signals, including photons, ions, hormones, 
peptides,  chemokines,  nucleotides  and  other  factors.  Despite  the  diversity  of  ligands 
acting  at  GPCRs  and  of  the  signalling  pathways  they  regulate,  all  GPCRs  share  a 
common core structure consisting of seven transmembrane spans. The first milestone in 
elucidating the structure of 7TM receptors was achieved in 2000, when bovine rhodopsin 
was crystallized from mixed micelles and the protein structure of this receptor was solved 
at  2.8Å  (8)  (see  Figure  1-2).  This  study  delineated  a  “structural  template  for  other 
GPCRs”, consisting of a bundle of seven transmembrane α helices connected by six loops 
of  different  lengths.  A  second  GPCR  structure  was  obtained  seven  years  later  when 
Kobilka and his group resolved the crystal structural of the β2-adrenergic receptor in 2007 
(9, 10). Other GPCR crystal structures published to date comprise the dopamine receptor 
D3R  (11),  the  muscarinic  M2R  (12)  and  M3R  (13)  receptors,  CXCR4 (14),  µ  opioid 
receptor (15), δ opioid receptor (16), κ opioid receptor (17),  the nociceptin receptor (18), 
the adenosine A2A receptor (19) and the histamine H1 receptor (20). 
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Figure 1.1 The G-protein coupled receptor unit  
A  G-protein  coupled  receptor  consists  of  a  single  polypeptide  chain  composed  of  7 
transmembrane domains connected by 3 extracellular loops and 3 intracellular loops. It possesses 
an extracellular N-terminus, an intracellular C-terminus and binds to a heterotrimeric G protein 
(α,β, γ) at the plasma side of the membrane. The plasma membrane or lipid bilayer is shown in 
grey.  
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Figure 1.2 Ribbon drawing of Bovine Rhodopsin  
The crystal structure of bovine rhodopsin, published by Palczewski et al. (8), was resolved using 
X-ray diffraction with a resolution of 2.8 Å. The structure was exported from the PDB entry 1F88 
using Molsoft Browser Pro 4. This model contains several copies of the rhodopsin structure as 
well as heterogenic compounds such as ligands, co-factors, etc. The chains are coloured using a 
rainbow/spectral color gradient.  
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Analysis of these structures reveals that GPCRs display a rich complexity across 
receptor  subtypes  but  exhibit  a  significant  structural  similarity  (5,  7).  The  currently 
accepted model of GPCR structure postulates that these seven transmembrane α helices 
(7TMH) are connected by three extracellular loops (EL1-3) and three intracellular loops 
(IL1-3). The extracellular region comprises the N-terminus of the GPCR. Its organization 
is mediated by a disulphide bridge, conserved in most GPCRs, between extracellular loop 
II (EL2) and the extracellular end of helix III, ensuring the arrangement of the 7TM 
motif. The extracellular domain is characterized by a high structural diversity that allows 
GPCRs  to  recognise  a  wide  repertoire  of  ligands  of  different  shapes,  sizes  and 
electrostatic properties, with class C GPCR binding domains in the EC domain itself. 
Despite this structural diversity however, the binding pockets of GPCRs are rigid and 
undergo restricted conformational rearrangements during the activation process (5, 7). A 
number  of  interhelical  bonds  and  hydrophobic  interactions  between  highly  conserved 
residues in GPCRs were found to impart the stability of the transmembrane region (8). In 
fact,  the  7TM  bundle  comprises  hydrophobic  amino  acid  residues  together  with 
functionally important signature motifs including the D[E]RY motif in helix III, which is 
part of the ‘ionic lock’, the WXP motif in helix VI and the NPXXY motif in helix VII (7). 
It also harbours a number of kinks elicited by Pro residues, which segregate the receptor 
into  ligand  binding  and  receptor  signalling  “modules”  (5).  Crystallographic  studies 
indicate that the overall structure of the 7TM fold is highly conserved in GPCRs but also 
delineate  the  diversity  observed  in  the  loop  regions  and  the  pitch  and  orientation  of 
individual helices in the helical bundle.  
 
1.1.2 GPCR activation 
A central feature of GPCR signalling is that the ligand does not physically traverse 
the plasma membrane but conveys its signal to the cellular milieu through conformational 
changes in the receptor protein. Hence, the binding of a ligand to the receptor provokes a 
switch from its inactive to its active conformation, which opens up the helical bundle and 
exposes the binding site of the receptor for its cognate G-protein at the cytoplasmic side 
of the receptor (10, 21-23). As the Nobel press release presenting the 2012 Chemistry 
prize, awarded to Kobilka and Lefkowitz for their work on GPCRs, beautifully states: “If 
a ligand grips the bundle at one end, the bundle opens up like a bouquet of roses at the 
other end” (23). Structural studies of the β2 adrenergic receptor have shown that this 
conformational change is mediated by the displacement of helix 6 and the subsequent 
opening of a hydrophobic cleft on the intracellular side of the receptor. Consequently, the Chapter 1  Introduction 
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C-terminal  helix  of  Gα  enters  this  cleft,  inducing  major  structural  changes  in  the  G 
protein leading to its activation (21). The desensitization of the GPCR is initiated by its 
interaction  with  GRKs,  or  G  protein-coupled  receptor  kinases,  leading  to  its 
phosphorylation, usually at its carboxy-terminal end. This in turn elicits the binding of β-
arrestins, which sterically hinder additional G protein coupling and ensure the termination 
of the agonist response (3).  
 
G proteins are heterotrimeric entities composed of three subunits, namely Gα, Gβ 
and Gγ expressed by 16, 5 and 12 genes in mammals, respectively. The Gα subunit can 
be further divided into four sub-families consisting of Gαs, Gαi, Gαq/11 and Gα12/13 (22). 
The G-protein constitutes a molecular switch that cycles between a GDP-bound form in 
its  inactive  state  versus  a  GTP-bound  form  in  its  active  conformation.  Upon  ligand 
binding, the GPCR interacts with its associated G protein to catalyse the release of GDP 
from Gα and the subsequent binding of GTP. This mechanism provokes a conformational 
modification that reduces the affinity of Gα for Gβγ, leading to the dissociation of the two 
subunits.  The  GTP-bound  Gα  and  the  released  Gβγ  can  now  interact  with  effector 
proteins such as adenylyl cyclase and phospholipases to initiate numerous intracellular 
signalling cascades. The intrinsic GTP hydrolase activity of Gα, triggered by binding of 
RGS, or regulator of G protein signalling, reinstates the GDP-bound form of Gα and 
restores its affinity for Gβγ, thus reforming the inactive heteromeric unit (23). 
 
1.1.3 GPCR oligomerization  
  “The  eminent  German  thinker  Arthur  Schopenhauer  wrote  with  philosophical 
clarity that all truth passes through three stages. First it is ridiculed. Second, it is violently 
opposed. Third, it is accepted as being self-evident. These observations aptly apply to 
GPCRs:  an  understanding  of  their  oligomerisation  has  evoked  much  passion  and 
continuing investigation” (24).  The traditional positions on GPCR activity insisted that 
they signal as single monomeric units composed of identical subunits. The first notion of 
GPCR  oligomerisation  was  advanced  by  Agnati  and  Fuxe,  who  envisaged  a  possible 
intramembrane neuropeptide and monoamine receptor-receptor interaction to explain the 
cross-talk between the two entities (25). The notion of GPCRs as monomeric signalling 
entities was further questioned by evidence from biochemical, physical and functional 
studies, pointing to a possible interaction between GPCRs (26). For instance, radio-ligand 
binding  studies  revealed  the  existence  of  interactions  between  neurokinin  and  5-HT1 
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and α2 adrenergic receptors, to name a few (27). The first physical proof of dimerization, 
however,  emerged  from  atomic-force  microscopy  analysis  of  the  rhodopsin  receptor, 
which was found to form paracrystalline arrays of dimers in mouse disc membranes (28).  
 
  The  existence  of  dimers  was  further  substantiated  by  the  discovery  that  certain 
GPCRs,  namely  the  members  of  the  class  C  or  metabotropic  group  of  GPCRs,  are 
obligate heteromers. In fact, the constitutive dimerization of these receptors is a pre-
requisite for the expression of a fully active and pharmacologically defined receptor at the 
plasma membrane (1, 14, 26). The γ-aminobutyric acid (GABA) receptor, composed of 
two subunits GbR1 and GbR2, constitutes an example of a mandatory heteromer. When 
expressed individually in heterologous systems, the GbR1 subunit possesses a carboxy-
terminal  ER  retention  motif  RXR(R)  that  retains  the  receptor  in  the  endoplasmic 
reticulum (ER), while GbR2 is expressed at the cell surface but is not able to activate 
downstream pathways on its own. This is explained by the fact that the GbR1 subunit 
harbours the structural elements crucial for ligand binding but not for G-protein coupling, 
while the GbR2 subunit mediates G-protein coupling but cannot bind ligands. The co-
expression of the two subunits results in their dimerization, thus masking the ER retention 
motif  and  permitting  the  assembly  of  a  functional  signalling  GABAB receptor  that  is 
targeted to the cell surface (22, 29-32).  
 
  Research in both native and recombinant expression systems has identified other 
examples of GPCRs in which a single subunit is inactive in the absence of its dimeric 
partner  (1,  33).  For  instance,  the  co-expression  of  taste  receptors  T1R2/T1R3,  or 
T1R1/T1R3 is necessary to produce functional taste receptors that detect sweet and umami 
(34). Moreover, studies of the dopamine family of receptors have demonstrated that they 
dimerize  with  themselves  and  other  receptors  to  yield  ‘multireceptor  networks’  with 
novel  functional  properties  (35).  In  fact,  ligand  binding  studies  have  confirmed  the 
formation of D2R oligomers, thought to be involved in the pathology of schizophrenia 
(36, 37). The D2R receptor was also found to heterodimerize with the D3R receptor, 
resulting  in  complexes  with  reduced  agonist  affinity  and  augmented  coupling  with 
adenylyl cyclase (35, 38). An additional example of dopamine receptor oligomerisation is 
D1R/D2R,  which  requires  agonist  binding  to  both  receptor  subunits  for  G  protein 
activation and might contribute to dopamine-mediated synaptic plasticity in the brain. 
The selective activation of either receptor was found to provoke the co-internalization of 
these  D1R/D2R  heterodimers  (39-42).  Another  oligomerisation  partner  of  D1R  is  the Chapter 1  Introduction 
	 ﾠ 7	 ﾠ
dopamine D3 receptor, resulting in a dimer that enhances the dopaminergic response in 
striatal neurons co-expressing both receptors (43, 44). Dopamine receptors have also been 
reported to oligomerize with other receptors, including the adenosine 2A receptor, the 
CB1  cannabinoid  receptor,  the  metabotropic  glutamate  type  5  receptor  and  the 
somatostatin-2 and -5 receptors (35, 45-50).  
 
  The formation of hetero-oligomers between P2 receptors, which are of particular 
interest to this study, has also been substantiated by numerous studies. For instance, the 
A1 receptor was shown to engage in heteromeric assemblies with the P2Y1 receptor in 
cotransfected HEK293T cells, generating A1 receptors with P2Y-like agonist affinities 
(51). The existence of an A1R/P2Y1R dimer was further demonstrated in vivo using co-
immunoprecipitation experiments and the oligomer was found to localize to rat cortex 
(52),  hippocampus  and  cerebellum  membranes  (53).  A  proposed  function  for  this 
A1R/P2Y1R dimer is the attenuation of neurotransmitter release from synaptic vesicles 
(53). Additional mentions of P2 hetero-dimerization encompass the interaction between 
A1  and  the  dopamine  D1  receptor  to  form  a  functionally  active  complex  thought  to 
impinge on receptor trafficking and desensitization (54). A1R can also heteromerize with 
the metabotropic glutamate type 1α receptor, resulting in the modulation of glutamate 
excitotoxicity (27).  
 
The A2A receptor can dimerize with the metabotropic glutamate type 5 receptor and 
was found to engage in synergistic interactions at both the biochemical and behavioural 
levels. A study conducted by Ecke et al has also shown that the P2Y1 and P2Y11 receptors 
associate physically when co-expressed in HEK293T cells using co-immunoprecipitation, 
immunoprecipitation and FRET experiments (55). This hetero-oligomerisation alters the 
agonist profile of P2Y11, allowing it to acquire novel functions when in tandem with 
P2Y1. The study also revealed that oligomer formation induced the internalization of 
P2Y11, a receptor that does not undergo endocytosis by itself. This finding suggests that 
the crosstalk between P2Y1 and P2Y11 receptors has a regulatory role and might be used 
by the cell to favour one GPCR signalling pathway over the other.  
 
1.1.4 The role of chaperones in GPCR oligomer formation 
  The discovery that GPCRs are able to oligomerize has raised important questions. 
One such interrogation is where and how these complexes are formed and expressed at 
the  cell  surface.  While  heteromers  can  arise  transiently  in  the  plasma  membrane, Chapter 1  Introduction 
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accumulating evidence suggests that receptor dimerization and the assembly of GPCRs 
with their signalling complex may occur early during biogenesis, prior to trafficking to 
the plasma membrane (22, 56). Moreover, studies indicate that molecular chaperones may 
contribute  to  the  proper  folding  of  receptors  as  well  as  the  assembly  of  signalling 
complexes, indicating that these complexes may be delivered to the plasma membrane as 
“complete signalling units” (22).  
 
  The oligomerisation literature suggests that receptor dimerization can occur in the 
endoplasmic reticulum (ER), where it might play a role in ER quality control and exit by 
masking the ER-retention motifs of some receptor sequences (1, 22, 57). One of the first 
evidences of constitutive dimerization during biogenesis emerged from mutagenesis of 
the β2-adrenergic receptor, targeting the putative dimerization interface. These studies 
showed that inhibiting β2AR dimerization caused its retention in the ER, thus supporting 
the  hypothesis  of  receptor  oligomerisation  in  this  cellular  compartment  (57).  Other 
examples  of  oligomerisation  in  the  ER  encompass  the  D4  receptors  (58),  GABAB 
receptors  (29)  and  serotonin  5-HT2C  receptors  (59).    Studies  have  also  proposed  a 
possible involvement of molecular chaperones in the assembly of oligomeric complexes 
in the ER (60-62). An example of chaperone implication in receptor oligomerisation is 
RTP4, reported to mediate the folding of the µ- δ opioid heteromer, thus masking the ER 
retention motif and permitting the export of the complex to the cell surface. Interestingly, 
RTP4 is thought to stay bound to the µ-δ opioid heteromer at the plasma membrane and 
participate in the regulation of heteromer specific signalling (63). Another chaperone is 
calreticulin, which enhances the maturation and heterodimerization of the B2 bradykinin 
receptor  with  the  angiotensin  II  type  1  receptor  (AT1R)  in  heterologous  and  in  vivo 
models  (60,  61).    These  combined  findings  delineate  a  novel  scenario  of  GPCR 
dimerization, in which receptor oligomers and GPCR signalling complexes composed of 
multiple interaction partners are gathered during biogenesis in the ER and delivered to the 
cellular membranes as pre-assembled functional units. This mechanism might contribute 
to  the  diversification  and  specificity  of  GPCR  signalling  complexes  observed  in 
mammalian cells.  
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Heteromer 
Methods used to 
investigate receptor 
association 
Crosstalk  Reference 
GABAB1:GABAB2  TR-FRET-HTRF using 
Snaptag or antibodies 
Increased agonist 
response of dimer 
versus two tetramer 
(64) 
H1:α1BAR  CoIP and TR-FRET  Cross-activation of 
G-proteins 
(65) 
D1:D2  CoIP, confocal 
microscopy, BiFC   
Novel 
pharmacological 
profile 
(41, 66-68) 
D1:D3  FRET, confocal 
microscopy, BiFC 
D3 stimulation 
enhances D1 agonist 
affinity 
(43) 
A2A:D2  BiFC, FRET, CoIP, 
Immunofluorescence 
microscopy 
A2A decreases 
affinity of D2 for 
dopamine, Co-
internalization and 
cross-
desensitization 
(45, 69) 
D2:CB1:A2A  BiFC, BRET, sequential 
BRET-FRET (SRET), 
confocal microscopy  
Mediation of 
neuronal 
computation 
modulating striatal 
dopamine 
neurotransmission 
(70-72) 
A2A:CB1  Colocalization, CoIP, 
BRET 
CB1 signaling 
dependent on A2A 
activation  
(73) 
mGlu5:A2A:D2  Colocalization, CoIP, 
BiFC, BRET and SRET,  
Gs, Gi/o and Gq 
pathway regulation, 
and DARP-32, Erk 
and c-fos crossraods 
(74) 
mGlu2A:5-HT2A   BRET, CoIP, 
colocalization 
mGLu2 regulates 
hallucinogen-
induced coupling to 
Gi/o of 5-HT2A 
(75) 
A1:P2Y1  CoIP, confocal 
microscopy, BiFC 
Generation of an 
adenosine receptor 
with P2Y-like 
agonist 
pharmacology, and 
inhibition of 
adenylyl cyclase 
activity via Gi/o 
(51-53) 
Table 1.1 GPCR heteromers  
This  table  provides  a  list  of  heteromers  that  have  been  well  described  in  the  literature.  The 
techniques  employed  to  investigate  receptor  oligomerization  and  the  functional  crosstalk  that 
arises from protomer interactions are detailed for each heteromer.  
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1.1.5 The dynamics of GPCR oligomerisation  
  Zoli  et  al.  state  that  the  term  ‘heterodimerization’  was  coined  to  delineate  the 
‘specific interaction’ between different types of G protein-coupled receptors (62, 76). 
Current research on GPCR dimers aims at investigating how they function by studying: 
1) the agonists, partial agonists and antagonists of these dimers; 2) their binding site and 
optimal  ligand  occupancies;  3)  the  stoichiometry  of  the  signalling  complex;  4)  the 
location of the dimerization interface and the identity of the interacting residues; and 5) 
the nature of the conformational change involved in this dimerization (77).  
 
  As  the  phenomenon  of  GPCR  oligomerisation  constitutes  a  relatively  recent 
newcomer to the universe of GPCR research, it is not yet possible to seek complete and 
satisfying answers to these questions in the current literature. However, studies tackling 
heteromerisation dynamics suggest that ligand binding to one receptor protomer might 
provoke a conformational change in the neighbouring receptor within the oligomer unit, 
leading  to  an  intricate  signalling  cascade  (78).  A  possible  insight  into  the  spatial 
organization and binding interface of GPCR heteromers comes from imaging studies, 
which shed some light on the mechanisms of interaction between the monomeric subunits 
of oligomers. In 2003, Liang et al. published the first 3D molecular model of a GPCR 
oligomer, describing it as “the first semi-empirical model of a higher order structure of a 
GPCR in native membranes.” The model was resolved using atomic force microscopy 
(ATM) maps of rhodopsin in the native disk membrane and showed the arrangement of 
rhodopsin  molecules  in  densely  packed  two-dimensional  arrays  of  dimers  (28,  79). 
According to this model, TM4, TM5 and the intracellular loop connecting TM3 and TM4 
(IL2) of the rhodopsin dimers (shown in Figure 1-2) are implicated in the formation of 
rhodopsin dimers, or intra-dimeric interactions. These dimers then form rows through 
contacts between TM1, TM2 and the intracellular loop connecting TM5 and TM6 (IL3) 
(79).  Further  studies  of  the  dopamine  D2  (D2DR)  homo-dimers  corroborated  the 
participation of TM4 and TM5 in dimer formation and indicated that TM4 also partakes 
in the conformational rearrangements corresponding to the agonist bound state of the 
dimer (80).  
 
  Data  from  computational  studies  and  molecular  simulations  of  dimerization  on 
oligomeric  proteins  such  as  trimeric  bacteriorhodopsin  identified  a  number  of 
dimerization  interfaces  with  contacts  between  TM4-TM4,  TM4-TM6  and  TM5-TM6. 
Molecular  predictions  also  ascertained  that  a  protomer  undergoes  a  conformational Chapter 1  Introduction 
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change in the presence of its partner even when all the protomers are in the inactive state. 
Given that GPCRs have been found to interact through multiple interfaces, leading to 
spatial rearrangements of the protomeric subunits, they can form a panoply of oligomeric 
complexes with diverse pharmacological profiles, distinct from the signalling imprints of 
the individual protomeric receptors. This diversity makes it difficult to dress an inventory 
of  all  the  biologically  important  interactions  resulting  in  dimerization  and  of  their 
biological functions (77).  
 
  The  exact  nature  of  the  GPCR  dimerization  interface  has  not  yet  been  fully 
unravelled.  However,  the  literature  describes  two  models  of  dimerization  for 
transmembrane proteins. In the first model, two monomers touch each other, leading to 
the formation of a contact dimer. In the second model, the hinge loop of the dimer opens, 
causing the domains to exchange and produce a domain-swapped dimer (81) (shown in 
Figure 1.3). The concept of 3D domain swapping is well reviewed and accepted as a 
mechanism of oligomeric protein formation from monomeric constituents. According to 
this model, one entire domain from the monomeric subunit of a dimer is exchanged for 
another domain from the partner subunit, resulting in an “intertwined” dimer or higher 
oligomer  (82,  83).  Domain  swapping  has  not  been  widely  invoked  in  the  context  of 
GPCR oligomerisation. However, a number of computational and simulation studies have 
mentioned a possible role for the swapping of domains 5 and 6 in the formation of GPCR 
dimers (81, 84-86).    Chapter 1  Introduction 
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A. 
 
B.  
 
Figure 1.3 Possible models of GPCR dimerization adapted from Gouldson et al.  (81, 
84, 86) 
A. 1,2-contact dimer. In contact dimers, receptor monomers are in direct contact through exterior 
residues.  B.  5,6-domain  swapped  dimer.  Domain  swapping  requires  the  exchange  of 
transmembrane domain between the monomeric units of the dimers at the same sites involved in 
monomer formation. The shown dimer results from domain swapping at the 5-6 interface.  Chapter 1  Introduction 
	 ﾠ 13	 ﾠ
1.1.6 Receptor mosaics  
  The  discovery  that  seven  transmembrane  receptors  interact  to  form  oligomeric 
assemblies with novel structural and functional features has generated a novel paradigm 
in  GPCR  signalling.  This  shift  in  understanding  has  in  turn  engendered  specific 
terminologies that articulate the difference between the various forms in which GPCRs 
exist and signal. In a review published in 2010, Agnati et al. advanced a number of 
definitions used “in the study of protein networks at the plasma membrane level, and 
hence,  also  of  the  receptor  function  and  the  assembly  of  GPCRs  into  an  integrative 
centre” (87).  
   
  The  basic  unit  of  GPCR  signalling  is  the  ‘microprocessor’.  This  term  was  first 
proposed by Kenakin to indicate that seven transmembrane receptors are not simply “on-
off” switches. Rather they are sophisticated machines capable of elaborating information 
by  adopting  various  structural  conformations.  In  fact,  GPCRs  represent  clusters  of 
“interchanging  conformations”  known  as  ensembles.  Ligand  binding  provokes 
modifications in these ensembles by favouring certain conformations compared to others, 
thus triggering the switch from inactive to active receptor states. The expanding GPCR 
literature suggests that conformational changes in different regions of the microprocessor 
may account for its ability to interact with different downstream effectors (87).  
 
  The next level of GPCR organisation is the receptor homodimer or heterodimer. 
This  term  refers  to  the  coupling  of  receptors  in  the  cellular  membrane  to  produce  a 
functional centre with novel structural and functional characteristics. Each receptor in the 
dimer  is  termed  a  ‘protomer’.  Homodimers  are  pairs  of  the  same  protomer,  while 
heterodimers are formed from distinct receptors. An oligomer is a multimeric protein 
formed from a small number of subunits in a state of reversible association with each 
other (87). The interaction between these two receptors, or receptor-receptor interactions 
(RRIs), is defined as the binding of a ligand to the orthosteric or allosteric sites of one 
receptor,  causing  a  modification  in  the  ligand  recognition,  decoding  and  trafficking 
processes of another receptor via allosteric interactions (88).  
 
  Recently,  increasing  evidence  from  coimmunoprecipitation  (CoIP), 
bioluminescence  resonance  energy  transfer  (BRET),  fluorescence  resonance  energy 
transfer  (FRET)  and  bimolecular  fluorescence  complementation  (BiFC)  studies  has 
pointed  to  the  possible  existence  of  a  higher  level  of  GPCR  organisation.  In  fact,  it Chapter 1  Introduction 
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appears that GPCRs can form higher-order receptor oligomers composed of more than 
two protomers, in addition to classical homo- and hetero-dimers (22, 87-89). For instance, 
studies  using  combined  bioluminescence/fluorescence  energy  transfer  and 
complementation techniques revealed that four D2 receptors or more associate to form 
higher order networks at physiological expression levels (90). Furthermore, higher-order 
oligomeric assemblages composed of at least three A2A receptors were detected using 
combined BRET-BiFC (91). Coimmunoprecipitation studies using three different epitope 
tags have also shown the existence of aggregates consisting of trimeric M2 muscarinic 
cholinergic receptor associations in Sf9 cells (92). 
 
  Moreover,  investigators  have  utilized  novel  techniques,  combining  Protein 
fragment complementation approaches (PCA), BiFC and sequential BRET/FRET (SRET) 
to identify the existence of higher order assemblies of A2A homo- and heterodimers with 
CB1  cannabinoid/D2  dopamine  receptors  (22,  71,  88,  91,  93).  This  compilation  of 
findings has supported the hypothesis that GPCRs can form high-order oligomers, or 
“islands of clusters” described as receptor mosaics (94). The notion of receptor mosaics 
was discussed by Agnati et al. in a number of papers (94-97), and postulates “that one can 
produce  markedly  different  molecular  aggregates  of  receptors  by  putting  together  the 
same building blocks to construct functionally different assemblies” (97). 
 
  According to Agnati, receptor mosaics are defined as macromolecular assemblies of 
more than two receptors that physically interact to form various spatial arrangements or 
topologies (87, 98). Moreover, receptor mosaics participate in both horizontal membrane 
networks (HMN) and vertical membrane networks (VMN). HMNs consist of proteins 
integrated  into  the  membrane  and  grouped  in  specific  topologies  to  form  functional 
signalling-processing modules. VMNs, on the other hand, are molecular networks that 
extend to the cytoplasm and nucleus (87). Receptor mosaics can signal to both VMNs and 
HMNs,  thus  diversifying  the  elaboration  of  information,  and  they  possess  several 
mechanistic characteristics. First, a RM is functional only when one receptor regulates the 
biochemical and functional features of at least one other receptor of the assembly via 
allosteric RRIs (87). Second, the conformational re-distributions and ligand binding of 
each protomer is governed by the conformations and allosteric interactions with the other 
members of the cluster (87). Finally, the spatial arrangements and  “allosteric” pathways 
interconnecting the RM members forge the RRIs that occur between the protomers (87, 
99-101).  On  another  note,  the  RM  possesses  “emergent  properties”  endowed  with Chapter 1  Introduction 
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recognition  and  decoding  mechanisms  distinctive  from  those  of  the  protomers,  a 
phenomenon described as “phenotype-plastic receptors” (87, 102).  
 
  In  summary,  recent  research  has  debunked  the  traditional  perception  of  GPCR 
receptors as monomeric units, revealing the inherent complexity of seven transmembrane 
signalling. The proposed nomenclature postulates the following hierarchical organization. 
The basic level consists of the “first-order microprocessor” which induces an intracellular 
cascade of the first order. If this unit interacts with another membrane protein, it gives 
rise  to  a  first  order  HMN.  The  second  level  is  formed  from  the  “second-order 
microprocessor” or dimer, which evokes an intracellular signalling cascade of the second 
order.  It  can  also  produce  a  second-order  HMN  if  it  interacts  with  other  membrane 
proteins. The third organizational level consists of higher-order microprocessors or RMs, 
which produce signalling cascades of the higher order. They result in higher-order HMNs 
when they interact with some membrane protein (87).  
 
1.1.7 The physiological relevance of GPCR oligomerisation 
  As  the  literature  reveals,  the  cellular  membrane  houses  “hubs”  of  information 
transmission  and  processing  in  the  form  of  monomers,  homo-  and  heteromers  and 
receptor mosaics. Oligomerisation is envisioned to fulfil an important physiological role 
by orchestrating a network of novel and diverse functions. First, heterodimerization could 
alter  the  agonist  affinities  of  individual  receptors,  thus  generating  entities  with  novel 
agonist  and  antagonist  pharmacologies.  The  A1R-P2Y1 complex  offers  an  example  of 
such  signalling  diversification  through  oligomerisation,  whereby  the  association 
engendered an A1R with P2Y1R-like agonist patterns (51).  Furthermore, the β-AR and 
AT1R  dimer  provides  an  example  of  cross-inhibition,  whereby  the  blockade  of  one 
protomer results in the uncoupling and inhibition of its interacting partner (103, 104).  
 
  Second, oligomer formation could modify the selectivity of GPCRs for distinct G-
protein  subsets,  thus  polarizing  the  hetero-oligomer  towards  different  downstream 
signalling cascades upon agonist activation. For example, the D1-D2 heterodimer couples 
to Gq/11, leading to PLC-mediated intracellular calcium increase, a pathway that is not 
observed for the Gs/olf-linked D1R or the Gi-linked D2R (41, 66). In another instance, the 
5-HT2A-mGluR2  heteromer,  a  target  of  hallucinogenic  drugs,  was  found  to  undergo 
conformational changes that allow 5HT2ARs to couple to Gi/o in addition to Gq/11 upon 
ligand  binding  (75,  105).  Moreover,  the  µ-  and  δ-opioid  dimers  were  reported  to  be Chapter 1  Introduction 
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insensitive to pertussis toxin (PTX), as opposed to the individual component receptors 
(42).  
 
Third, oligomerisation might regulate desensitization and trafficking mechanisms 
by potentiating the internalization of receptors that cannot internalize on their own. For 
instance,  the  dimerization  of  the  µ-  and  δ-opioid  receptors  provokes  the  cross-
internalization  of  the  µ-opioid  upon  activation  of  δ-opioid,  thus  reducing  µ-opioid 
receptor-induced analgesia (22). Furthermore, the oligomerisation of the α1A and α1B- 
adrenergic  receptor  subtypes  induced  the  co-internalization  of  the  two  protomers 
following agonist activation (106). This phenomenon was similarly observed for P2Y1 
and P2Y11. In fact, oligomerisation of these two receptors induced the co-internalization 
of P2Y11, which does not undergo endocytosis by itself (55). These integrated regulatory 
effects could help maintain the population of GPCRs in the cell under tight control while 
augmenting the diversity of GPCR signalling.   
 
1.1.8 Functional crosstalk  
  The extensive GPCR research conducted in the past two decades has substantiated 
the existence and functional relevance of GPCR heteromers and higher-order complexes. 
Thus,  receptor  oligomerisation  is  now  believed  to  constitute  a  major  tool  of 
communication  and  crosstalk  between  seven  transmembrane  receptors,  allowing  the 
diversification and fine-tuning of GPCR signalling. However, oligomerisation or physical 
crosstalk is not the only mechanism of receptor communication. In fact, 7TM interactions 
can  arise  from  colocalized  receptors  partaking  in  signalling  pathways,  or  from  the 
synergistic regulation of signalling at crossroads, namely at the plasma membrane, the 
cytoplasm or nucleus, a phenomenon termed functional crosstalk (34). The mGlu1a and 
GABAB receptors illustrate this trend. For instance, the coactivation of both receptors 
augmented mGlu1a-evoked calcium signalling (107, 108). Although oligomerisation was 
thought  to  occur,  coimmunoprecipitation,  BRET  and  Homogenous  Time  Resolved 
Fluorescence  (HTRF)  coupled  to  Snaptag  labelling  showed  no  evidence  of  physical 
contact between the two receptors (64, 109). Instead, the crosstalk was found to arise 
from signalling crossroads, whereby GABAB receptors activated the βγ subunits of Gi/o, 
which in turn enhanced the calcium response of the mGlu1a-activated Gq (108, 109).  
 
In summary, the interaction between heteromeric/oligomeric GPCRs is underpinned 
by three mechanisms (34):  Chapter 1  Introduction 
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1-  Two  receptors  undergo  functional  crosstalk  at  the  signalling  level,  without 
direct physical contact 
2-  Two receptors form a dimer. However, the crosstalk is not elicited by direct 
physical interaction but by functional crosstalk at the signalling level 
3-  Two receptors form a dimer, resulting in functional and physical crosstalk. 
This major means of receptor communication has been thoroughly described 
in this chapter 
 
1.2 Purinergic receptors  
 
1.2.1 Historical perspective on purine and pyrimidine discovery 
Purine receptors are a subfamily of GPCRs activated by purine nucleotides and 
nucleosides such as adenosine and ADP. The first report of extracellular signalling by 
purines was published in 1929 by Drury and Szent-Gyӧrgyi (110), and described the 
effect of simple extracts from heart muscle, brain, kidney and spleen on the mammalian 
heart. Upon isolation and testing of the extract, the analysed substance was found to be 
similar  or  closely  related  to  adenylic  acid  (adenosine  monophosphate,  AMP).    When 
administered  by  intravenous  injection  in  the  guinea  pig,  it  resulted  in  a  block  of  the 
atrioventricular junctional tissue, thus impairing the conduction of cardiac impulses from 
the atria to the ventricles and inducing high-grade heart block. This strong action was not 
detected in the cat, rabbit and dog where adenylic acid only triggered a reduction of the 
heart rate (transient sinus bradycardia). Other observed effects of adenylic acid included 
vasodilation in the coronary arteries and peripheral vessels, provoking a decrease in blood 
pressure. Adenosine, obtained from yeast nucleic acid, produced an action identical to 
adenylic acid.  
 
Another important hint of the role of purines as extracellular messengers was the 
discovery  that  dorsal  root  ganglia  neurones  of  the  rabbit  ear  release  a  vasodilator 
substance, which is neither acetylcholine nor histamine. Furthermore, denervation was 
found to increase the sensitivity of the rabbit’s ear to this transmitter (111, 112). The 
response evoked by the substance had a latency period of about 10 sec. and was not 
abolished  by  atropine.    Subsequent  research  revealed  that  the  chemical  transmitter 
responsible  for  antidromic  vasodilation  was  ATP  (113).  In  1970,  Burnstock  et  al. 
proposed that the autonomic nervous system harbours a component, distinct from the Chapter 1  Introduction 
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adrenergic and cholinergic nerves, which releases ATP as a neurotransmitter (114). This 
third  component  was  later  termed  “purinergic”  and  is  highly  expressed  in  the 
gastrointestinal  tract  (115,  116).  Further  identification  and  investigation  of  the 
extracellular actions of adenyl purines confirmed the existence of “purinergic” receptors 
(117).  Based  on  the  analysis  of  the  pharmacological  profiles  of  the  various  adenyl 
purines, Burnstock suggested that the receptors for the nucleotides ATP and ADP, whose 
structures are shown in Figure 1-6, were likely to be different from the receptors for 
nucleosides, leading to the subsequent division of purine receptors into P1 (adenosine) 
and P2 (ATP and ADP) receptors. P2 receptors were further subdivided into two different 
subtypes,  P2X  and  P2Y,  based  on  different  response  profiles  to  ATP  analogues  and 
selective antagonism (118). Additional evidence supported the existence of P2Y receptors 
that  respond  to  pyrimidines  as  well  as  purines  (119).  The  cloning  of  P2  receptors 
confirmed and extended the discrimination between P2 receptors to molecular structure, 
transduction mechanisms and effector systems (120). Seven subtypes of P2X and eight 
subtypes of P2Y have been identified to date (121-123).   
 
1.2.2 Synthesis and breakdown of purines 
Purines  constitute  a  family  of  heterocyclic  aromatic  compounds  composed  of  a 
five-membered  nitrogen  containing  ring,  or  pyrimidine,  fused  to  a  six-  membered 
nitrogen  containing  ring,  or  imidazole.  They  occur  in  high  concentrations  in  living 
organisms.  For  instance,  two  of  the  four  bases  of  nucleic  acids  are  purines,  namely 
adenosine and guanine. Other purines include xanthine, caffeine and uric acid. Purines are 
components  of  an  important  array  of  biologically  significant  molecules,  such  ATP, 
cAMP, NADH and Coenzyme A, and as such partake in a number of vital metabolic 
cycles. One such cycle is that of adenyl purine biosynthesis, which is initiated with a 
purine base such as adenine. The subsequent addition of a 5-carbon sugar or ribose to the 
nitrogen base of the purine results in the formation of a nucleoside. The addition of a 
phosphate  group  to  the  sugar  portion  of  this  nucleoside  generates  a  nucleotide,  also 
known  as  adenylic  acid  or  adenosine  5’-monophosphate  (AMP).  When  a  second 
phosphate  is  added  to  AMP,  a  nucleoside  diphosphate,  or  adenosine  5’-diphosphate 
(ADP) is produced. The addition of a third phosphate to ADP engenders a nucleoside 
triphosphate, known as adenosine 5’-triphosphate (ATP). Adenyl purines can be salvaged 
through the breakdown of ATP into adenosine and adenine. These are then absorbed into 
red blood cells, which cannot synthesize ATP de novo, to permit nucleotide synthesis 
(124, 125). However, if the recycled adenosine and adenine remain unsalvaged, they are Chapter 1  Introduction 
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catabolised. Purine catabolism occurs by deamination of adenosine to form inosine by 
adenosine  deaminase,  which  is  then  cleaved  to  generate  hypoxanthine  and  further 
oxidized to xanthine. The end product of purine degradation in man is uric acid. 
 
Of  the  above-mentioned  adenyl  purines,  ATP  constitutes  the  major  energy 
“currency”  of  mammalian  cells  and  is,  subsequently,  the  most  widely  studied  adenyl 
purine. The breakdown of ATP into di- and mono-phosphates liberates energy that is 
employed by the cell to power a panoply of biological functions, including synthesis of 
biomolecules, signal transduction, active transport across the cell membrane, maintenance 
of resting membrane potential, neurotransmission and neuromodulation.  
 
  ATP  is  synthesized,  stored  into  vesicles  and  released  as  a  paracrine/autocrine 
molecule in the peripheral and central nervous systems (123, 126, 127). It functions as a 
fast excitatory neurotransmitter in the sympathetic, parasympathetic and enteric systems 
(128, 129). The concentration of nucleotides packaged into vesicles has been estimated to 
be 1000mM (127), whereas that of nucleotides secreted into the extracellular space ranges 
from 0.1 to 10µM (123). An extensive body of literature has demonstrated that ATP is 
released as a co-transmitter in conjunction with a number of other transmitters in the 
peripheral  and  central  nervous  systems  (129).  The  first  evidence  of  sympathetic  co-
transmission was reported by Westfall et al. who discovered that ATP and norepinephrine 
function as co-transmitters in the vas deferens of the guinea pig (130, 131). Later research 
revealed  that  ATP  is  released  as  a  co-transmitter  with  noradrenaline  in  sympathetic 
nerves (132, 133), with acetylcholine in a number of tissues (134), as well as with 5-
hydroxytryptamine, glutamate, dopamine and γ-aminobutyric acid (GABA) in the central 
nervous system (127).  
 
  Neuronal cells are not the only source of ATP, as it is also secreted from non-
neuronal cells, such as astrocytes (135), glial cells (136) and pancreatic β cells (137), in 
response  to  a  vast  array  of  stimuli,  including  hypoxia,  mechanical  stress,  agonists, 
acidosis,  receptor  stimulation,  inflammation  and  osmotic  shock  (123,  126,  138).  The 
concentration of ATP in the extracellular space is tightly regulated through an intricate 
balance  between  its  release,  catabolism  and  inter-conversion.  Consequently,  several 
enzymatic families are thus implicated in the breakdown of ATP released from neuronal 
and non-neuronal cells, including ecto-nucleotidase triphosphate diphosphoryl hydrolases Chapter 1  Introduction 
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(E-NTPDases)  and  ectonucleotide  pyrophosphatase  kinases  (E-  NDPK)  (139).  The 
structures of ADP and ATP are shown in Figure 1.4.    Chapter 1  Introduction 
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A.  
B.   
 
Figure 1.4 Structure of adenosine diphosphate and adenosine triphosphate  
A.  Pseudo  3D  view  of  the  molecular  structure  of  ADP  visualized  using  UCSF  Chimera. 
Adenosine  diphosphate,  known  as  ADP,  is  a  nucleoside  diphosphate  composed  of  three 
components, an adenine base (beige and blue), a ribose sugar at the centre (beige and red) and a 
negatively  charged  diphosphate  chain  (red  and  orange).  The  chemical  formula  of  ADP  is 
C10H15N5O10P2. B. Pseudo 3D view of the molecular structure of ATP visualized using UCSF 
Chimera. Adenosine triphosphate, known as ATP, is a nucleoside triphosphate composed of three 
components, an adenine base (beige and blue), a ribose sugar at the centre (beige and red) and a 
negatively  charged  triphosphate  chain  (red  and  orange).  The  chemical  formula  of  ATP  is 
C10H16N5O13P3.  
 
 
1.2.3  Historical perspective on purine receptor discovery 
In  a  seminal  review  published  for  the  NC-IUPHAR  Committee,  Kenakin  et  al. 
proposed that “a completely” defined receptor would possess a unique pharmacological 
profile based on agonist and antagonist data, a known endogenous ligand, and a distinct 
amino acid sequence” (140). Due to the paucity of selective purinoceptor antagonists and 
their stability/insolubility (141, 142), the first proposed nomenclatures of purinoceptors 
were mainly delineated based on relative agonist potencies. This enterprise was further 
confounded by the fact that multiple purine receptor types can coexist on a single cell. 
The advent of recombinant DNA technology helped refine purinoceptor classification in 
light of molecular and structural findings coupled to pharmacological profiles.  
The first evidence of the existence of adenosine receptors was advanced by Sattin 
and Rall in a key paper published in 1970 (143). In this work, the investigators monitored 
the  content  of  cyclic  AMP  in  guinea  pig  cerebral  cortex  slides  and  reported  that  it Chapter 1  Introduction 
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increases 20-30 folds five minutes after exposure to 0.05 mM adenine. They also noted 
that  methylxanthines  (0.5  mM)  blocked  the  effect  of  adenosine,  a  blockade  that  was 
reversed  by  elevating  adenosine  concentration.  Van  Calker  et  al.  later  showed  that 
adenosine exerts a dual action in glial-like cells, leading to the increase and inhibition of 
cAMP concentration, respectively. This pointed to the existence of two different types of 
adenosine receptors, named A1 and A2 (144).  
 
Burnstock proposed a “basis for distinguishing two types of purinoceptors” (118), 
according to four criteria: a) the selective action of antagonists, namely methylxanthines, 
which  competitively  inhibit  adenosine  but  not  ATP;  b)  the  relative  potencies  of  the 
multiple adenyl purines at the different purine receptors; c) the activation of adenylate 
cyclase by adenosine, but not ATP; and d) the stimulation of prostaglandin synthesis by 
ATP,  but  not  by  adenosine.  The  two  subtypes  were  termed  P1  and  P2,  activated  by 
adenosine and ATP respectively.  
 
Later,  Burnstock  and  Kennedy  postulated  that  P2  receptors  could  be  further 
subdivided into two distinct subgroups, called P2X and P2Y, respectively, in light of 
differing response profiles to various ATP analogues. The P2X subtype, for instance, 
exhibited  the  following  agonist  profile:  αβmeATP>  βγmeATP  >ATP  ≈  2meSATP  ≈ 
ADP,  whereas  P2Y  receptors  were  preferentially  activated  by  2meSATP  >  ATP  ≥  
αβmeATP ≈ βγmeATP (118).  
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1.3  P2Y receptors 
 
1.3.1 Nomenclature  
P2Y  receptors  are  metabotropic  purine  and  pyrimidine  nucleotide  receptors  that 
belong  to  the  superfamily  of  rhodopsin-like  G  protein-coupled  receptors.  Eight 
mammalian  P2Y  receptors  are  currently  recognized:  P2Y1,2,4,6,11,12,13,14  (123). 
Pharmacologically,  these  receptors  can  be  divided  into  4  general  groups:  1)  adenine-
nucleotide-preferring receptors activated by ADP and ATP, namely human and rodent 
P2Y1-12-13 and human P2Y11; 2) uracil nucleotide-preferring receptors which respond to 
either UDP or UTP, i.e. P2Y4 and P2Y6; 3) receptors of mixed selectivity, P2Y2 and 
P2Y4;  and  4)  receptors  that  respond  to  sugar  nucleotides  UDP-glucose  and  UDP-
galactose only, mainly P2Y14 (123, 145). The missing numbers constitute nonmammalian 
orthologues or receptors that possess sequence homology to P2Y receptors but do not 
respond to nucleotides (123). For instance, p2y3 may be a chicken orthologue of P2Y6, 
while p2y8 and tp2y may be Xenopus and turkey orthologues of P2Y4. P2y7 might be a 
leukotriene B4 receptor, while p2y5 and p2y10 are orphan receptors (123).  
  
Furthermore,  phylogenetic  studies  examining  the  evolutionary  relationships 
between  the  members  of  the  P2Y  family  have  distinguished  between  two  distinct 
subgroups of P2Y receptors (146). The first subgroup consists of the P2Y1,2,4,6,11 receptors 
which share 29 to 46% sequence homology, whereas the second subgroup comprises the 
P2Y12,13,14 receptors characterised by 21 to 48% homology (123). Alignment of the amino 
acid sequences of all members of the P2Y family reveals 21-57% identity between the 
various receptors (145). This phylogenetic partitioning can further be duplicated at the 
level of signal transduction mechanisms, as the two P2Y subgroups also diverge in their 
selectivity  to  G-proteins.  In  fact,  the  receptors  of  the  first  subgroup,  i.e.  P2Y1,2,4,6,11, 
couple  preferentially  to  Gq/11 leading  to  the  activation  of  the  PLCβ/IP3  pathway  and 
mobilization of intracellular calcium. Conversely, the members of the second subgroup, 
i.e. P2Y12,13,14, principally mediate their functional effects through coupling to members 
of the Gi/o family of G proteins (123).  
 
An additional level of complexity transpires when amino acid structure is taken into 
account.  P2Y  receptors  are  G-protein  coupled  receptors  consisting  of  a  seven 
transmembrane motif. Particular amino acid motifs in TM6 and TM7 are thought to be 
crucial  for  the  binding  to  GPCRs  of  extracellular  nucleotides  (147,  148).  Evidence 
suggests that all human P2Y receptors possess the TM6 H-X-X-R/K motif required for Chapter 1  Introduction 
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agonist  activity  (147,  149).  However,  the  two  subgroups  differ  in  a  defining  motif 
situated on TM7 and implicated in ligand binding. For instance, the P2Y1,2,4,6,11 subclass 
possesses a Q/K-X-X-R motif in TM7, which is substituted by a K-E-X-X-L motif in the 
P2Y12,13,14  subclass,  a  disparity  that  might  affect  ligand  binding  affinities  in  these 
receptors (123). 
 
In summary, the literature suggests that P2Y receptors can be segregated into two 
distinct subclasses based on a tripartite model encompassing 1) phylogenetic or sequence 
differences; 2) structural dissimilarities, notably the presence of differing motifs thought 
to be involved in ligand binding; and 3) differential coupling to G proteins (123). The 
tissue  distribution,  G  protein  coupling  and  pharmacology  of  P2Y  receptors  are 
summarized in table 1.2  
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Receptor 
Subtype 
(Accession 
Number) 
Chromosome 
Location 
Tissue 
Distribution  G-protein  Agonists 
(pEC50) 
Antagonists 
(pIC50) 
hP2Y1 
U42029,  
U42030, 
 S81950 
3q25.2  Wide, including 
platelets, heart, 
skeletal muscle, 
neuronal tissues, 
digestive tract 
Gq/11  2-MeSADP 
(8.7-7.9), 
2MeSATP 
(8.5-6.9),ADP 
(8.0-6.6), ATP 
(6.5-5.0), 
ATPγS (6.4), 
ADPβS (6.1-
6.0) 
 
MRS 2279 
(7.3), MRS 
2179 (6.5), 
PPADS (5.4), 
Suramin (5.8), 
BZATP (pKi, 
5.4), 
2MeSATP 
(pKi, 5.3), 
ATP (pKi, 5.2) 
hP2Y2 
NM_002564 
11q13.5  Wide including 
lung, heart, 
skeletal muscle, 
spleen, kidney 
Gq/11  UTP (7.7-6.2), 
UTPγS (6.6), 
ATP (7.1-6.6), 
ATPγS (6.2- 
5.8),GTP (4.9) 
AP4A (6.6-6.1) 
Suramin (4.9-
4.3), Reactive 
Blue  
hP2Y4 
U40223, 
X91852, 
X96597 
Xq13  Placenta, lung, 
Vascular smooth 
muscle, brain, 
liver 
Gq/11  UTP (7.6-5.6) 
UTPγS (5.8) 
ATP (5.2-5.0) 
GTP (5.2) 
PPADS (4.8), 
ATP (pkb, 6.1), 
Reactive Blue 
2 (4.7) 
hP2Y6 
U52464, 
AF007891 
11q13.5  Wide including 
lung, heart, aorta, 
spleen, placenta, 
thymus, intestine, 
brain 
Gq/11  UDPβS (7.6) 
UDP (7.0-6.5) 
UTP (5.2- 5.0) 
ADP (4.5-4.2) 
Reactive Blue 
2 (4.5), 
MRS2567, 
PPADS 
hP2Y11 
NM_002566 
19p13.2  spleen, intestine, 
immune system, 
brain, 
pituitary 
Gq/11 and Gs  ATPγS (5.5-
4.6), dATP 
(5.1-5.0), 
BzATP (5.1-
4.2), ATP (4.9-
4.2), 2-
MeSATP (4.6-
4.3), αβ-
meATP (4.1-
3.9) ,βγ-
meATP (3.7) 
Suramin (4.8), 
AMPS (3.5-
2.5), NF157 
hP2Y12 
AF313449, 
AF321815, 
AB052684 
3q25.1  platelets, neural tissue  Gi/o  2-MeSATP 
(10-8.5),2-
MeSADP (10-
7.9),ADP (7.4-
6.5), ADPβS 
(7.0-6.4), ATP 
(6.2-5.9) 
AR-C69931 
(7.6), C-1330-
7 (7.4), 
Reactive Blue-
2 (5.9), 2-
MeSAMP 
(5.9-5.3), 
Suramin (5.4) 
hP2Y13  
NM_023914, 
NM_176894 
3q24  spleen, leucocytes, 
bone marrow, liver, 
brain 
Gi/o  ADP (8.0), 2-
MeSADP 
(7.9), 
2-MeSATP 
(7.1), ADPβS 
(7.4), ATP 
(6.6) 
ARC69931M
X, 
Reactive Blue 
2, Suramin, 
PPADS 
hP2Y14 
NM_014879 
3q21-25  placenta, adipose 
tissue, 
spleen, intestine, 
brain 
Gi/o  UDP-glucose 
(7.1), UDP-
galactose (6.4) 
UDP-N-
acetylglucosa
mine (6.1)  
 
 
Table 1.2 The P2Y family of purinoceptors 
This table offers a description of chromosome location, cellular distribution, G-protein coupling 
and agonist potency of the various members of the P2Y family of purine receptors.  	 ﾠ 	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1.3.2  Structure-function relationships of P2Y receptors  
P2Y receptors belong to the family of class A G protein-coupled receptors and as 
such exhibit the seven transmembrane domain tertiary structure characteristic of GPCRs. 
They consist of 308 to 377 amino acids, have a mass of 41 to 53 kDa after glycosylation 
(121)  and  share  17  to  61%  identity  (150).  In  depth  understanding  of  the  structural 
mechanisms  that  underlie  agonist  binding  and  conformational  modifications  in  P2Y 
receptors,  and  GPCRs  in  general,  has  been  hindered  by  the  lack  of  high-resolution 
structural models of GPCRs due to their refractoriness to crystallization. In view of such 
obstacles, the main resources researchers have utilized to analyze the structure-activity 
relationships of P2Y receptors are structural homology to rhodopsin and P2Y receptor 
models  employed  for  sequence  analysis,  site-directed  mutagenesis  and  homology 
modelling studies.  
 
One of the first studies to provide insights onto the molecular underpinnings of 
ATP  binding  to  P2Y  receptors  utilized  P2Y2  receptors  (147).  Neutralization  of  three 
positively charged amino acid residues in TM6 and TM7 (His
262, Arg
265, Arg
292) of the 
receptors by substitution with uncharged leucine resulted in a 100-850 fold decrease in 
the potency of ATP and UTP without affecting their efficacy. This suggested that the 
modified residues interacted with the phosphate residues of ATP rather than the purine or 
pyrimidine groups of the nucleotides (147). Subsequent studies employing P2Y1 receptor 
models  further  highlighted  the  critical  involvement  of  positively  charged  lysine  and 
arginine residues situated on the exofacial side of TMs 3, 6 and 7 in docking of the α-
phosphate moieties of ATP (148, 151). The two disulfide bridges present in P2Y1 were 
also found to contribute to the structural stability of the receptor, possibly by stretching 
the second extracellular loop (ECL2) over the opening of the TM cleft in order to position 
amino acids within the binding pocket (152).  
 
1.3.3  Pharmacology 
A  broad  range  of  naturally  occurring  nucleoside  di-  and  triphosphates  serve  as 
agonists at P2Y receptors, each of which can be stimulated by several compounds. ADP 
serves as a full agonist at P2Y1, the dog orthologue of P2Y11, and P2Y12-13, but is a partial 
agonist at P2Y6 isoforms (150). ATP fully activates P2Y2, some orthologues of P2Y4 and 
P2Y11 (150). The pyrimidine UTP acts as a full agonist at all orthologues of P2Y2 and 
P2Y4 and has also been found to elicit a response at P2Y11 (153), while UDP is active at Chapter 1  Introduction 
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all orthologues of P2Y6 and P2Y13.  The P2Y14 receptor exhibits a unique agonist profile 
as its preferred agonist is UDP-glucose (150).  
Phosphate modifications of P2Y receptor agonists usually augment their stability 
toward breakdown by ecto-nucleotidases. The phosphorothioate ADPβS, for instance, is a 
potent agonist at P2Y1, P2Y12 (146) and P2Y13 (154), while UDPβS is active at P2Y6 and 
UTPγS  at  P2Y2  and  P2Y4.  The  2-thioalkyl  derivatives  (2-MeSADP  and  2-MeSATP) 
function as non-selective agonists at P2Y1, P2Y11, P2Y12 and P2Y13. The ribose-modified 
derivative BzATP stimulates P2Y2 and P2Y11.  
 
Structural analogues of adenosine bis-phosphates, such as MRS2179 and MRS2279, 
constitute potent antagonists of P2Y1 receptors (155). In contrast, no potent and selective 
antagonists  of  pyrimidine-activated  P2Y  receptors  have  been  developed  to  date. 
However, suramin has been reported to antagonise P2Y2 and P2Y11, Reactive blue 2 
blocks P2Y4 and P2Y6 and PPADS inactivates P2Y4, P2Y6 and P2Y11 (150). 
 
1.4  The P2Y1 receptor  
The P2Y1 receptor was first cloned from the chick brain and exhibited an agonist 
potency  order  of  2me-SATP  ≥  ATP  ≥  ADP  (156).  P2Y1  was  later  cloned  and 
characterized in human, rat, mouse, cow, turkey, guinea pig and Xenopus (123). In most 
species, ADP is more potent than ATP which functions as a partial agonist at P2Y1R and 
constitutes  an  antagonist  at  low  levels  of  receptor  reserve  (157).  The  first  selective 
antagonists used against the P2Y1 receptor were A3P5P and A3P5PS (158), later replaced 
by the more potent MRS2179 and MRS2279 (159), which exhibit high selectivity to 
P2Y1 as compared to other P2Y and P2X receptors (159, 160) and whose potency can be 
significantly increased by the modification of the 2-position of the adenine moiety (161, 
162) and  
 
Site-directed  mutagenesis  studies  helped  elucidate  some  of  the  key  residues 
implicated in ligand binding. According to the proposed model, Arginine 128 situated on 
TM3 and lysine 280 located on TM6 are thought to interact with the α and β phosphates 
of ATP, while arginine 310 (TM7) further contributes to the docking of the β phosphate 
and threonine 222 (TM5) to that of the γ phosphate (123). Glutamine 307 and serine 314 
at TM7 are thought to assure the docking of the adenine ring. Comparison of the human, 
mouse,  rat  and  hamster  amino  acid  sequences  of  P2Y1  revealed  97.3%  and  96.8% 
similarity  between  these  species  (shown  in  Table  1-2).  Amino  acid  segments Chapter 1  Introduction 
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corresponding to the transmembrane domains of human P2Y1 and residues crucial for 
ligand binding to this subtype were highly conserved across species. Moreover, the motifs 
GXXXN  (TM1),  LXXXD  (TM2),  DRY  replaced  by  HRY  (TM3)  in  P2Y1,  NPXXY 
substituted by DPXXY (TM7) in several P2YRs, RRS/QSKSE, thought to participate in 
interactions with a voltage-gated ion channel known as Tin, and DTSL, a canonical class I 
PDZ domain that binds the scaffold NHERF-2 were retained in the different species (163, 
164). These findings reveal that the structure of P2Y1 is highly conserved across various 
species.   
 
  The  study  of  P2Y1  mRNA  expression  patterns  using  quantitative  reverse 
transcription-PCR  techniques  made  it  possible  to  delineate  a  map  of  P2Y1  receptor 
distribution. hP2Y1 was found to be widely distributed throughout the human body, with 
high expression levels detected in the brain, prostate gland and placenta (165). It is also 
expressed in the pituitary gland, lymphocytes, spleen, heart, lung, liver, kidney, stomach, 
intestine, skeletal muscle, adipose tissue and pancreas at varying levels (166).  
 
P2Y1 receptors are mainly coupled to the Gq/11 pathway, which is insensitive to 
pertussis and cholera toxin. This pathway stimulates the formation of IP3 and DAG and 
the mobilization of intracellular calcium, resulting in the modulation of various signalling 
pathways,  namely  PKC,  PLA2,  Ca
2+-dependent  K
+  channels,  NOS  and  endothelium-
derived  relaxing  factor  (EDRF)  formation,  and  the  synthesis  of  endothelium-derived 
hyperpolarizing factor (EDHF).  The formed DAG stimulates PKC, which may in turn 
activate PLC, PLD, the MAPK pathway and voltage Ca
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%  P2Y1 Hamster  P2Y1 Rat  P2Y1 Mouse  P2Y1 Human 
P2Y1 Hamster  100  48.5  47.7  48.3 
P2Y1 Rat  49.3  100  97.1  95.2 
P2Y1 Mouse  48.8  98.4  100  94.9 
P2Y1 Human  49.3  97.3  96.8  100 
Table 1.3 Percentage of identity (%) between the amino acid sequences of different 
P2Y1 species subtypes    
 
The sequences of human (GenBank: AAB47091.1), mouse (NCBI: NP_001268945.1), rat and 
hamster  (GenBank:  AAL09156.1)  P2Y1  were  aligned  using  MacVector  13.0.4  by  ClustaIW. 
Identity  scores  revealed  97.3%  and  96.8%  similarity  between  human,  rat  and  mouse  P2Y1, 
respectively, revealing that the P2Y1 amino acid sequence is highly conserved across various 
species.  	 ﾠ
	 ﾠ
	 ﾠ One  of  the  main  functions  attributed  to  hP2Y1  is  its  participation  in  platelet 
physiology in tandem with hP2Y12 (167). P2Y1 deficient mice, for instance, suffer from 
impaired  platelet  aggregation,  increased  bleeding  time  and  resistance  to  collagen, 
adrenaline  or  ADP  induced  thromboembolism  (168,  169).  P2Y1  brings  about  platelet 
shape  change  through  a  rise  in  intracellular  Ca
2+  mediated  by  Gα/q11-induced  PLC 
stimulation  (170),  and  its  involvement  in  thrombin-dependent  tissue  factor  induced 
thromboembolism renders it a potential target for antithrombotic drugs. Other reported 
functions of P2Y1 include the formation and maintenance of postsynaptic specializations 
in neuromuscular junctions (171), the regulation of vascular tone in the placenta (172), 
modulation of bone formation and resorption (173), the parasympathetic inhibition of 
colonic smooth muscle (174) and possibly the inhibition of long-term depression in the 
prefrontal cortex (175).	 ﾠ
 
1.5  The P2Y11 receptor   
P2Y11 was first cloned from human placenta cells (176) and showed the following 
order of potency for agonist activity: AR-C67085MX≥ ATPγS ≈ BzATP > dATP > ATP 
> 2meSATP >>> ADP (176-178), suggesting that it is the only P2Y receptor selective for 
ATP. UTP was also reported to induce Ca
2+mobilization at the P2Y11 receptor (153). This 
receptor is competitively antagonized by suramin, AMPS and NF157 (150).  The closest 
homolog of P2Y11 is the P2Y1 receptor, with which it shares 33% amino acid identity, 
followed by the P2Y2 receptor (28%) (121).   
 
The human P2Y11 receptor possesses a unique profile among other P2Y receptors. 
In fact, it strongly couples to the dual activation of Gq/11 and Gs and as such is the only Chapter 1  Introduction 
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P2Y  receptor  linked  to  the  stimulation  of  adenylyl  cyclase  (149,  177,  179,  180). 
Experimental strategies including PLC inhibition, prostaglandin synthesis, chelation of 
intracellular calcium and down-regulation of PLC were employed to ascertain that the 
P2Y11-mediated increase in cAMP is indeed a function of Gs and not a by-product of IP3 
and PKC activity (178, 181).   
 
The gene for the P2Y11 receptor maps to chromosome 19p31 (182). It possesses a 
unique feature, namely the presence of a 1.9-kb intron sequence that interrupts its open 
reading  frame  and  separates  the  first  exon  of  the  gene  from  its  second  exon  (183). 
Furthermore, the hP2Y11 gene is contiguous to the gene encoding the human orthologue 
of SSF1 with which it was found to ubiquitously undergo intergenic splicing in human 
organs (183). The fusion protein produced from the chimeric transcripts, however, was 
only detected following recombinant overexpression.  
 
The hP2Y11 receptor is widely distributed throughout the human body. Northern 
blotting has detected significant levels of P2Y11 mRNA in the human spleen, intestine 
and  liver  (176,  183).  Quantitative  RT-PCR  analysis  has  further  revealed  that  hP2Y11 
mRNA is relatively highly expressed in all tissues compared to other P2Y genes (166). 
hP2Y11  is  most  abundant  in  the  brain,  pituitary,  spleen  and  lymphocytes,  localizes 
moderately to most other tissues, and is least present in liver, cartilage and bone (166).  
 
The  expression  profile  of  hP2Y11  and  its  differential  coupling  to  two  distinct 
signalling  pathways  points  to  its  critical  contribution  to  a  palette  of  physiological 
responses. hP2Y11 is involved in the modulation of the immune response by activation of 
human dendritic cells (DCs) (184). For instance, exposure to low levels of ATP triggers a 
graded  action  on  maturing  DCs.  This  up-regulates  the  expression  of  stimulatory 
molecules on one hand, but suppresses the production of cytokines such as TNF-α and 
IL-12,  on  the  other,  resulting  in  an  altered  chemokine-receptor  profile  (185).  Low 
concentrations of ATP have also been found to potentiate the migration of Monocyte-
derived  DCs  (MoDCs)  into  sites  of  inflammation.  Upon  arrival  to  the  epicentre  of 
inflammation, however, the accumulation of ATP inhibits cell movement, an effect that 
might prolong exposure to maturation inducing factors and aid in antigen internalization 
(186).  
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A number of studies also suggest a role for hP2Y11 in the differentiation of cells of 
the early human myeloid linkage. In fact, hP2Y11 has been reported to contribute to the 
ATP-induced  differentiation  of  HL-60  promyelocytic  leukemia  cells  through  the 
activation of protein kinase A (187, 188). RT-PCR and northern blot analysis similarly 
spotted  the  expression  of  hP2Y11  in  NB4  promyelocytic  leukemia  cells,  where  it  is 
envisioned to mediate the ATP-induced granulocytic commitment of the cells (189). The 
absence of hP2Y11 expression in neutrophils, which constitute terminally differentiated 
myeloid cells, implies a preferential action in the early stages of maturation.  
 
Another interesting patho-physiological role of hP2Y11 is the induction of secretion 
in  pancreatic  duct  epithelial  cells  (PDEC)  through  the  activation  of  cystic  fibrosis 
transmembrane  conductance  regulator  (CFTR),  a  cAMP-activated  Cl
-  channel  (190). 
Feng  et  al.  also  hinted  to  a  possible  implication  of  hP2Y11 in  mast  cell  physiology, 
whereby the receptor could attenuate cytokine production to help combat inflammation 
(191).  The  involvement  of  P2Y11  in  inflammation  further  extends  to  the  field  of 
cardiovascular disease, as the P2Y11 polymorphism Ala-87-Thr is associated with both 
increased  C-reactive  protein  and  heightened  risk  of  myocardial  infarction,  thus 
constituting a potential target for novel drug development (192).  
 
Other effects attributed to hP2Y11 embrace cell cycle arrest and sensitization to 
death in endothelial cells (193), abrogation of apoptosis in neutrophils (194), and the 
parasympathetic inhibition of colonic smooth muscle (174).  
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1.6 Interaction between P2Y1 and P2Y11 
One  of  the  most  striking  characteristics  exhibited  by  the  human  stomach  is  its 
capacity for accommodative relaxation, i.e. its ability to expand from around 75mL to 2L 
upon  food  ingestion,  a  capacity  mediated  by  hP2Y11  in  response  to  parasympathetic 
inhibition.  Parasympathetic  inhibition  is  provoked  by  the  rapid  hyperpolarization  of 
SMCs following the activation of calcium-activated potassium channels (SKCa and BKCa). 
This  phenomenon  is  mediated  by  several  autonomic  neurotransmitters,  including 
extracellular  ATP.  Upon  activation  by  ATP,  P2Y  receptors  evoke  a  rapid  rise  in 
intracellular Ca
2+ leading to the opening of SKCa and BKCa channels and to the subsequent 
hyperpolarization of the cell (174, 195). King and Townsend-Nicholson have provided 
evidence for the involvement of P2Y1 and P2Y11 receptors in the fast and slow relaxation 
of gut SMCs (174), proposing that P2Y11-mediated purinergic inhibition may only be 
fully active when the cells are constantly excited and depolarized.  cAMP, which acts as a 
molecular switch for the α subunit of BKCa, enhances the probability of the channel’s 
open state via subunit phosphorylation (196). The coupling of cAMP production to the 
mobilization of intracellular Ca
2+ thus seems to fine-tune the duration and amplitude of 
smooth muscle relaxations and the Gs-mediated P2Y11 activity provides a mechanism for 
modulating this relaxation. For such a delicate balance to be maintained, intricate cross-
talk between P2Y1 and P2Y11 may be required and could involve direct contact through 
oligomerisation. Additionally, P2Y11 activation might also be implicated in the inhibition 
of  insulin-mediated  lepton  production  and  stimulation  of  lipolysis.  These  interesting 
findings highlight the role of hP2Y11 in obesity and reveal its importance as a potential 
pharmaceutical target (197).  
 
The work undertaken for this doctoral project investigates the possible interactions 
between P2Y1 and P2Y11, thought to occur in the taenia coli of the guinea pig, by creating 
a  recombinant  model  co-expressing  both  receptors.  P2Y11,  which  induces  the  slow 
relaxation of SMCs, is of particular interest as it has been reported to crosstalk with other 
receptor subtypes, including P2Y1 and M3-muscarinic receptors (55, 198). M3 receptors 
mediate the excitation of SMCs upon activation by acetylcholine. Their excitatory action 
is  suppressed  by  the  non-selective  antagonist  atropine  and  can  also  be  inhibited  by 
extracellular  ATP  in  a  PLC-dependent  fashion  through  the  activation  of  P2YRs. 
Interestingly, the addition of forskolin to SMCs was found to result in an ambiguous 
effect on excitatory and inhibitory responses (198). For instance, the forskolin-mediated 
activation  of  adenylyl  cyclase  was  found  to  cause  a  hyperpolarization  of  the  cell.  In Chapter 1  Introduction 
	 ﾠ 33	 ﾠ
atropine-treated cells, inhibitory junction potentials (IJPs) were not affected by forskolin. 
However, in cells untreated with atropine, forskolin was reported to suppress IJPs and to 
induce  excitatory  junction  potentials  EJPs  (198).  This  complex  response  was  not 
influenced by a rise in intracellular cAMP concentration. A possible explanation of this 
observation is that cAMP increase activates protein kinase G, which in turn induces the 
opening of calcium-dependant potassium channels (174). However, this ambiguity could 
also point to possible interactions between M3 receptors and P2Y receptors, especially 
P2Y11, which couples to Gs.  
 
The  other  proposed  partner  of  P2Y11  is  the  P2Y1  receptor,  which  is  thought  to 
mediate the fast relaxations of smooth muscle cells. In a paper summarizing her doctoral 
work,  Ecke  reported  that  P2Y1 and  P2Y11 are  able  to  oligomerize,  thus  enabling  the 
desensitization  of  P2Y11.  In  fact,  when  expressed  alone,  the  P2Y11 receptor  does  not 
internalize.  In  the  presence  of  its  interacting  partner,  however,  P2Y11R  was  found  to 
undergo endocytosis and this oligomerisation-induced internalization was reduced by the 
knock-down of P2Y1 (55), suggesting that oligomerisation could regulate the expression 
levels of P2Y11 at the plasma membrane.  
 
1.7 Aims of the project  
Building on this foundation, the project undertaken for this thesis sheds light on the 
pharmacology and interaction of two components of the tripartite (hP2Y1- hP2Y11-M3) 
model involved in controlling gut smooth muscle function, namely P2Y1 and P2Y11. The 
driving motive behind this study is that a better understanding of the signalling profiles of 
co-expressing receptors, which often differ from those of individual receptor subtypes, 
offers novel avenues for the development of therapeutic targets. This is especially true if 
the co-expressing receptors participate in the formation of a functional heterodimer as it 
would  enable  structural  information  to  be  used  to  inform  drug  design.  In  particular, 
studying the interaction between P2Y1 and P2Y11 could permit the discovery of a drug 
that targets the relaxation of stomach SMCs in obese patients. Obesity constitutes a major 
eating  disorder  of  our  time  and  the  most  employed  anti-obesity  therapy  is  currently 
bariatric surgery, an invasive medical procedure associated with serious health hazards 
such  as  morbidity  and  mortality.  Pharmacologically,  three  anti-obesity  drugs,  namely 
rimonabant, sibutramine and orlistat, were previously available in the market, two of 
which  were  recently  withdrawn  due  to  adverse  health  effects.  For  instance,  the 
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of satiety but provoked undesirable psychiatric symptoms such as anxiety and depression. 
Sibutramine, withdrawn in 2010, caused blood vessel constriction and hypertension. The 
third drug, orlistat, is still available although it leads to faecal incontinence, produces 
minor weight loss and is only used as a temporary support for dietary regimes (199). 
These failings underpin the lack of safe and effective anti-obesity medicaments, thus 
highlighting the pressing need for further pharmacological research in this field. Given 
the huge potential of GPCRs as drug targets, the study of P2Y1 and P2Y11, which are 
directly involved in stomach relaxation, falls into the effort to palliate this shortage of 
treatment  options.  The  driving  ambition  behind  this  research  is  to  devise  a  chemical 
gastric band that could replace aggressive bariatric procedures. 
 
The aim of this thesis was thus to commence work in this area by investigating the 
pharmacology and ligand selectivity of P2Y1 and P2Y11 in a co-expressing system with 
the following three aims:  
 
Aim 1: To study the effect of co-expression on the signalling profile of P2Y1 and P2Y11, 
by characterizing the nucleotide-mediated calcium responses of a recombinant system co-
expressing both receptors.  
Aim 2: To distinguish between P2Y1 and P2Y11 signalling properties and identify ligand 
responses  specific  to  the  co-expressing  system  by  characterizing  the  pharmacological 
properties of the individual signalling profile of each receptor expressed in isolation.  
Aim 3: To use antagonists to characterize novel pharmacological sties identified by aims 
1 and 2.  
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Chapter 2 
Materials and Methods 
 
2.1 Tissue culture techniques  
The  following  sections  depict  the  basic  cell  culture  splitting  and  passaging 
techniques employed in this project, as well as the protocols used to generate the stably 
transfected CHO-K1-hP2Y11 clones 6 and 13 and the 1321N1-hP2Y1 cell line.  
 
2.1.1 Cell lines and cell culture conditions 
Adherent CHO-K1 (Chines Hamster Ovary) cells were acquired from the European 
Collection for Cell Cultures (ECACC). The cells were grown in either a T75 or T150 tissue 
culture  flask  using  a  50:50  Dulbecco’s  Modified  Eagle’s  Medium 
(DMEM/Sigma)/Ham’s Nutrient Mixture F-12 (Sigma) supplemented with 50mL of 10% 
Fetal  Bovine  Serum  (FBS/Sigma)  and  5mL  of  10%  L-Glutamine  (Sigma).  Adherent 
1321N1  human  astrocytoma  cells  (ECACC)  were  cultured  in  Dulbecco’s  Modified 
Eagle’s Medium supplemented with 50mL of FBS and 5mL of 10% L-Glutamine.  The 
used  media  were  stored  in  a  4°C  fridge  for  a  maximum  length  of  six  weeks  before 
replenishing the L-Glutamine. Cells were grown at 5% CO2 in a 37°C humidified tissue 
culture incubator (Heraeus) and were passaged, transfected and manipulated in a class II 
Laminar flow safety cabinet (Heraeus).  
 
2.1.2 Passaging, splitting and counting 
The cells were split and passaged when they reached 100% confluence, forming a 
monolayer that occupied the entire surface area of the flask. The manipulated cells were 
first  washed  with  10mL  of  Dulbecco’s  Phosphate-Buffered  Saline  (DPBS/Sigma) 
following aspiration of the existing cellular medium. The cells were then incubated in 
10mL of DPBS-EDTA buffer, containing 0.5mM EDTA, to detach them from the growth 
surface. The DPBS-EDTA buffer was left for three minutes at room temperature before 
the cells were lifted. The cells were then typically split and passaged at 1:5, 1:10 or 1:20 
with respect to the surface area of the flask depending on the speed of their growth cycle. 
The resuspended cells were then used to 1) reseed the flask or other flasks, 2) create 
freezer  ampules  for  storage  of  cell  lines  or  3)  prepare  96  well  plates  used  for  high-
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2.1.3 Cellular density measurement 
To determine the volume of cell suspension needed to achieve the desired split, the 
density of resuspended cells was measured using the CASY® Cell Counter and Analyser 
System  Model  TT  (INNOVATIS),  a  technology  that  performs  “standardized  cell 
counting methods, viability checks, aggregation correction, volumetric measurement with 
high measuring range dynamics.” A tailored setup, specifying the selected measuring 
parameters  (used  capillary,  X  axis  or  range  of  size  distribution,  sample  volume  and 
number of cycles), the evaluation parameters (dilution factor, Y axis, evaluation cursor, 
normalization cursor, % calculation, debris, aggregation correction, and mean volume) 
and output parameters (interface, page feed, print mode and graphic) was created and 
used throughout the project for all cell count measurements. After the cells were detached 
from the flask, approximately 1mL of the suspension was transferred into a clean 1.5mL 
Eppendorf test tube. 
 
In order to perform the cell count, a CASY
®-cup was first filled with 10mL of 
CASY
®ton buffer (Roche). 100µL of the aliquoted cell suspension was then added to the 
buffer, following which the lid of the cup was secured and the cup was tilted a few times 
to mix the sample. The vial of diluted sample was placed on the platform below the 
measuring capillary, allowing an external electrode to be inserted into the sample. The 
START button was pressed to initiate the measurement, which calculates the number of 
cells  present  in  a  given  sample  based  on  the  resistance  measurement  of  pulse  area 
analysis. During the measurement, 400µL of the sample was aspirated by a precision 
measuring capillary and slowly passed in a measuring pore, through which a low voltage 
was pulsed. The cells exhibited a size or dimension-dependent resistance to the voltage, 
whereby an isolated intact cell generated a higher resistance than a dead lysed cell. The 
resistance resulted from the nucleus membrane rather than the cell surface membrane, 
thus allowing the discrimination between living and dead cells. The density measurement 
was performed in triplicate. CASY
® automatically operates the necessary steps, taking 
into account the dilution factor. A size distribution of the sample thus appears in the 
display,  together  with  a  complete  numerical  evaluation  of  the  measurement  data, 
specifying  the  number  of  viable  cells  in  the  measured  sample  in  cells/mL  and  the 
percentage viability of the cells in the sample.  
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The density of resuspended cells was measured for each 1) cell passage and 2) 
FLIPR cell plate set-up in order to ensure that the same density of cells was plated across 
experiments for consistency and reproducibility purposes.  
 
2.1.4 Transfection of cells with plasmid DNA 
Generation  of  the  stable  CHO-K1  cell  line  expressing  human  P2Y11  was 
undertaken using the calcium phosphate-DNA precipitate formed in BES method, a high 
efficiency technique suitable for the stable transformation of cells with circular plasmid 
DNA.  Two  different  pools  of  CHO-K1-hP2Y11  were  generated  by  transfecting  two 
independent aliquots of cells, each plated at the same density, with different amounts of 
hP2Y11 cDNA. 
The exponentially growing untransfected CHO-K1 cells were grown in the tissue 
culture  flask  until  they  reached  100%  confluence.  The  cells  were  then  split  and 
transferred into a clean 50mL Falcon tube. The densities were then counted and cell 
suspensions of 20,000 to 25,000 cells/cm
2 were each plated in two 10cm petri dishes. The 
cells  were  incubated  overnight  in  10mL  of  DMEM/  Ham’s  F12  mixture  until  they 
achieved  100%  confluence  and  were  ready  for  transfection.    For  this  purpose,  two 
different mixtures of calcium phosphate-DNA, containing different amounts of hP2Y11 in 
pcDNA3 plasmid DNA, were prepared in order to establish two different pools of CHO-
K1-hP2Y11, pools 0.5 and 1.0. In a 15mL Falcon tube, 15µL of caesium-purified hP2Y11 
in pcDNA3 plasmid DNA (15µg) was mixed with 50µL of 2.5M CaCl2 and 435µL of 
ddH2O. The mixture was gently vortexed with the cap off, while 500µL of 2xBBS was 
added dropwise to the mixture, following which it was incubated for 20 minutes at room 
temperature. The entire mixture (1mL) was added dropwise to the untransfected CHO-K1 
cells and the mixture was gently swirled to allow even distribution of the DNA mix in the 
medium. The transfected CHO-K1 plate was then placed in a capsule filled with 3% CO2, 
sealed and incubated inside the 37°C incubator for 24 hours. After removal from the 3% 
CO2 chamber, the transfected CHO-K1-hP2Y11 pools 0.5 and 1.0 were passaged using 
2.5mL  PBS-EDTA,  transferred  to  a  T75  flask  each,  and  then  placed  in  the  5%  CO2 
incubator for an additional 24 hours before the selection for stable transformants was 
initiated using a protocol modified from Chen and Okayama (200).  
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2.1.5 Generation of stable cell lines  
After transfection of the CHO-K1 cells with hP2Y11 cDNA, the newly produced 
CHO-K1-hP2Y11 pools 0.5 and 1.0 were subjected to selection for three weeks in growth 
medium  containing  Geneticin  (G418).    The  cell  lines  were  washed  using  DPBS, 
replenished  with  fresh  DMEM/  Ham’s  F12  mixture  following  which  the  antibiotic 
Geniticin was introduced at a final concentration of 400µg/µL to the T75 flasks containing 
pools 0.5 and 1.0, respectively. The selected cell lines were kept in the 37°C incubator, 
washed with DPBS and replenished with fresh medium containing the antibiotic once 
every 5 days for approximately 3 weeks. During the selection process, mass death of 
untransfected cells, coupled to the expansion of cellular colonies bearing successfully 
transformed  cells  resistant  to  Geneticin,  were  observed.  When  cell  death  had  finally 
ceased,  and  the  successfully  transfected  cells  had  grown  to  100%  confluence,  the 
established CHO-K1-hP2Y11 pools were aliquoted for freezing purposes, and cloned to 
generate CHO-K1-hP2Y11 clones of varying hP2Y11 receptor density.  
 
2.1.6 Collection and freezing of stably transfected cell lines  
Freezer cryotubes were created and labeled for the long-term storage of the newly 
created cell lines. The monolayer of cells in the T75 flask was first washed with DPBS 
then detached using 15mL DPBS-EDTA buffer at room temperature for two minutes. The 
cell suspension was transferred to a clean 50mL Falcon tube, centrifuged for 5min at 
1000rcf, following which the tube was removed from the centrifuge and the supernatant 
was aspirated. A 10% DMSO-FBS mixture was prepared by adding 9mL of thawed FBS 
to 1mL of DMSO.  The cell pellet was resuspended in the DMSO-FBS mixture, and the 
obtained  preparation  was  distributed  into  cryotubes  (1mL/tube).  The  ampoules  were 
stored in a -80°C freezer.  
 
  The steps described in the previous section were also employed for the creation of a 
stably transfected CHO-K1-hP2Y11 clones 6 and 13 as well as a 1321N1-hP2Y1 cell line, 
which was generated using hP2Y1 in pcDNA3 plasmid DNA provided by Dr. Andrea 
Townsend-Nicholson.    
 
2.1.7 Cloning by limiting dilution  
Limited dilution cloning was used in order to isolate single clones derived from a 
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the parent cell cultures, seeding aliquots of the obtained suspensions in the wells of 96 
well plates, then screening the plates for wells containing monoclonal cell colonies.  
 
  The confluent cells were detached from a flask, transferred to a clean 50mL Falcon 
tube and counted to determine the volume of cell suspension required to generate a 5x10
4 
cells/mL dilution. The appropriate volume of cells was transferred to a sterile 1.5mL 
Eppendorf tube and culture medium was loaded to achieve the final volume. Sequentially, 
1mL of the obtained 5x10
4 dilution was dispensed into another tube and loaded with cell 
medium to generate a dilution of 5x10
3 cells/mL. 1mL of this dilution was then added to 
another tube following which culture medium was loaded to produce a 5x10
2 cells/mL 
dilution. Five additional serial dilutions were performed using this final dilution (5x10
2 
cells/mL). In fact, for each pool respectively, 5.6mL of the 5x10
2 cells/mL dilution were 
added to 44,4mL medium to generate a dilution of 10 cells/well. Then, 25mL of this 
dilution were added to 25mL of medium to produce a dilution of 5 cells/well and this 
sequential dilution was repeated (2.5 cells/well and 1.25 cells/well) until a final dilution 
of 0.625 cells/well was obtained.  Of these different dilutions, only the 1.25 cells/well and 
0.625 cells/well dilutions were retained for both pools. The 1.25 and 0.624 dilutions were 
loaded onto a separate 96 well plate each at a concentration of 180µL/well for each pool 
respectively. The resulting plates were incubated in the 5% CO2 incubator at 37°C for 
approximately 3 weeks. Each plate was regularly screened using a light microscope and 
the wells containing a single colony were marked and regularly checked. Of the various 
wells  containing  single  clonal  lines,  30  clones  (wells)  were  randomly  selected  and 
allowed  to  grow  to  confluence.  The  24  most  confluent  wells  were  passaged  and 
transferred into a T75 flask each for further experimentation. They were also aliquoted 
into cryotubes for storage at -80°C. 
 
2.2 The calcium mobilization assay 
  The  Fluorometric  Imaging  Plate  Reader  (FLIPR)  is  a  technology  employed  for 
intracellular calcium mobilisation assays. The basic premise behind these assays is that 
studied cells are loaded with a calcium-sensitive dye that emits fluorescent signals upon 
the binding of calcium mobilized from intracellular stores in response to activation of Gαq 
coupled GPCRs. This technique constitutes a standard approach for the pharmacological 
characterization  and  determination  of  relative  potencies  of  ligands  at  receptors,  thus 
allowing a quantification of agonist effects. The used dye is commercially available and 
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conducted in this project utilized the Fluo-4 NW Calcium Assay Kit (Starter Pack with 
Buffer, Invitrogen™/ Molecular Probes®, F36206). The Fluo-4 dye is supplied with pre-
treatment of the acetoxymethyl esters, which provide high permeability through the cell 
membrane. Moreover, the dye absorbs strongly at a wavelength of 488nm upon excitation 
by an LED laser. Because of this strong absorption, Fluo-4 exhibits high fluorescence 
emission, and is able to detect calcium concentration at a Kd of 345nM. In the FLIPR 
assay, the Fluo-4 dyes were loaded, per the manufacturer’s instructions, in an assay buffer 
containing 1) HEPES to maintain an optimal pH level of 7.3 and 2) probenecid to avoid 
anion exchange protein extrusion of the dyes.  
 
2.2.1 Cell Plating 
  Cells  were  grown  in  a  T75  flask  until  they  became  100%  confluent,  washed  in 
DPBS and lifted in 10mL DPBS-EDTA as previously described. The cells were counted 
in order to measure the volume of suspension required for a 2x10
6 cells/mL dilution. The 
appropriate volume of cells was then added to the medium for a final volume of 15mL, 
and 100µL of the mixture was seeded onto each well of a 96 well poly-D-Lysine black 
plastic plate with clear bottom (final concentration approximately 10,000 cells per well). 
The plate was then incubated for 48 hours at 37°C in the cell-culture incubator, or until a 
confluent monolayer of cells was observed in each well.  
 
2.2.2 Dye loading 
  77mg of probenecid powder were resuspended in 1050µL of assay buffer and the 
mixture  was  vortexed  until  a  homogeneous  solution  was  obtained.  The  dye  vial  was 
heated for 15 min in a 37°C incubator. After removal from the incubator, 10.5mL of 
assay buffer and 105µL of probenecid were dispensed into the dye vial, following which 
the lid was secured and the vial was tilted a few times to ensure the even mixing of the 
components. The content of the vial was then poured into a plastic reservoir. Meanwhile, 
the 96-well FLIPR cell plate was taken out of the incubator, and the medium was flicked 
off into the sink.  Using an eight-channel pipette, 100µL of dye mixture was loaded into 
each well of the 96 wells of the plate. The plate was then wrapped in aluminum foil to 
protect the dye from the light and incubated in the 37°C incubator for 30 minutes, then 
for an additional 30 minutes at room temperature to allow the dye to load.   
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2.2.3 Creating ligand plates  
  In order to investigate the functional response of the assayed cells to agonists and 
antagonists of interest, serial dilutions were created for each drug. The concentrations 
were  calculated  in  –log  units  and  the  correct  volumes  needed  for  the  dilutions  were 
determined. The serial dilutions were prepared as 10x concentrated stocks in DPBS. The 
agonist dilutions were loaded separately into clear V-bottom 96 well plates (Greiner Bio-
one). Seeing as each well of the drug plate contains about 15-30µL of ‘dead space’ where 
the aspiration of the liquid becomes difficult, a sufficient volume of ligands (15-30µL) 
was thus added to each well of the drug plate to ensure proper removal of the agonist 
during the assay. Antagonist dilutions, on the other hand, were added, when required, to 
the incubating cells at a volume of 10µL within the first five minutes of the one hour 
incubation in order to allow a minimum of 25 minutes for the antagonist-receptor binding 
equilibrium to occur.  
 
2.2.4 Running the FLIPR assay  
  The calcium measurement assays were conducted using the FLIPR® (Fluorometric 
Imaging  Plate  Reader)  Tetra  High  Throughput  Cellular  Screening  System  (Molecular 
Devices). This technology comprises an integrated 96-, 384-, or 1536- well pipettor and 
can accommodate multiple reagent reservoirs. The FLIPR machine captures an image of 
each well of the plate simultaneously using a cooled charge-coupled device (CCD) at the 
speed of an image per second, a feature that is fundamental to the measurement of the 
rapid calcium response initiated by GPCRs. Hence, the FLIPR machine emits a beam at 
488nm as mentioned above, and records the change in fluorescence signal emitted by the 
dye loaded onto the cells over a given time course, thus drawing a calcium profile of the 
studied agonists.  
 
  After an hour of incubation at 37°C, the lid of the cell and agonist plates were 
removed.  The  plates  were  placed  in  their  respective  reading  positions  in  the  FLIPR 
machine previously set at 37°C, and the tips were loaded. Before agonist addition into the 
cell plate, a test signal reading in arbitrary fluorescence units (RFU) was conducted in 
order  to  evaluate  the  dye-loading  efficiency  and  variability  across  the  cell  plate. 
Furthermore, the CCD camera has a specific saturation level above which the camera 
cannot  resolve  changes  in  fluorescence.  The  maximum  saturation  of  the  CCD  in  the 
FLIPR Tetra reportedly occurs at 9000RFU, and the standard deviation error should be 
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was lowered from 0.4 to 0.1. The shutter speed and the laser power were also adjusted 
based on the initial fluorescence levels prior to agonist activation to ensure optimal signal 
detections.  Once  the  signal  test  was  performed,  and  the  camera  gain  and  excitation 
intensity parameters were fixed, the reading run was initiated.  
 
  The  internal  robotic  system  of  the  FLIPR®  Tetra  machine  was  programmed  to 
aspirate 21µL agonist/antagonist from the drug plate, to dispense 11µL of the aspirated 
volume into each well of the cell plate. The agonists were aspirated from each well at the 
same time, and simultaneously dispensed into the corresponding wells on the cell plate. 
The fluidics of FLIPR® Tetra do not employ the gas pressure system and the pipette tips 
were thus immersed into the medium during dispensing. Moreover, the machine utilizes 
an LED excitation system whereby fluorescent signals are emitted from the dye following 
excitation and passed through an emission filter (515-575nm for FLIPR® Tetra). These 
emission filters connect to the CCD camera located underneath the cell plate, allowing 
fluorescent signals to be collected every second.  
 
  Following initiation of the run, the agonists were added to the cell plate at t=10 
seconds, allowing a visualization of the baseline fluorescence existing in the studied wells 
prior to agonist addition (t=0 to 9 seconds). Upon agonist introduction into the cell plate, 
the change in calcium fluorescence due to the mobilization of calcium from intracellular 
stores was recorded over 180 seconds by the CCD camera and the output was sent to a 
PC coupled to the FLIPR device. The recorded data saved and exported onto the Excel 
software  for  statistical  analysis.  They  were  then  subjected  to  further  analysis  using 
GraphPad Prism.  
   
2.3 Data analysis  
  The  statistical  and  quantitative  analysis  of  data  was  conducted  using  Microsoft 
Excel and GraphPad Prism®. Excel was used for primary calculations based on raw data 
from FLIPR Tetra
® to generate a ΔF/F0 value for each well in the analysed plate. Figure 
2.1 shows a time course trace obtained from the well of a FLIPR plate as visualised in an 
Excel sheet. F0 constitutes the average baseline calcium fluorescence measured between t 
= 0 to t = 9 seconds prior to agonist addition and is expressed in relative fluorescence 
units  (RFU).  ΔF  represents  the  average  calcium  fluorescence  in  relative  fluorescence 
units (RFU) due to agonist addition to the well and is calculated using the following 
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following agonist addition and usually occurs between t = 10 to t = 13 seconds. This 
decrease is thought to result from the mechanical action of the tip dispensing the agonist. 
Fmax represents the maximum calcium response to the agonist and usually occurs between 
t = 20 to t = 30 seconds. The Fmax and Fmin values were calculated using the appropriate 
Excel  formulas  within  constrained  intervals  to  ensure  that  the  calculated  Fmin strictly 
corresponds to the calcium decrease caused by agonist addition. The obtained ΔF value 
was  divided  by  the  average  baseline  fluorescence  of  the  well,  or  F0,  to  generate  an 
absolute unitless value of the increase in calcium fluorescence produced by the agonist: 
            F = (Fmax – Fmin)/ F0 = ΔF/ F0.  
 
	 ﾠ
Figure 2.1 Estimation of the increase in calcium fluorescence using a kinetic FLIPR 
trace   
The graph shows a kinetic signal trace for a given well of a FLIPR plate as displayed in an Excel 
sheet. The x-axis corresponds to the time course of the calcium response to a given agonist in 
seconds while the y-axis shows the change in fluorescence over time in relative fluorescence units 
(RFU). F0 represents the baseline fluorescence detected prior to agonist addition from t = 0 to 9 
seconds. Fmin is the minimum calcium fluorescence measured following agonist addition while 
Fmax is the peak calcium fluorescence elicited by the agonist. The increase in calcium fluorescence 
for a given well is calculated by normalizing ΔF against F0 using the following formula: (Fmax-
Fmin)/F0 = ΔF/F0.  
 
 
   The Prism® software was employed for the analysis of data processed using Excel, 
including  curve  fitting  through  non-linear  regression  and  statistical  comparison  of 
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calculated parameters using unpaired t-tests and one-way analysis of variance (ANOVA). 
Each  represented  data  set  consisted  of  three  or  more  replicates  (n=3)  for  each 
concentration level. The following section presents an in-depth analysis and comparison 
of the mathematical fits utilized to analyze the performed dose-response experiments. 
 
  The activity of purinoceptors in the studied cell lines (CHO-K1-hP2Y11 clone 6 and 
13, 1321N1-hP2Y1 and 1321N1-hP2Y11) was examined through FLIPR using 8 agonists 
that  will  be  described  in  detail  in  the  Results  chapters.  The  obtained  results  were 
thoroughly analysed according to several mathematical fits. The aim of this comparison 
was  to  detect  the  mathematical  fit  that  best  describes  the  dynamics  of  a  receptor’s 
response to a drug and to pinpoint a rigorous strategy of computing the representative 
EC50 values. The necessity of conducting this evaluation was dictated by the fact that the 
studied CHO-K1-hP2Y11 system comprises several expressed receptors, each of which 
can be activated on its own or in combination with other receptors upon stimulation by 
agonists  like  ATP.  This  co-expression  results  in  an  altered  pharmacological  profile, 
whereby the response of a given receptor protomer to agonists can be significantly shifted 
to the left or the right in the presence of its interacting partner(s) as opposed to the 
receptor when expressed on its own in a null system. Not only is the response shifted to 
the left or right, but some curves do not achieve a clear maximum, making it difficult to 
interpolate an EC50 in the absence of a known maximum. These observed tendencies 
prompted the search for 1) a method to determine the complexity of a response from 
looking at a curve and 2) tools to distinguish between the different components of the 
response. The evaluated methods were 1) the Hill plot method, 2) Prism three-parameter 
equation,  3)  Prism  four-parameter  equation,  4)  Prism  five-parameter  (asymmetric) 
equation, 5) Prism biphasic equation, and 6) Gaddum/Schild EC50 shift.  
 
2.3.1. The Hill equation  
Two methods were employed to determine the EC50 value of an agonist response. 
Historically, and prior to the development of the computational power required for non-
linear  regression  analyses,  EC50  values  were  obtained  from  graphical  plots.  The  first 
attempts to quantify agonist concentration and receptor response relationships emerged 
from  the  study  of  haemoglobin  binding  and  cooperativity,  which  provided  the  first 
insights into receptor behaviour. In 1910, Archibald Vivian Hill, then Scholar of Trinity 
College,  Cambridge,  proposed  a  number  of  equations  in  an  effort  to  describe  the 
relationship between oxygen tension and the percent saturation of haemoglobin (Hb) with Chapter 2     Materials and Methods 
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oxygen (201, 202). His aim was to introduce a general mathematical formula capable of 
accounting for the differential measurements of Hb saturation by oxygen in solutions of 
various  salts,  as  recorded  by  Joseph  Barcroft.  Hill  hypothesized  that  the  presence  of 
different aggregates of Hb in solution could translate into the co-existence of various 
possible  equilibrium  states  between  oxygen  and  Hb,  resulting  in  various  oxygen-Hb 
dissociation curves. He concluded that his equation (III), now known as the Hill equation, 
is the best suited for predicting the dynamics of the studied system, since “the oxygen 
dissociation  curves  of  haemoglobin  under  various  conditions  all  obey  the  following 
equation: 
 
y= Kx
n/(1+Kx
n) (III) 
 
  where y is the percentage of haemoglobin saturation with oxygen, and x the partial 
pressure  of  O2.  K  and  n,  which  are  two  constants,  constitute  the  parameters  of  this 
equation (201, 202).  
 
Hill,  however,  was  perfectly  aware  that  his  equation  lacked  a  tangible  physical 
basis: “My object was rather to see whether an equation of this type can satisfy all the 
observations, than to base any direct physical meaning on n and K” (202, 203). Hill’s 
observation pinpoints the major shortcoming of the Hill method, i.e. that it postulates a 
typical  behavior  of  the  system  independent  of  the  actual  parameters/context  of  the 
interaction. Despite this caveat, the Hill equation was adopted and extended to all major 
fields of bioscientific enquiry due to its inherent ‘curve-fitting descriptive’ powers. For 
instance,  the  discipline  of  pharmacokinetic-pharmacodynamic  modelling,  aimed  at 
elucidating the relationship between drug dose and drug effect, is centered on a derivation 
of the original Hill equation:  
 
E=EmaxC
x/EC
a
50 + C
x 
 
  where E is the predicted effect of the drug, Emax the maximum effect, C the drug 
concentration at time t and EC50 is the drug concentration for which half of the maximum 
effect is obtained. α is the Hill coefficient of sigmoidicity (204). 
  
In a critical review of the Hill equation and its various implications, Goutelle et al. 
indicate  that  this  “aspect  of  the  Hill  equation  is  descriptive,  pseudo-deterministic. Chapter 2     Materials and Methods 
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However,  the  use  of  the  Hill  equation  in  this  way  is  restricted  to  its  mathematical 
properties” (205). Despite its failings, the Hill equation/model remains unavoidable as all 
currently employed curve fitting equations/models constitute derivations of this original 
equation.  In  a  discussion  I  had  with  him  about  the  Hill  equation,  Professor  David 
Colquhoun concluded: “The Hill equation plots a curve through point predictions. If we 
look at it empirically, the Hill equation gives a reasonable fit. Thus, you have no option 
but to stick by it.” 
 
2.4 A brief description of Prism equations and fits  
 
2.4.1 Stimulation equations  
With  this  background  in  mind,  the  different  mathematical  options  and  in-built 
parameter  options  that  Prism  offers  were  explored.    The  Prism  software  fits  curves 
according to a certain set of mathematical assumptions, which for the most constitute 
derivations or modifications of the original Hill equation. However, its flexibility lies in 
that it is able to compare between different fits in order to determine the fit that best 
describes  a  given  dose-response  curve.  Several  curve  fitting  models  are  available, 
including the three-parameter dose-response model, the four-parameter (variable slope) 
model, the 5 parameter or asymmetric model, which can be utilized to quantify what 
Prism qualifies as ‘asymmetric’, or complex curves as well as the biphasic curve, which 
accounts for responses with two distinct phases.  
 
The three parameter dose-response model is most suited for fits that do not involve 
many data points (Figure 2.1). It generates dose-response curves that possess a standard 
slope, equivalent to a Hill slope of 1.0. The four-parameter dose-response curve, on the 
other hand, is intended for larger data sets. It does not presuppose a Hill slope of 1.0 but 
rather interpolates the slope from the data, hence its appellation (variable). This “logistic 
equation” generates a curve by fitting the top and bottom plateaus, the EC50 and the Hill 
slope  factor,  thus  yielding  a  curve  that  is  ‘symmetrical’  around  its  midpoint.  This 
equation, however, fails to account for curves that are not symmetrical, a shortcoming 
that was overcome by adding a fifth parameter, S or unitless symmetry parameter, to 
create a five-parameter logistic equation. An asymmetric curve is generated when S is 
distinct from 1.0. In contrast to the straight-forwardness of software computation which Chapter 2     Materials and Methods 
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calculates  the  Hill  slope  and  EC50  of  a  given  agonist  response,  the  Hill  plot  method 
involves a two-step operation, consisting of transformation followed by linear regression.  
 
 Software equation:  Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X))) 
 
where top and bottom correspond to the plateaus in the units of the Y axis.  
Given that the four-parameter or variable slope equation was the preferred fit for 
most of the analysed data sets, this equation was adopted as the most suitable model for 
curve fitting and calculation of EC50 values of obtained experimental results. In the case 
of data that could not be fit using non-linear regression analysis, connecting lines were 
drawn across the data points and the EC50 values were generated using the Hill equation. 
These  various  mathematical  approaches  are  valid  for  the  analysis  of  single-site 
concentration response curves.  
 
  To  perform  the  Hill  transformation  of  monophasic  curves,  the  Ymax value  or 
highest agonist concentration, which yields the greatest calcium response, is entered for 
software calculations. If the highest concentration of ligand tested does not produce the 
maximum response, a value from a lower concentration corresponding to the greatest 
response is input instead. A linear regression line is plotted through the data points and 
the resulting intercept with the X-axis constitutes the logEC50 of the ligand. However, in 
cases where the data progressed from its minimum to its maximum over four log units of 
agonist concentration and the above-mentioned equations failed to fit a curve through the 
analysed  data-points,  the  data  were  fit  using  the  biphasic  curve  (Figure  2.2).    The 
biphasic-response curve consists of two single monophasic curves, each of which has its 
own Ymax value. The software calculates the LogEC50 value of both the high- and low-
affinity sites, as well as the fraction or proportion of the maximum response due to the 
more potent phase. The nH1 and nH2 values, or Hillslopes of the two portions of the 
response were restricted to 1 for agonist stimulation responses as recommended by the 
Prism
® software help.  
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A.           B.  
   
Figure 2.2 Examples of dose-response curve fits  
 
A. Sigmoidal curve. A sigmoidal monophasic response is symmetrical and is normalized to run 
between 0% and 100%. It has a single EC50 value, which denotes the concentration of agonist that 
yields a response halfway between the bottom and the top. The Prism software estimates the Hill 
slope or steepness of the curve. B. Biphasic curve. The biphasic curve is a derivation of the 
monophasic curve and consists of two distinct phases or components of the response, a high-
affinity site and a low-affinity site. Each phase has its own EC50 value, shown on the graph as 
EC50-1 and EC50-2. 
 
 
2.4.2 Inhibition equations  
In 1947, Heinz Schild, from the Pharmacology Department of University College 
London proposed a method for determining the affinity of an antagonist for its receptor. 
As David Colquhoun points outs, the greatest achievement of Schild was to show that a 
physical  constant  such  as  the  equilibrium  constant  for  binding  of  an  antagonist  to  a 
receptor could be determined even when agonist action is unknown (206). According to 
the Schild equation,  
 
r = 1 + cB 
 
  where r is the dose ratio and cB is the concentration of the antagonist B, which 
constitutes a multiple of its equilibrium constant for binding to its site (206). cB is thus 
defined as:  
 
  cB = [B]/KB  
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The advantage of this equation is that it relies solely on antagonist concentration, 
signifying  that  the  concentration,  affinity  or  efficacy  of  the  agonist  as  well  as  the 
relationship between agonist occupancy and response are irrelevant to these calculations. 
Thus, the dose ratio, or extent of the rightward shift of the agonist dose-response curve 
due to the antagonist, is independent of the nature and magnitude of the agonist response 
(206) (Figure 2.3).  
 
 
A.           B.  
 
 
Figure 2.3 Models of competitive antagonism  
 
A.  Schild  experiment.  A  Schild  experiment  consists  in  adding  different  concentrations  of 
antagonist to increasing concentrations of agonist. In the theoretical example shown above, the 
inhibitor is competitive. It provokes a rightward shift of the agonist response and a reduction in 
agonist potency, thus converting the biphasic agonist response to a monophasic response with a 
significantly lower EC50 value. B. Gaddum/EC50 shift. The curves from A. were fit using the 
Gaddum/EC50 shift equation, which provides a measure of the antagonist action exerted by the 
inhibitor. The antagonist caused a parallel rightward shift of the agonist response, indicating that 
the inhibitor is competitive.   
 
 
  The Schild experiments conducted in the CHO-K1-hP2Y11 clones were analysed 
using  the  Prism
®  software  in  two  steps.  First,  the  various  dose-response  curves, 
corresponding to agonist response in the presence of different concentrations of a given 
antagonist, were analysed to draw the Schild graph. Using global non-linear regression, 
which can define a family of curves as opposed to a single curve, each of the calcium 
curves  was  fit  individually  using  a  comparison  of  two  equations,  namely  the  four-
parameters equation versus the biphasic equation, to ensure that the best fit was achieved. 
Next, the data were analysed using the Gaddum/EC50 shift equation to determine the KB 
and  pA2  values  of  the  tested  antagonist.  The  equation  generates  a  number  of  values 
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shared by the various dose-response curves of the Schild experiment, including 1) the 
EC50 and logEC50 value of the agonist response in the absence of inhibitor, 2) the pA2 
value which corresponds to the negative logarithm of the antagonist concentration needed 
to shift the dose-response curve by a factor of 2, 3) the KB value or the equilibrium 
dissociation constant  (Molar) of the inhibitor binding to the receptor, 4) the Hill slope or 
steepness of the family of studied curves, and 5) the Schild slope which measures how 
well the  observed rightward shift agrees with the prediction of competitive antagonism. 
In  fact,  if  the  inhibitor  is  competitive,  the  Schild  slope  should  equal  1.0.  To  further 
confirm the prediction of competitive antagonism generated by the Gaddum equation, a 
Schild plot was also drawn for each Schild experiment. To obtain the concentration ratio 
values, the data was fit using the sigmoidal-dose response curve (variable slope) and the 
log of the dose ratios or log(DR-1) appeared in the summary table attached to the main 
table of results. Unfortunately, in some instances the software failed to calculate the dose 
ratios  for  all  the  antagonist  concentrations  used.  This  prompted  me  to  calculate  the 
log(DR-1) values manually, using the equation DR = 1 + cB = 1 + ([B]/Kb). The log(DR-
1) values were then plotted in a separate data file and fit using linear regression analysis. 
If the antagonist is competitive, the slope of the obtained line should be 1.0. The Schild 
plot results obtained from both software and manual calculations were closely compared 
to ensure that the results were compatible and accurate.  
 
Finally,  the  inhibition  curves  gathered  from  inhibition  experiments  in  1321N1-
hP2Y1,  1321N1-hP2Y11  and  the  CHO-K1-hP2Y11  clones  were  analysed  using  a 
comparison  of  two  equations,  the  log(inhibitor)  versus  normalized  response-  variable 
slope (three parameters) versus the log(inhibitor) versus  normalized response- variable 
slope  (four  parameters),  to  determine  the  best  fit  for  the  curves.  The  used  equations 
calculate the IC50 value of the studied antagonist, corresponding to the concentration of 
inhibitor  required  to  reduce  agonist  response  half  way  between  the  top  and  bottom 
plateaus of the curve.  
 
2.5 Statistical Analysis using Prism®   
  The results described in this thesis were obtained from a minimum of three trials or 
repeats (n≥3) each performed in triplicate or quadruplicate for a given experiment. The 
biological  repeats  (n)  were  performed  using  the  same  cell  line,  plated  at  a  similar 
concentration  of  detached  cells  and  grown  to  a  comparable  confluence  level  for  all 
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were performed for all trials, following which the plates were incubated with the Fluo-4 
dye and run using an identical FLIPR protocol. The obtained results were expressed as 
the mean + s.e.m of all performed repeats for a given experiment.  Analyses of statistical 
significance  were  performed  using  GraphPad  Prism®.  The  two-tailed  t-test  (95% 
confidence interval), which conducts a comparison between two unmatched groups, and 
one-way  ANOVA  analysis,  which  performs  a  comparison  between  three  or  more 
unmatched groups, were chosen to assess the difference in mean values.  
 
2.6 Molecular Biology Techniques  
 
2.6.1 RNA extraction from animal cells 
  CHO-K1-hP2Y11  clones  6  and  13  cells  were  grown  in  a  T175  flask  until  they 
reached a 100% confluence following which they were washed in DPBS and detached 
using DPBS-EDTA. The cell suspension was transferred to a clean 50mL Falcon tube and 
centrifuged for 5 minutes at 1000 rpm. The supernatant was discarded and the harvested 
cell pellet was frozen in the -20°C freezer. For RNA extraction purposes, the cell pellet 
was thawed on ice, resuspended in 7.5 mL of denaturation solution and left on ice for 15 
min. The cell suspension was sheared using a 19-21G syringe needle until the pellet was 
dissolved. It was loaded onto a 2.5 mL caesium chloride cushion (5.7M Caesium chloride 
(Sigma), 0.1 M EDTA (Gibco) pH 7.5, Sodium Acetate pH 5.5) in Polyallomer Quick-
Seal  TM  Centrifuge  tubes  (Beckman).  The  ultracentrifugation  tubes  containing  the 
different cell suspensions were precisely balanced against each other, with mineral oil 
where necessary, to exclude air bubbles from the tubes, after which they were heat-sealed 
using  the  Beckman  tube-sealer  (Beckman,  Palo  Alto,  California).  The  tubes  were 
centrifuged overnight for more than 14 hours at 31.000 rpm in a SW41 rotor at 20°C in a 
Beckman Coulter OPTIMA L-100 XP centrifuge. Upon completion of the run, the tubes 
were removed from the ultra centrifuge. To extract the RNA, the supernatant including 
the DNA band was collected using a syringe to about 1 cm of the bottom of each tube. 
The remaining liquid was decanted and the tubes were inverted to drain. The bottom 1 cm 
of the tubes was cut and 20µL of 100% ethanol was added to the RNA cell pellet to 
permit its visualization. The bottom of the tubes was then inverted to drain, after which 
the content of the tubes was washed using 150µL TES buffer (10 mM Tris-Cl (Sigma) pH 
7.4, 5 mM EDTA, 1% SDS made from 10% SDS (Gibco)) then transferred to clean 
Eppendorf tubes. Two additional washes with 150µL TES buffer were performed and the Chapter 2     Materials and Methods 
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consecutively obtained volumes were transferred to the same Eppendorf tube. 450µL of 
chloroform: isoamyl alchol mixture solution (24:1, Sigma) was added to the Eppendorf 
tubes containing the washed RNA, mixed and centrifuge for 5 min at 13.5 rpm in a mini-
centrifuge  (Eppendorf).  The  upper  aqueous  phase  containing  the  extracted  RNA  was 
removed and transferred to a new Eppendorf tube. 350µL of the Tris-EDTA-SDS buffer 
was  then  added  to  the  remaining  phase  and  the  content  of  the  tube  was  mixed  and 
centrifuged for 5 minutes at 13.5 rpm. The upper phase was aspirated and added to the 
product yielded by the first extraction. The final volume of 800µL was subsequently 
divided into two, whereby 400µL of solution were added to a 1.5 mL Eppendorf tube 
each. To precipitate the RNA, 40uL of sodium acetate (3M) and 1mL of ethanol were 
added to the tubes. The obtained volume was mixed and left at 20°C overnight to allow 
the RNA to precipitate. The RNA was then recovered by centrifugation for an hour at 
12,000rpm and 4°C. The obtained supernatant was decanted and the RNA pellet was 
washed  using  500µL  of  70%  ethanol.  Each  tube  was  centrifuged  for  five  minutes  at 
13,000rpm for 5 minutes, following which the liquid was aspirated. A second wash was 
performed using 500µL of 100% ethanol followed by centrifugation at 13,000rpm for 2 
minutes. The liquid was then decanted and the tube was covered with a tissue paper and 
kept open for 30 min to dry. The RNA was resuspended in 100µL of RNase free distilled 
water. 
 
2.6.2 Quantification of nucleic acids 
The  extracted  RNA  was  quantified  using  Nanodrop  measurements,  which  can 
determine  the  absorbance  of  a  given  sample  at  different  wavelengths.  The  RNA 
concentration was measured in ng/µL and the OD260/280 ratio of the analysed sample was 
determined. This ratio indicates the purity of RNA, whereby a ratio of approximately 2 is 
accepted as pure for RNA.   
 
2.6.3 DNase treatment of RNA  
  The  extracted  RNA  was  treated  using  RQ1  RNase-free  DNase,  a  DNase  I 
(endonuclease)  which  degrades  both  double  and  single-stranded  DNA 
endonucleotidically, producing 3´-OH oligonucleotides. It was used to make sure that any 
contaminating  DNA  was  removed  from  the  RNA  sample  prior  to  RT-PCR,  thus 
warranting the integrity of the RNA. The DNase digestion reaction was set up as follows:  Chapter 2     Materials and Methods 
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xµL of RNA (10-20µg) 
1µL of RQ1 RNase-Free DNase 10X Reaction Buffer  
or 1µL of 5 x transcription buffer from the Superscript III  enzyme (Invitrogen™) 
RQ1 RNase-Free DNase (1u/µg RNA) 
Nuclease-free water to a final volume of 10µL  
 
The mixture was incubated at 37°C for 30 minutes. It was then loaded with sterile 
distilled water up to a final volume of 200µL and extracted using phenol: chloroform. For 
this purpose, 400 µl of Phenol-cloroform:isoamyl alcohol mixture (25: 24: 1, Sigma) was 
added to the mixture and the tube(s) was centrifuged for 5 minutes at maximum speed. 
The upper aqueous phase was removed and transferred to a new 1.5 ml Eppendorf tube 
and the previous step was repeated a second time. To precipitate the RNA, 0.1V of 3M 
sodium acetate (NaOAc) and 2.5V of 100% ethanol were added to the decanted phase and 
the tube was placed at -20°C overnight. It was then centrifuged at maximum speed for 30 
minutes. The supernatant was decanted and 1 ml of 100% Ethanol was added to the 
pellet, and the tube(s) was left at room temperature for 2 minutes. The tube(s) was then 
centrifuged  for  15  minutes  at  maximum  speed  following  which  the  supernatant  was 
discarded. The pellet was additionally washed with 1ml of 70% Ethanol and the tube(s) 
was spun in the centrifuge for 5 minutes at maximum speed. The ethanol containing the 
supernatant was discarded and the pellet(s) was dried at room temperature for 5 minutes. 
 
2.6.4 Single-stranded cDNA synthesis 
The purified RNA was converted to single-strand cDNA using SuperScript
® II 
Reverse  Transcriptase  (Invitrogen™),  a  DNA  polymerase  that  synthesises  a 
complementary DNA strand from single stranded RNA, DNA or RNA: DNA hybrid. The 
enzyme is genetically engineered through point mutations in its RNAse H active centre to 
reduce RNAse activity, thus eliminating RNA degradation during single-strand cDNA 
synthesis, and increase thermal stability. The kit contains 1) SuperScript
® II RT, 2) 5X 
First-Strand Buffer (250 mM Tris-HCl, pH 8.3 at room temperature; 375 mM KCl; 15 
mM MgCl2), and 3) 0.1 M DTT. Each of the reagents employed for the synthesis reaction 
was mixed and centrifuged before use.  Chapter 2     Materials and Methods 
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For a single-strand cDNA synthesis reaction, a 20µL reaction volume was used 
for  500ng  of  RNA.  The  following  components  were  added  to  a  nucleus-free 
microcentrifuge tube:  
 
1µL of Oligo(dT)12-18 (500µg/ mL) 
xµL of RNA (500ng) 
1µL of dNTP Mix (10mM)  
sterile distilled water to a final volume of 12µL 
 
The mixture was heated to 65°C for 5 minutes and quickly chilled on ice. The 
contents of the tube were collected by brief centrifugation then the following reagents 
were added to the tube:  
 
  4µL of 5X First-Strand Buffer  
  2µL of 0.1 M DTT 
  1µL of RNaseOUT™ (40 units/ µL) 
 
The contents of the tube were gently mixed then incubated at 42°C for 2 minutes. 
1µL of SuperScript
® II RT (200 units) was added to the tube and mixed by pipetting 
gently up and down. The mixture was incubated at 42°C for 50 minutes following which 
the reaction was inactivated by heating at 70°C for 15 minutes.  
 
2.6.5 PCR primers design  
Forward and reverse primer sequences were designed for 1) hamster P2Y1, 2) 
hamster P2Y2, 3) human P2Y11, 4) the housekeeping hamster GAPDH and β-actin using 
MacVector  12.7.4.  The  primers  were  generated  according  to  three  constrained 
parameters, including size: 20-25 nucleotides, melting temperature or Tm (°C): 60-75  
and  percentage  G+C  content:  45-65.  The  final  primers  were  selected  from  a  list  of 
primers and are described below. Oligonucleotides were synthesized by Eurofins MWG 
Operon. 
1- Human P2Y11 cds AF030335:  
[F3]     53-74      5'- ACAAACTCAGTGGGTTCCAGGG -3' 
                   22 nt forward primer 
                   pct G+C:   54.5   Tm:   56.6 
[B2]     361-339     5'- TGATGCAGGTGATGAAGATGACG -3' 
                    23 nt backward primer 
                    pct G+C:   47.8   Tm:   57.3 Chapter 2     Materials and Methods 
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2- Hamster P2Y1 cds AY049063: 
[F1]     54-77      5'- TTCCATGTAAACCTCTATGGCAGC -3' 
                   24 nt forward primer 
                   pct G+C:   45.8   Tm:   56.3 
[B2]     303-280     5'- AACTTCGTAGGTACTCATCGGTGG -3' 
                   24 nt backward primer 
                   pct G+C:   50.0   Tm:   55.4 
 
3- Hamster P2Y2 cds AF314034: 
[F1]    114-137     5'- ACCTGTGCTCTACTTCGTCACCAC -3' 
                   24 nt forward primer 
[B2]     392-371     5'- AGGAAGCAGAGGGTAAAAACGG -3' 
                   22 nt backward primer 
                   pct G+C:   50.0   Tm:   55.6 
 
4- Hamster GAPDH  NM-001244854: 
[F3]    228-250     5'- CAAGTTCAAAGGCACAGTCAAGG -3' 
                   23 nt forward primer 
                   pct G+C:   47.8   Tm:   55.5 
[B2]     537-516     5'- TAAGCAGTTGGTGGTGCAGGAC -3' 
                   22 nt backward primer 
                   pct G+C:   54.5   Tm:   56.5 
 
5- Hamster βACT NM-001244575: 
[F1]    172-195     5'- GCCCAGAGCAAGAGAGGTATTCTG -3' 
                   24 nt forward primer 
                   pct G+C:   54.2   Tm:   57.4 
[B1]     421-400     5'- ACAGCACAGCCTGAATGGCTAC -3' 
                   22 nt backward primer 
                   pct G+C:   54.5   Tm:   55.8 Chapter 2     Materials and Methods 
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2.6.6 Polymerase Chan Reaction (PCR) 
PCR reactions were carried out to amplify the above-mentioned genes in order to 
verify whether they are expressed in CHO-K1-hP2Y11 clones 13 and 6. 25µL reactions 
were prepared in flat cap PCR tubes and contained:  
12.5µL 2xACCUZYME™  Mix or 2xBioMix™  or 2xBioMixRed™ (Bioline) 
1.5µL forward primers  
1.5µL reverse primers  
2µL cDNA  
7.5µL distilled water  
The PCR reactions were conducted in the PCR Express Thermal Cycler (Thermo 
Hybaid)  and  performed  in  three  stages.  The  first  stage  consisted  of  a  5  minutes 
denaturation at 95°C for a single cycle. This was followed by a second stage comprising 
1) 30 seconds of denaturation at 95°C for 30 cycles, 2) 30 seconds of primer annealing at 
the annealing temperature corresponding to each gene for 30 cycles and 3) 1 minute of 
extension at 72°C for a single cycle. The final stage consisted of a 5 minutes extension at 
72°C for one cycle. The finished reaction was held at 4°C. In order to check the presence 
of the amplified PCR products, agarose gel electrophoresis was performed.  
2.6.7 Gel electrophoresis 
To view the PCR products, a 2% agarose gel in 1x TAE buffer was prepared and 
the gel was pre-stained with ethidium bromide (10 mg/ml). cDNA samples were prepared 
by adding 0.5µL of 5x Loading Buffer (Bioline) to 2.5µL of PCR reaction. The gel was 
run in 1x TAE buffer for 30 minutes at 100V. The Invitrogen 1 Kb Plus DNA ladder was 
used  as  standard  marker.  DNA  bands  were  visualized  under  a  UV-  Transiluminator 
(Syngene). Chapter 3  Creation and Characterization of Recombinant CHO-K1-hP2Y11 Clones 6 and 13 
	 ﾠ 57	 ﾠ
Chapter 3  
Creation and Characterization of Recombinant CHO-K1-
hP2Y11 Clones 6 and 13 
 
3.1 Introduction  
P2Y1 and P2Y11 receptors contribute to the relaxation of gut smooth muscle and a 
study  of  their  interaction  would  shed  light  on  the  mechanisms  of  this  relaxation. 
Characterization of the coordinated signalling of two independent P2Y receptors would 
be more readily done in a cell line rather than in a complex tissue, using the detection 
tools  applicable  to  GPCRs.  As  previously  explained,  GPCRs  transmit  their  signals 
through  the  activation  of  a  number  of  G  protein  targets,  which  in  turn  lead  to  the 
mobilization, or production, of secondary intracellular messengers, such as calcium and 
cAMP, respectively.  
 
A number of different functional assays for GPCRs have been developed in order to 
permit  the  screening  of  GPCR  agonist  and  antagonist  activity,  thus  aiding  in  the 
identification of candidate drugs for this group of pharmacologically relevant proteins. 
These screens include assays of fluorescence and/or chemiluminescence detection, which 
measure calcium, cAMP or IP accumulation. Of these various tools, only calcium assays 
constitute  a  High-Throughput  Screening  (HTS)  technique.  The  Fluorometric  Imaging 
Plate Reader (FLIPR), an HTS calcium device, is available at UCL and will thus be 
selected as a suitable platform for the characterization of both P2Y1 and P2Y11 activity 
within recombinant cell lines. In order to distinguish between the activity of each of these 
two receptors, a selective agonist will be selected for each receptor subtype depending on 
its particular pharmacological profile when activated by a series of nucleotide analogues. 
BzATP will be used to characterize P2Y11 while the nucleotide ADP will be employed 
for P2Y1.  
 
This chapter will describe the establishment of a co-expression model of P2Y1 and 
P2Y11 using CHO-K1, which expresses P2Y1 endogenously, as the parental cell line into 
which hP2Y11 will be transfected. This chapter will also describe the use of BzATP to 
correlate functional responses with P2Y11 receptor expression levels in individual P2Y11-
expressing CHO-K1 clones. The relative expression levels of P2Y1 and P2Y11 in gut Chapter 3  Creation and Characterization of Recombinant CHO-K1-hP2Y11 Clones 6 and 13 
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smooth muscle are, at present, unknown. Following an initial estimation of recombinant 
P2Y11 receptor densities, a further characterization of the clones expressing the highest 
and the lowest level of hP2Y11 receptor protein, respectively, will be performed in order 
to establish pharmacological profiles that can be used to select the recombinant model 
that most closely fits the ex vivo model of the guinea pig taenia coli. 
 
  Previous research has identified the formation of a P2Y1:P2Y11 heteromer (55), 
providing  an  opportunity  to  examine  the  pharmacological  properties  of  P2Y1  in  the 
presence of two different densities of hP2Y11. Since the oligomerisation of GPCRs may 
alter the pharmacological profile of the individual receptor components, resulting in a 
novel entity with modified agonist and antagonist affinities, the work undertaken in this 
chapter  will  investigate  the  calcium  responses  in  the  high  expressing  versus  low 
expressing CHO-K1-hP2Y11 clones using a set of 8 purinergic agonists. The resulting 
data will be compared using appropriate statistical tools to evaluate calcium responses. 
Differences in the agonist profiles of P2Y1 and hP2Y11 between the clones could reflect 
the creation of novel sites of agonist activity or oligomerisation of the two purinoceptors 
that could be attributed to the difference in hP2Y11 receptor density. 
 
3.2 Selection of Clonal Cell Lines Expressing hP2Y11  
 
3.2.1 Creation and characterization of stably transfected CHO-K1 cells 
expressing the human P2Y11 receptor  
  A  recombinant  CHO-K1  cell  line  expressing  the  human  P2Y11 receptor  was 
created  using  an  hP2Y11  construct  comprising  the  cDNA  sequence  of  the  receptor 
(GenBank accession number AF030335), cloned between the HindIII and XbaI sites of 
the  pcDNA3  vector  (shown  in  Figure  3.1).  This  construct  was  employed  to  stably 
transfect  CHO-K1  cells  (shown  in  Figure  3.2).  The  CHO-K1  cell  line  expresses 
endogenous P2Y1 (207), P2Y2 (208) and P2X7 (209) . Two different pools of CHO-K1-
hP2Y11 were created by transfecting two distinct aliquots of cells, each plated at the same 
density, with different amounts of hP2Y11 cDNA. The stably transfected pools expressing 
hP2Y11 were subsequently selected using the antibiotic Geneticin.  
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Figure 3.1 The hP2Y11 in pcDNA3 construct  
 
The cDNA sequence (GenBank accession number AF030335) of the human hP2Y11 receptor, 
which is 1113 bp long, was cloned between the HindIII and XbaI sites of the human expression 
vector, pcDNA3 (6474bp), which ensures high-expression stable transfection in mammalian cells. 
This vector possesses a CMV promoter as well as ampicillin and neomycin-resistance markers. 
The formed construct was used to transfect CHO-K1 cells in order to create a CHO-K1 cell line 
stably expressing the human P2Y11 receptor. 
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Figure 3.2 Miscroscopic visualization of CHO-K1 and CHO-K1-hP2Y11 cells  
 
A. CHO-K1 cells pre-transfection. 5x magnification of CHO-K1 cells prior to their transfection 
with the human P2Y11 receptor cDNA. B. CHO-K1-hP2Y11 colony. 5x magnification of a colony 
of CHO-K1 cells after their transfection with human P2Y11 cDNA. The formed CHO-K1-hP2Y11 
colonies were screened using 100µM BzATP to determine different levels of hP2Y11 coupling. C. 
CHO-K1-hP2Y11  clone  13.  10x  magnification  of  CHO-K1-hP2Y11  clone  13,  which  was 
identified as the clone expressing the highest coupling of hP2Y11.  
 
 
  A Ca
2+ signalling assay using FLIPR was employed in order to determine whether 
the transfected hP2Y11 receptor protein was expressed in each of the two pools: pool 1.0 
and pool 0.5. Figure 3.3 shows the functional responses of pools 0.5 and 1.0 to 100µM 
UTP and increasing concentrations of BzATP at 37°C, the physiological temperature of 
mammalian cells. The curves shown in this figure represent the mean of four independent 
experiments, each performed in triplicate, and were fitted using non-linear regression 
with a comparison of two different equations (the three parameter versus the variable 
slope or four parameter equation) to determine the best fit for each curve. Graph A. 
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the calcium response to each agonist concentration using the F/F0 method, while graph B. 
presents the curves generated for peaks measured using area under the curve method 
(AUC). This double analysis was performed to determine whether the data integrated 
using these two methods would look similar. Table 3.1 lists the calcium response in F/F0 
versus AUC for each BzATP dose used.  
 
As the figure shows, BzATP elicited a concentration-dependent response in pools 1.0 and 
0.5 for both methods, signifying that the transfection was successful. The pools gave 
sigmoidal  dose-response  curves  that  achieved  their  maximum  over  two  log  units  of 
agonist concentration, ranging from 10nM to 1µM BzATP (log value: -6 to -8).The EC50 
and pEC50 values for pools 0.5 and 1.0 using the F/F0 versus AUC method are shown in 
Table 3.2. Using unpaired t-tests, there was no statistically significant difference between 
the EC50 values calculated from the F/F0 versus AUC measurement for pool 0.5 (p value 
= 0.9455) and pool 1.0 (p value = 0.6605). Furthermore, BzATP displayed the same 
potency in pool 0.5 versus 1.0 using both measurements (p value = 0.4224 and 0.4863, 
respectively). Moreover, ANOVA analysis revealed no statistically significant difference 
between the pEC50 values of pools 1.0 and 0.5 using the F/F0 versus AUC measurement 
(p value = 0.6581). These statistical tests imply that the BzATP response in the pools is 
consistent across the two peak analysis methods and both can be safely utilized to fit the 
calcium data. For the purposes of this project, the F/F0 method was adopted for peak 
analysis of all the presented data.   
 
 
Agonist 
Concentration 
Calcium Response  
Pool 0.5 F/F0             Pool 0.5 AUC           Pool 1.0 F/F0                  Pool 1.0 AUC 
-4  1.83  3413  1.96  4021 
-4.5  1.76  3332  1.98  3955 
-5  1.73  3225  1.92  3826 
-5.5  1.44  2971  1.52  3331 
-6  1.02  2131  0.75  2261 
-7  0.12  1302  0.08  1355 
-8  0.08  1315  0.07  1293 
Table 3.1 The calcium response to BzATP in pools 0.5 and 1.0 using F/F0 versus 
AUC analysis  
 
The calcium peaks elicited by increasing concentrations of BzATP, ranging from -8 to -4, in 
pools 0.5 and 1.0 were measured using the F/F0 versus area under the curve (AUC) methods. The 
values represent the mean of four different experiments, each performed in triplicate.  
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Figure  3.3  BzATP  elicits  a  calcium  response  at  37°C  in  CHO-K1  cells  stably 
expressing the human P2Y11 receptor 
 
The calcium response to increasing concentrations of BzATP was determined at 37°C for two 
stably  transfected  pools  of  CHO-K1  expressing  the  human  P2Y11  receptor.  The  results  are 
expressed as the average ± s.e.m of four independent experiments, each performed in triplicate. 
The response to 100µM UTP is shown for pool 0.5 (■) and pool 1.0 (■). A. The calcium peaks 
were calculated using the F/F0 method. B. The calcium peaks were calculated using area under the 
curve (AUC) analysis.  
 
 
  EC50  (µM) 
         F/F0                       AUC 
pEC50  
    F/F0                     AUC 
Pool 0.5  1.29 ± 0.17  1.27 ± 0.20  5.90 ± 0.06  5.92 ± 0.07 
Pool 1.0  1.42 ± 0.05  1.52 ± 0.22  5.85 ± 0.01  5.83 ± 0.06 
Table 3.2 The calcium response elicited by BzATP in pools 0.5 and 1.0 
 
The EC50 and pEC50 values of BzATP were determined in pools 0.5 and 1.0 for the F/F0 and AUC 
data.  The  results  are  expressed  as  the  mean  EC50  and  the  mean  pEC50  of  four  independent 
experiments, each performed in triplicate.  
    
 
 
3.2.2  Identification  of  CHO-K1-hP2Y11  clonal  cell  lines  expressing 
different densities of hP2Y11  
CHO-K1-hP2Y11 clones of differing receptor densities were generated through 
dilution sub-cloning of pools 0.5 and 1.0. The 24 most rapidly growing clones were then 
selected  and  screened  using  100µM  BzATP  at  37°C.  Figure  3.4  shows  the  average 
calcium response obtained for each of the 24 clones. As the figure shows, the tested 
CHO-K1-hP2Y11 clones yielded varying calcium responses upon application of a fixed 
concentration  of  BzATP.  One-way  ANOVA  analysis  was  performed  to  evaluate  the 
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statistical significance of the observed differences in response. The p values obtained 
from this analysis made it possible to distribute the 24 screened clones into 5 groups with 
a single level of calcium response each (shown in Figure 3.5).   
 
  As the figure shows, CHO-K1-hP2Y11 clone 13 gave the highest calcium response 
to  100µM  BzATP  and  was  therefore  picked  as  the  clone  of  reference  to  which  the 
calcium responses of the remaining clones were compared. The responses of clones 7 
through 12 showed no statistically significant difference to clone 13 and thus formed a 
group of clones with a comparable calcium response profile. Clones 2 and 19, clones 1 
and  24,  and  clones  6,  17  and  18  were  statistically  significantly  different  to  clone  13 
(p<0.05; p<0.01 and p<0.001, respectively). Due to the lack of quantitative techniques 
allowing the precise determination of receptor density in cellular membranes, and for the 
purposes of this work, the level of calcium response of the screened clones to 100µM 
BzATP  was  considered  as  an  indicator  of  receptor  density,  whereby  a  high  level  of 
calcium response would correlate with a high density of receptor expression, and a low 
level of response with a low density of receptors in the cellular membrane. Accordingly, 
clone  13  was  identified  as  the  highest  expressing  clone,  or  the  clone  expressing  the 
highest density of the hP2Y11 receptor protein, while clone 6 was identified as the lowest 
expressing  clone  or  the  clone  expressing  the  lowest  density  of  the  hP2Y11  receptor 
protein. These two clones were selected for further study in order to establish the specific 
pharmacological  profile  of  P2Y11  when  co-expressed  with  P2Y1  in  the  recombinant 
CHO-K1-hP2Y11 cell line.  
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Figure 3.4 100µM BzATP elicits a calcium response in CHO-K1 clones expressing 
the human P2Y11 receptor 
 
The  calcium  response  to  100µM  BzATP  was  determined  at  37°C  for  24  CHO-K1  clones 
expressing the human P2Y11 receptor. The results are expressed as the average ± s.e.m. of three 
independent experiments, each performed in triplicate.	 ﾠ	 ﾠ
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Figure  3.5  CHO-K1  clones  expressing  the  human  P2Y11  receptor  give  varying 
responses to 100µM BzATP 
 
The 24 CHO-K1-hP2Y11 clones shown in Figure 3-5 have been ordered from left to right from 
largest response to smallest. One-way ANOVA was used to determine the statistical significance 
of differences in response. Clone 13 was identified as giving the greatest calcium response to 
100µM BzATP. Clones 12-7 showed no statistically significant difference to clone 13. Clones 
2,19 gave significantly lower responses to clone 13 (P<0.05). Clones 1,24 gave significantly 
lower responses to clone 13 (p<0.01). Clones 17,18, 6 gave significantly lower responses to clone 
13  (p<0.001).  Clones  13  and  6  were  identified  as  the  highest  and  lowest  responding  clones, 
respectively, of the 24 clones screened and were selected for further study.  
 
 
3.3 Verification of hP2Y11 expression in clones 13 and 6 using RT-PCR 
  To  confirm  that  the  hP2Y11  receptor  was  successfully  transfected  into  the 
recombinant CHO-K1-hP2Y11 clones 6 and 13 and provide an estimate of the levels of 
receptor expression in these cell lines, mRNA was extracted from both clones and reverse 
transcribed into cDNA. PCR reactions were performed using forward and reverse primers 
for  P2Y1,  P2Y2,  P2Y11  and  the  control  housekeeping  genes  β-actin  and  GAPDH 
(Glyceraldehyde-3-phosphate  dehydrogenase).  For  both  clones  6  and  13,  each  PCR 
reaction generated a product that matches the calculated length for the corresponding 
amplified gene, and the distances are shown in Figure 3.6. These results confirm the 
success  of  the  transfection,  demonstrating  that  P2Y1,  P2Y2  and  hP2Y11  are  all  co-
expressed in clones 6 and 13. The PCR reactions for both clones were then run on a 
single agarose gel to compare the band sizes corresponding to P2Y1, P2Y2 and hP2Y11 
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and quantify the relative levels of hP2Y11 expression in clone 6 versus 13.   However, the 
bands were very faint and the quality of the gels poor. Attempts to improve the quality of 
the obtained bands were unsuccessful and the experiments were not carried forward.   
 
 
  A.  
 
Lane 1      Lane 2     Lane 3       Lane 4         Lane 5       Lane 6 
  B. 
 
Lane 1       Lane 2       Lane 3           Lane 4        Lane 5        Lane 6 
Figure 3.6 Agarose Gel Electrophoresis of PCR products in clones 6 and 13  
 
A. Amplification products for clone 6. Lane 1 shows the 1 control KB plus DNA ladder. The band in lane 2 
corresponds  to  β-actin  and  migrated  to  250bp,  which  matches  the  expected  size  of  the  fragment  (250 
nucleotides). The band in lane 3 is GAPDH, which migrated to approximately 300 bp and matches the 
expected length of this fragment (310 nucleotides). The bands in lanes 3,4 and 5 are P2Y1, P2Y2 and 
hP2Y11 respectively and migrated to 250, 270 and 300 bp, respectively, matching the expected lengths of 
the corresponding genes (250, 279 and 309 nucleotides, respectively). B. Amplification products for clone 
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3.4 Calcium responses of clonal CHO-K1-hP2Y11 cell lines  
     This section describes the characterization of clones 13 and 6 using a set 
of eight carefully chosen agonists targeting the three P2Y receptors expressed in CHO-
K1-hP2Y11 cells: P2Y1, P2Y2, and hP2Y11.  The agonists were selected according to their 
potency at activating their target receptors (210). For instance, hP2Y11 was characterized 
using three agonists of different potencies, BzATP, αβmeATP and βγmeATP (BzATP > 
αβmeATP > βγmeATP). The activity of P2Y1 was studied using ADP, which has been 
reported to potently activate this receptor (157),  while that of P2Y2 was tested using 
UTP. Three other purinergic agonists, namely ATP, 2meSATP and ATPγS, which can 
activate  more  than  one  receptor,  were  used  to  examine  the  combined  activity  of  the  
purinoceptors. ATP acts at P2Y1, P2Y2 and P2Y11 (157, 174, 208, 211) although it is most 
potent  at  P2Y2  and  P2Y1  than  P2Y11.  2meSATP  activates  both  P2Y1 and  P2Y11  but 
exhibits a higher affinity for P2Y1 as opposed to P2Y11 (157, 208). ATPγS is an agonist of 
P2Y1, P2Y2 and P2Y11, respectively (157, 174, 208, 211).  
 
The  calcium  response  to  each  of  the  tested  agonists  was  measured  in  three 
separate  experiments  performed  in  triplicate  and  the  obtained  data  were  analysed  to 
calculate a mean EC50 for each ligand. The EC50 values of clones 13 and 6 were then 
compared  using  unpaired  t-test  analysis  to  determine  differences  in  agonist  profiles 
between the clones.  
 
 
3.4.1  Functional  characterization  of  agonist  responses  in  CHO-K1-
hP2Y11 Clone 13, the ‘high’-expressing P2Y11 clone  
Following the identification of CHO-K1-hP2Y11 clone 13 as the clone expressing 
the highest density of hP2Y11 receptor, the potency of a set of 4 ligands (BzATP, ATPγS, 
ATP  and  αβmeATP)  was  tested  using  FLIPR  at  37°C.  Figure  3.7  shows  the  mean 
calcium response of clone 13 cells following the addition of the agonists at increasing 
concentrations, ranging from 1nM to 100µM (log values: -9 to -4). The tested agonists 
successfully induced calcium mobilization in a concentration-dependent manner, whereby 
increasing  agonist  concentrations  resulted  in  the  release  of  increasing  amounts  of 
intracellular calcium from intracellular stores, as reflected by the increase in fluorescence 
detected by the FLIPR Tetra.  
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  The concentration-response curves of the four studied ligands were analysed using 
non-linear regression with a comparison of two different equations (variable slope, or 
four parameter, equation versus asymmetric, or five parameter, equation) to determine the 
best fit for each dataset. The calcium response to ATP, ATPγS and BzATP is sigmoidal 
monophasic and occurs over two log units of agonist concentration, namely 10nM to 
1µM (log value: -8 to -6) for ATP and ATPγS and 100nM to 10µM (log value: -7 to -5) 
for BzATP. Non-linear regression analysis reveals that the preferred fit for these ligands 
is the variable slope, or four parameter, equation. The maximum calcium response to 
BzATP and ATPγS occurs at 100µM, while ATP achieved its maximum response at 
10µM. Using one-way ANOVA analysis, there is no statistically significant difference 
between the maxima for BzATP, ATPγS, ATP and 100µM UTP control in clone 13 (p 
value= 0.97). The maximum responses and the Hill slope of the concentration-response 
curves are listed in Table 3.3.  
 
 
Agonist 
        Hill Slope 
 
Maximum Response 
(F/F0) 
Maximum Response 
(% of 100µM UTP) 
ATP      1.10 ± 0.3   1.99 ± 0.15      101± 5% 
ATPγS      1.29 ± 0.1   1.91 ± 0.15       97 ± 4% 
BzATP      1.50 ± 0.2  1.99 ± 0.1  101.5 ± 1.7 
Table 3.3 Steepness and maxima of the BzATP, ATP and ATPγS curves in clone 13  
 
The Hill slopes of the concentration-response curves for BzATP, ATP and ATPγS in clone 13 
were  estimated  using  non-linear  regression  analysis.  The  maximum  response  to  each  agonist 
(F/F0) was determined and expressed as a percentage of the maximum response to the 100µM 
UTP control. The values shown in this table constitute the average ± s.e.m of three independent 
experiments, each performed in triplicate.  
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Figure 3.7 Concentration-response curves of BzATP, ATPγS, ATP and αβmeATP 
on Ca
2+ mobilization in CHO-K1-hP2Y11 clone 13  
 
The calcium response to increasing concentrations of BzATP (■), ATPγS (▲), ATP (▼) and 
αβmeATP (◆) at 37°C in CHO-K1-hP2Y11 clone 13, which expresses the highest density of the 
human P2Y11 receptor of all clones characterised. The results are expressed as the average ± s.e.m 
of  three  independent  experiments,  each  performed  in  triplicate.  The  response  of  clone  13  to 
100µM UTP is shown.  
 
 
  In contrast, non-linear regression failed to fit a curve to the αβmeATP data and its 
EC50 value could not be determined. In fact, the calcium response to this ligand began at 
10µM and did not reach a clear asymptote by the highest concentration of agonist applied 
(100µM). The maximum αβmeATP response is 0.97 ± 0.2, constitutes 49 ± 11% of the 
100µM UTP control and is statistically significantly different from both 100µM UTP and 
the maximal responses to BzATP, ATPγS and ATP (**, p value= 0.003). The  αβmeATP 
curve is connected using a dotted line for visualization purposes. 
 
  Following this initial round of characterization, CHO-K1-hP2Y11 clone 13 was 
subjected to a second round of investigation using a different set of four agonists (ADP, 
UTP,  2meSATP  and  βγmeATP)  at  37°C.  Figure  3.8  shows  the  mean  concentration 
response curves for these ligands, generated using non-linear regression analysis. The 
tested agonists were applied at increasing concentrations, ranging from 0.1nM to 100µM 
(log values: -10 to -4) and elicited calcium mobilization in a time-dependent fashion.  
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Figure 3.8 Concentration-response curves of ADP, UTP, 2meSATP and βγmeATP 
on Ca
2+ mobilization in CHO-K1-hP2Y11 clone 13  
 
The calcium response to increasing concentrations of ADP ( ), UTP ( ), 2meSATP ( ) and 
βγmeATP ( ) at 37°C in CHO-K1-hP2Y11 clone 13, which expresses the highest density of the 
human P2Y11 receptor of all clones characterised. The results are expressed as the average ± s.e.m 
of  three  independent  experiments,  each  performed  in  triplicate.  The  response  of  clone  13  to 
100µM UTP is shown.  
 
 
As the Figure shows, the calcium response potentiated by UTP is sigmoidal and 
achieves its maximal value over two log units of agonist concentration, ranging from 
10nM to 1µM (log value: -8 to -6). The preferred model for the UTP data is the variable 
slope (four parameter) equation, which fits a monophasic curve to the data. The calcium 
response to UTP reaches its maximum at a concentration of 100µM. Using a one-way 
ANOVA test, there is no statistically significant difference between the maxima for ADP, 
UTP, 2meSATP and 100 µM UTP response in clone 13 (p value= 0.67).  
 
  The calcium responses produced by ADP and 2meSATP were different from those 
of  the  other  six  agonists  tested.  Although  they  were  concentration-dependent,  the 
responses  progressed  from  their  minimum  to  their  maximum  over  four  log  units  of 
agonist  concentration.  Non-linear  regression  analysis  using  a  comparison  of  two 
equations  (four  parameter  versus  five  parameter  equation)  was  unable  to  fit  a  curve 
through these datasets, suggesting that they might be better fit with a biphasic as opposed 
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to a monophasic equation. In fact, all three individual ADP and 2meSATP trials resulted 
in a biphasic concentration-response curve with two distinct plateaus. The first phase of 
the ADP response ranges over two log units of agonist concentration, from 10nM to 1µM 
(log value: -8 to -6,) while the second phase spans over two log units, ranging from 1µM 
to 100µM (log value: -6 to -4). The maximum response is achieved at 100µM ADP. The 
fraction of the curve, or proportion of the maximal response due to the high-affinity site, 
is 0.6 ± 0.05, indicating that this site accounts for approximately 60% of the calcium 
response to ADP. The maximum response (F/F0) to ADP is 1.83 ± 0.13, achieved at 
100µM, and can be expressed as 101 ± 5.4% of the 100µM UTP response. In the case of 
2meSATP, the high affinity site  of the response ranges from 1nM to 100nM (log value: -
9 to -7) whereas the low affinity site occurs between 100nM and 10µM (log value: -7 and 
-5).  The  fraction  of  the  curve  is  0.67  ±  0.04,  indicating  that  the  higher  affinity  site 
comprises  approximately  70%  of  the  calcium  response  elicited  by  2meSATP.  The 
maximum response is achieved at 100µM 2meSATP. The maximum responses and Hill 
slopes of the concentration-response curves for ADP, 2meSATP and UTP are listed in 
Table 3.4.  
 
 
Agonist 
        Hill Slope 
       nH1                    nH2 
Maximum Response 
(F/F0) 
 Maximum Response 
(% of 100µM UTP) 
ADP       1.4 ± 0.3     5 ± 2.5   1.83 ± 0.13       101 ± 5.4% 
2meSATP       3.4 ± 1.6  1.4 ± 0.8   1.70 ± 0.021         94 ± 3.5% 
UTP  1.2 ± 0.2   1.82 ± 0.09      100% 
Table 3.4 Steepness and maxima of the ADP, 2mesATP and UTP curves in clone 13  
 
The Hill slopes of the concentration-response curves for ADP, 2meSATP and UTP in clone 13 
were estimated using non-linear regression analysis. nH1 and nH2 refer to the Hill slopes of the 
high and low affinity sites of the biphasic ADP and 2meSATP curves. The maximum response to 
each agonist (F/F0) was determined and expressed as a percentage of the maximum response to 
the 100µM UTP control. The values shown in this table constitute the average ± s.e.m of three 
independent experiments, each performed in triplicate.  
 
 
As in the case of αβmeATP, non-linear regression analysis failed to fit a curve to 
the βγmeATP data, which was represented using a dotted connecting line. These data 
gave an ambiguous fit, failing to reach a maximum response within the concentration 
range of agonist tested, and it was not possible to determine an EC50 value for this ligand. 
The maximum response to βγmeATP is 0.8 ± 0.1, obtained at a concentration of 100µM 
βγmeATP,  constitutes  43  ±  3%  of  100µM  control  and  is  statistically  significantly Chapter 3  Creation and Characterization of Recombinant CHO-K1-hP2Y11 Clones 6 and 13 
	 ﾠ 72	 ﾠ
different from both 100µM UTP and from the maximal responses of ADP, UTP and 
2meSATP, as revealed by one way ANOVA analysis (***, p value= 0.0001).  
 
The mean EC50 and pEC50 values of the tested agonists were calculated using non-
linear analysis and are listed in Table 3.5. Although the data analysis was carried using 
log values, the EC50 value was used as a measure of variation instead of the pEC50 value 
in all the sections of this project. Four out of six agonists (BzATP, ATP, ATPγS and 
UTP) gave a monophasic response with a single EC50 value. ADP and 2meSATP gave 
biphasic  responses  with  two  distinct  EC50 values.  αβmeATP  and  βγmeATP  failed  to 
produce a complete calcium response and are not shown in the table. The high affinity 
site of 2meSATP elicited the most potent calcium response in clone 13 while the low 
affinity sites of ADP and 2meSATP produced the least potent responses. The agonist 
potencies  at  these  low  affinity  sites  were  not  statistically  significantly  different, 
suggesting that ADP and 2meSATP might be activating the same unknown population of 
receptors detected at this site.  In summary, the order of potency of the 8 agonists in clone 
13 is: 
2meSATP (1) > ATP > UTP > ADP (1) > ATPγS > BzATP > ADP (2) ≈ 2meSATP (2) 
> βγmeATP ≈ αβmeATP 
 
 
Agonist 
EC50 
(nM + S.E.M.)	 ﾠ
pEC50	 ﾠ
2meSATP	 ﾠ(EC50-ﾭ‐1)	 ﾠ 	 ﾠ	 ﾠ	 ﾠ	 ﾠ21	 ﾠ+	 ﾠ10	 ﾠ 7.76	 ﾠ
ATP	 ﾠ 	 ﾠ	 ﾠ	 ﾠ	 ﾠ47	 ﾠ+	 ﾠ20	 ﾠ 7.41	 ﾠ	 ﾠ
UTP	 ﾠ 	 ﾠ	 ﾠ	 ﾠ	 ﾠ89	 ﾠ+	 ﾠ22	 ﾠ 7.08	 ﾠ	 ﾠ
ADP	 ﾠ(EC50-ﾭ‐1)	 ﾠ 	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ110	 ﾠ+	 ﾠ6	 ﾠ 6.98	 ﾠ
ATPγS	 ﾠ 	 ﾠ274	 ﾠ+	 ﾠ48	 ﾠ 6.58	 ﾠ	 ﾠ
BzATP	 ﾠ 1,270	 ﾠ+	 ﾠ150	 ﾠ 5.90	 ﾠ	 ﾠ
ADP	 ﾠ(EC50-ﾭ‐2)	 ﾠ 	 ﾠ12,700	 ﾠ+	 ﾠ1,770	 ﾠ 4.91	 ﾠ
2meSATP	 ﾠ(EC50-ﾭ‐2)	 ﾠ 	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ	 ﾠ13,430	 ﾠ+	 ﾠ674	 ﾠ 4.87	 ﾠ
Table 3.5 The calcium response elicited by nucleotides and nucleotide analogues in 
CHO-K1-hP2Y11 clone 13 
 
The EC50 and pEC50 values of a set of 8 agonists were determined in CHO-K1-hP2Y11 clone 13. 
The results are expressed as the mean EC50 and the mean pEC50 of three independent experiments, 
each performed in triplicate. Agonists are ranked from highest to lowest potency. Two agonists, 
2meSATP and ADP, gave a biphasic response with two distinct EC50 values.  
 
 Chapter 3  Creation and Characterization of Recombinant CHO-K1-hP2Y11 Clones 6 and 13 
	 ﾠ 73	 ﾠ
3.4.2 Functional characterization of agonist responses in CHO-K1-
hP2Y11 Clone 6, the ‘low’-expressing P2Y11 clone  
Following characterization of the high expressing CHO-K1-hP2Y11 clone 13, the 
calcium responses elicited by the eight previously described agonists were investigated in 
CHO-K1-hP2Y11 clone 6, which expresses a low density of hP2Y11. The characterization 
was carried out as previously, in two sets of four agonists using FLIPR. Figure 3.9 shows 
the mean calcium response of clone 6 upon the addition of BzATP, ATPγS, ATP and 
αβmeATP at 37°C. The agonists were applied at increasing concentrations, ranging from 
10nM  to  100µM  (log  values:  -8  to  -4)  and  produced  calcium  responses  in  a  dose-
dependent manner.  
 
 
 
Figure 3.9 Concentration-response curves of BzATP, ATPγS, ATP and αβmeATP 
on Ca
2+ mobilization in CHO-K1-hP2Y11 clone 6 
 
The calcium response to increasing concentrations of BzATP (■), ATPγS (▲), ATP (▼) and 
αβmeATP (◆) at 37°C in CHO-K1-hP2Y11 clone 6, which expresses the lowest density of the 
human P2Y11 receptor of all clones characterized. The results are expressed as the average ± s.e.m 
of three independent experiments, each performed in triplicate. The response of clone 6 to 100µM 
UTP is shown.  
 
 
  The  response  curves  of  the  four  agonists  were  generated  through  non-linear 
regression analysis using a comparison of two fits (variable slope, or four parameter, 
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equation and asymmetric, or five parameter, equation) and represent the mean of three 
independent experiments performed in triplicate. The preferred fit for the BzATP, ATPγS 
and ATP data in clone 6 is the variable slope, or four parameter, equation, resulting in 
sigmoidal monophasic curves. ATPγS achieved its minimum to maximum response over 
two log units of agonist concentration ranging from 10nM to 1µM (log value: -9 to -7) 
agonist concentration, whereas ATP and BzATP reached their plateaus between 100nM 
and  10µM  agonist  (log  value:  -7  to  -5).  BzATP  and  ATPγS  reached  their  maximum 
calcium response at 100µM, while ATP achieved its maximum at 10µM. Using one-way 
ANOVA analysis, there is no statistically significant difference between the maxima for 
BzATP,  ATPγS,  ATP  and  the  100µM  UTP  response  in  clone  6  (p  value=  0.4).  The 
maximum responses and Hill slopes of the concentration-response curves are listed in 
Table 3.6.  
 
 
Agonist 
        Hill Slope 
 
Maximum Response 
(F/F0) 
Maximum Response 
(% of 100µM UTP) 
ATP  0.75 ± 0.13   1.5 ± 0.08  117 ± 5% 
ATPγS  1.16 ± 0.13   1.4 ± 0.06  112 ± 5% 
BzATP  1.28 ± 0.07  1.4 ± 0.08  111 ± 3% 
Table 3.6 Steepness and maxima of the BzATP, ATP and ATPγS curves in clone 6  
 
The Hill slopes of the concentration-response curves for BzATP, ATP and ATPγS in clone 6 were 
estimated using non-linear regression analysis. The maximum response to each agonist (F/F0) was 
determined and expressed as a percentage of the maximum response to the 100µM UTP control. 
The values shown in this table constitute the average ± s.e.m of three independent experiments, 
each performed in triplicate.  
 
 
  As in clone 13, non-linear regression was unable to fit a curve to the αβmeATP 
data and it was not possible to calculate an EC50 value for this agonist. The calcium 
response started at 10nM (log value: -8) and failed to reach a plateau by 100µM (log 
value:  -4),  the  highest  concentration  tested.  The  maximum  calcium  response  (F/F0) 
produced by αβmeATP is 0.9 ± 0.07, constitutes 67 ± 3% of the 100µM UTP control, and 
is statistically significantly different from both 100µM UTP and the maximal responses 
of BzATP, ATPγS and ATP (**, p value= 0.0015). A dotted connecting line was inserted 
across the data points for visualization purposes. 
 
  Following this initial characterization, the potencies of the second set of agonists  
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calcium responses following the addition of increasing agonist concentrations ranging 
from 1 nM to 100 µM (log value: -9 to -4) at 37°C. The concentration-response curves for 
each agonist were plotted using non-linear regression analysis. No biphasic responses 
were  detected  for  either  ADP  or  2meSATP  in  clone  6,  as  opposed  to  the  biphasic 
behaviour observed for both agonists in clone 13. The preferred fit for the ADP, UTP, 
and 2meSATP data was the variable slope, or four parameter equation, resulting in a 
monophasic sigmoidal curve for all three agonists. The calcium response produced by 
ADP  and  2meSATP  was  achieved  over  approximately  two  log  units  of  agonist 
concentration, ranging from 1nM to 100nM (log value: -9 to -7, approximately). The 
calcium response generated by UTP, however, occurred over 1 log unit, spanning from 10 
nM to 100 nM (log value: -8 to -7), resulting in a curve with a steep slope. ADP and 
2meSATP elicited their maximum response at 100µM while UTP reached its maximum 
at 10µM. . Using a one-way ANOVA test, there is no statistically significant difference 
between the maxima for ADP, UTP and 2meSATP and 100 µM UTP response in clone 6 
(p value= 0.7). The maximum responses and Hill slopes of the concentration-response 
curves for these agonists are displayed in Table 3.7.  
 
	 ﾠ
Figure 3.10 Concentration-response curves of ADP, UTP, 2meSATP and βγmeATP 
on Ca
2+ mobilization in CHO-K1-hP2Y11 clone 6  
 
The calcium response to increasing concentrations of ADP ( ), UTP ( ), 2meSATP ( ) and 
βγmeATP ( ) at 37°C in CHO-K1-hP2Y11 clone 6, which expresses the lowest density of the 
human P2Y11 receptor of all clones characterised. The results are expressed as the average ± s.e.m 
of three independent experiments, each performed in triplicate.       
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Agonist 
        Hill Slope 
 
Maximum Response 
(F/F0) 
Maximum Response 
(% of 100µM UTP) 
ADP     1.4 ± 0.18   1.6 ± 0.01         95± 6.4% 
2meSATP    1.04 ± 0.27   1.6 ± 0.07   96.3 ± 3% 
UTP    2.0 ± 0.6   1.7 ± 0.15  100% 
Table 3.7 Steepness and maxima of the ADP, 2meSATP and UTP curves in clone 6  
 
The Hill slopes of the concentration-response curves for ADP, 2meSATP and UTP in clone 6 
were  estimated  using  non-linear  regression  analysis.  The  maximum  response  to  each  agonist 
(F/F0) was determined and expressed as a percentage of the maximum response to the 100µM 
UTP control. The values shown in this table constitute the average ± s.e.m of three independent 
experiments, each performed in triplicate.  
 
 
  In  contrast  to  the  calcium  responses  generated  by  ADP,  UTP  and  2meSATP, 
βγmeATP, like αβmeATP, gave a response that started at 10nM (log value: -8) and was 
not able to reach a plateau by 100µM (log value: -4), the highest concentration tested. 
Non-linear  regression  analysis  yielded  an  ambiguous  fit  to  the  data  and  it  was  not 
possible to determine an EC50 value for this ligand. Unlike the other agonists tested, the 
maximum calcium response produced by βγmeATP is 1.2 ± 0.03 at a concentration of 
100µM ligand, and is statistically significantly different from both 100µM UTP and from 
the maximal responses of BzATP, ATPγS and ATP, as revealed by one-way ANOVA 
analysis (*, p value= 0.0125). This response constitutes 71.2 ± 5.6% of the 100µM UTP 
response.  The  data  were  connected  using  a  dotted  line  is  shown  for  visualization 
purposes. The EC50 and pEC50 values of the tested agonists are shown in Table 3.8. The 
rank order of agonist potency for clone 6 is: 
 
2meSATP > ATP > ADP > UTP > ATPγS > BzATP > βγmeATP > αβmeATP 
	 ﾠ
Agonist 
EC50 
(nM + S.E.M.) 
pEC50 
2meSATP  21 + 6  7.70 
ATP  33 + 6  7.50 
ADP  35 + 19  7.67 
UTP  67 + 22  7.24 
ATPγS  260 + 39  6.59 
BzATP  992 + 100  6.00 
Table 3.8 The calcium response elicited by nucleotides and nucleotide analogues in 
CHO-K1-hP2Y11 clone 6. 
 
The EC50 and pEC50 values of a set of 8 agonists were determined in CHO-K1-hP2Y11 clone 6. 
The results are expressed as the mean EC50 and the mean pEC50 of three independent experiments, 
each performed in triplicate. No biphasic response was detected for either ADP or 2meSATP in 
clone 6.	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3.5  hP2Y11  receptor  density  influences  calcium  responses  elicited  by 
nucleotides and nucleotide analogues 
 
3.5.1  Comparison  of  time-dependent  responses  in  CHO-K1-hP2Y11 
clone 13 and CHO-K1-hP2Y11 clone 6 
To determine whether hP2Y11 receptor density influences the calcium response to 
the  potent  P2Y11 agonist  BzATP  in  clones  13  versus  6,  the  changes  in  fluorescence 
elicited  by  100µM  BzATP  (log  value:  -4)  over  a  time  course  of  180  seconds  were 
investigated using FLIPR. Figure 3.11 shows the time-dependent calcium response to 
100µM BzATP in the clones. The curves represent the mean response obtained from 
three different experiments, each performed in triplicate, minus the baseline fluorescence 
measured  prior  to  the  addition  of  the  ligand.  The  data  points  are  shown  using  a 
connecting  line  only,  as  symbols  and  error  bars  have  been  excluded  to  facilitate  the 
visualisation of the represented curves.  
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Figure 3.11 The time dependence of the response to 100µM BzATP in CHO-K1-
hP2Y11 clone 13 and CHO-K1-hP2Y11 clone 6 
 
The calcium response to 100µM BzATP was measured over time in CHO-K1-hP2Y11 clone 13 
(
____), which expresses the highest density of the human P2Y11 receptor, and CHO-K1-hP2Y11 
clone 6 (
____), which expresses the lowest density of the human P2Y11  receptor in all clones 
screened.  The  curves  represent  the  mean  calcium  response  obtained  from  three  independent 
experiments, each performed in triplicate, minus the baseline fluorescence which was measured 
prior  to  the  introduction  of  ligand  at  t=10  seconds.  The  results  are  expressed  as  relative 
fluorescence units. Error bars have been omitted to ensure a better visualisation of the curves.   
 
 
The  ligand  was  added  at  t  =  10  seconds  in  the  assay,  allowing  the  device  to 
measure the baseline calcium level that exists in the cells prior to stimulation with the 
ligand. The initial decrease in fluorescence detected at t = 10 seconds for both curves is 
typically  observed  following  ligand  addition.  BzATP  induces  an  increase  in  calcium 
fluorescence, corresponding to the release of calcium from intracellular stores in both 
clones 13 and 6. The agonist response proceeds from its minimum to its maximum and 
tails off within 180 seconds. A larger increase in fluorescence is observed for clone 13 as 
opposed to clone 6, although the peak response is achieved within the same time of 
agonist addition for both clones. The maximum calcium responses to BzATP for the 
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clones, calculated using column statistics and area under the curve analysis, are shown in 
Table 3.9. There was a statistically significantly difference between clones 13 and 6 using 
both methods  (***, p value= 0.0004; ***, p value = 0.0002, respectively). The area 
under the curve is 448,604 ± 25,785 for clone 13 and 221,732 ± 8,250 for clone 6 and 
these values are statistically significantly different (**, p value = 0.0011).  
	 ﾠ
	 ﾠ
Clone 
Maximum Response (RFU) 
Column Statistics     AUC 
13  3048 ± 220  4428 ± 220 
6           599.1 ± 46  1503 ± 45.6 
Table 3.9. Maximum calcium response to 100µM BzATP in clones 13 versus 6  
The maximum response to a fixed concentration of BzATP was calculated for clones 13 and 6 
using column statistics and area under the curve analysis. The values represent the average ± 
s.e.m of three different experiments, each performed in triplicate, and are expressed in relative 
fluorescence units (RFU).  
 
 
3.5.2 Comparison of agonist potencies in CHO-K1-hP2Y11 clone 13 and 
CHO-K1-hP2Y11 clone 6  
  As  described  in  the  introduction  to  this  chapter,  the  aim  of  the  functional 
characterization undertaken in clones 13 and 6 is to identify a recombinant co-expression 
model that reflects the co-expression of P2Y1 and P2Y11 in guinea pig taenia coli. As part 
of this, it was necessary to vary the expression level of hP2Y11 as the relative levels of 
expression of P2Y1 and P2Y11 in the taenia coli are unknown. Consequently, a series of 
statistical analyses, comparing the efficacies and potencies of each of the agonists tested 
in clones 13 versus 6, was performed. The dose response curves of each of the ligands 
tested in the clones were plotted on a single graph to facilitate the comparison process, 
and are shown in Figures 3.12 and 3.13. The mean average responses of the clones to 
100µM BzATP are employed as controls in each figure. 
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C.           D.  
	 ﾠ 	 ﾠ
E.          F. 
 
G.          H.	 ﾠ
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Figure  3.12  Visualization  of  differences  in  agonist  responses  in  CHO-K1-hP2Y11 
clone 13 and CHO-K1-hP2Y11 clone 6  
The calcium responses of CHO-K1-hP2Y11 clone 13 and CHO-K1-hP2Y11 clone 6 to each agonist 
tested are shown on a single graph to aid comparison of the functional responses in each clone. A) 
BzATP; B) ATPγS; C) ATP; D) αβmeATP; E) ADP; F) UTP; G) 2meSATP and H) βγmeATP. 
The control bars show the calcium response of clones 13 and 6 to 100µM BzATP.  
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A.	 ﾠ
 
B. 
	 ﾠ
 
Figure  3.13  Comparison  of  agonist  responses  in  CHO-K1-hP2Y11  clone  13  and 
CHO-K1-hP2Y11 clone 6  
 
The calcium responses of CHO-K1-hP2Y11 clone 13 and CHO-K1-hP2Y11 clone 6 to two distinct 
sets  of  agonists  are  shown  on  two  different  graphs  to  aid  in  comparison  of  the  functional 
responses in each clone. A. set 1: BzATP, ATPγS, ATP and αβmeATP; B. set 2: ADP, UTP, 
2meSATP and βγmeATP. The control bars show the calcium response of clones 13 and 6 to 
100µM BzATP.  
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  As the figures reveal, the calcium responses elicited by the first set of agonists 
(BzATP, ATPγS, ATP) in clones 13 and 6, are all monophasic. Using an unpaired t-test, 
there is a statistically significant difference between the maximal response of BzATP 
with respect to 100µM UTP response in clone 13 versus clone 6 (*, p value= 0.0475), 
indicating that BzATP reaches a different maximum in these clones. Statistical analyses 
of the maximal responses of ATPγS, ATP and αβmeATP with respect to 100µM UTP in 
clones  13  and  clone  6  reveals  no  statistically  significant  difference  between  the  two 
clones, signifying that these agonists have similar maxima in both the high expressing 
and low expressing clones. In order to compare between the potencies of the calcium 
responses elicited by these agonists in the clones, the ratio of the mean EC50 value in 
clone 13 was divided by the mean EC50 in clone 6 for each of the agonists tested and 
unpaired t-tests were performed (shown in Table 3.10). The resulting ratio is 1.28 and 
there is no statistically significant difference between the EC50 values calculated in both 
clones (p value= 0.19). The ratio of ATPγS is 1.05 (p value= 0.98) while that of ATP is 
1.42 (p value= 0.54). These analyses indicate that BzATP, ATPγS and ATP have the 
same potency in each clone. In summary, statistical analyses show that ATPγS and ATP 
have similar efficacies and potencies in clone 13 and clone 6, whereas BzATP has a 
higher efficacy but the same potency in the high expressing versus low expressing clone. 
 
  The second set of agonists tested (ADP, UTP, 2meSATP) was also subjected to the 
same  series  of  numerical  comparisons.  Statistical  analysis  shows  that  there  is  no 
significant difference between the maximal responses of ADP, UTP and 2meSATP with 
respect to 100µM UTP response in clone 13 versus clone 6, indicating that these ligands 
have similar efficacies in both clones.  
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Agonist 
Ratio 
(clone 13/ clone 6)  p value  
BzATP  1.28  0.19 
UTP                  1.33  0.52 
ATP  1.42  0.54 
ATPγS  1.05  0.84 
2meSATP (EC50-1)  1.00  0.98 
ADP (EC50-1)   3.14*       0.0246
 
ADP (EC50-2)    362**       0.0020
 
2meSATP (EC50-2)     639***       0.0001
 
Table 3.10 Comparison of agonist potencies of the calcium response in CHO-K1-
hP2Y11 clone 13 and CHO-K1-hP2Y11 clone 6 
 
The ratio of the mean EC50 in CHO-K1-hP2Y11 clone 13 divided by the mean EC50 in CHO-K1-
hP2Y11 clone 6 is shown for each of the agonists tested. An unpaired t-test was used to compare 
the EC50 values for each agonist in clone 13 versus clone 6. The p values for each comparison are 
shown. Each of the two EC50 values obtained for both ADP and 2meSATP in clone #13 were 
compared with the single EC50 value obtained for these agonists in clone #6 (* = p<0.05; ** = 
p<0.01; *** = p<0.001).  
 
 
The mean EC50 values of the agonists tested in clones 13 and 6 were also compared 
in order to evaluate the potencies of these ligands in the two clones. As Figures 3.13 and 
3.14 show, both ADP and 2meSATP generated biphasic responses with two EC50 values 
each in clone 13, as opposed to monophasic responses with a single EC50 value in clone 
6. The EC50 values of these two agonists in clone 13 versus clone 6 were compared using 
unpaired t-tests. Statistical analysis shows that there is a statistically significant difference 
between the EC50 values of both the high affinity and low affinity sites of ADP in clone 
13  and  the  mean  EC50  of  ADP  in  clone  6  (*,  p  value=  0.0246;  **,  p  value=  0.002, 
respectively). The ratio of the EC50 of the high affinity site of ADP (13) with respect to 
the EC50 of this agonist in clone 6 is 3.14, while the ratio of the low affinity site is 362, 
signifying  that  ADP  has  different  potencies  in  clone  13  as  compared  to  clone  6.  In 
contrast,  the  EC50  value  of  the  high  affinity  site  of  2meSATP  in  clone  13  is  not 
statistically significantly different from the EC50 of this ligand in clone 6 (p value = 0.98; 
ratio =1.00), indicating that the same population of receptors might be involved in the 
response to this drug in the high affinity site of clone 13 and the single 2meSATP site in 
clone 6.  However, the EC50 of the low affinity site of 2meSATP (13) is statistically 
significantly different from the EC50 of 2meSATP in clone 6 (***, p value= 0.0001; 
ratio= 639), signifying that 2meSATP has different potencies in the low affinity site of 
clones 13 versus 6.  
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  Unlike ADP and 2meSATP, UTP generates a monophasic response in both clones. 
The  ratio  of  the  EC50  of  clone  13  with  respect  to  clone  6  is  1.33  and  there  is  no 
statistically significant difference between the EC50 values calculated in both clones (p 
value= 0.52), indicating that this drug possesses a similar potency in clones 13 and 6.  
 
3.6 Summary of the functional studies  
Following the creation of two stable pools of CHO-K1 expressing hP2Y11, twenty-
four clones expressing different densities of hP2Y11 were created and screened for their 
response to 100µM BzATP. Using one-way ANOVA analysis, clone 13 was identified as 
producing the greatest calcium response while clone 6 was identified as producing the 
lowest calcium response, and these two clones were retained for further investigation.  
 
A set of eight agonists (BzATP, ATPγS, ATP, αβmeATP, ADP, UTP, 2meSATP 
and βγmeATP) was chosen for the in-depth pharmacological characterization of clones 
13 and 6. Analysis of the obtained agonist responses revealed that BzATP, ATPγS, ATP 
and UTP exhibited similar potencies in clones 13 and 6 while αβmeATP and βγmeATP 
failed  to  produce  a  complete  calcium  response  in  both  clones.  In  contrast,  ADP  and 
2meSATP elicited a biphasic response in clone 13 versus a monophasic response in clone 
6. This difference in behaviour may reflect the formation, at higher expression levels of 
hP2Y11, of a P2Y1: P2Y11 heteromer with a novel calcium profile, thus accounting for the 
low affinity site of the biphasic ADP and 2meSATP responses in clone 13.  
 
3.7 Generation of co-immunoprecipitation and BiFC constructs   
  The original experimental design of this project envisaged a functional as well as 
molecular approach to test the interaction between hP2Y1 and hP2Y11 receptors using co-
immunoprecipitation  and  BiFC  experiments  in  1321N1  cells.  Unfortunately,  these 
experiments  were  not  completed  due  to  difficulties  in  finalizing  the  constructs.  This 
section  provides  a  brief  description  of  the  generation  of  co-immunoprecipitation 
constructs  undertaken  prior  to  abandoning  this  part  of  the  project.  Two  co-
immunoprecipitation constructs: 1) Myc-hP2Y1 + stop and 2) HA-hP2Y11 + stop were 
first designed using the construct layout shown in Figure 3.14. hP2Y1 cDNA was then 
amplified using a set of forward and reverse primers. The resulting product bearing the 5’ 
and  3’  additions  was  1180  bps  long  and  was  clearly  visualized  using  agarose  gel 
electrophoresis.  This  fragment  was  assembled  through  ligation  into  a  pCR-Blunt  II- 
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reaction product was transfected into Mach1T1
R phage-resistant chemically competent 
E.coli, following which the transformation was plated on kanamycin selective agar plates. 
A small-scale isolation of plasmid DNA (Miniprep) was performed and a Restriction 
Enzyme digestion was conducted to test for the successful insertion of Myc-hP2Y1 into 
the  Topo  vector.  The  purified  DNA  was  cut  with  NheI  and  EcoRV,  yielding  two 
fragments of the right size corresponding to the Topo vector (3519bps) and Myc-hP2Y1 
(1180bps) respectively.  
 
 
 
Figure 3.14 Construct layout for P2Y1 and P2Y11.  
A. Construct design for co-immunoprecipitation. B. Construct design for BiFC.    
 
 
  Cesium-chloride gradient large-scale isolation of plasmid DNA was subsequently 
carried out to amplify Myc-hP2Y1, following which the purified DNA was digested using 
EcoRI and EcoRV, respectively, to determine the orientation of Myc-hP2Y1 insertion into 
the  TOPO  vector.  Two  insertion  orientations  are  possible  for  Myc-hP2Y1  due  to  its 
asymmetric 5’ and 3’ ends (NheI and EcoRV, respectively). Since the TOPO vector and 
construct  both  harbor  an  EcoRV  recognition  site,  each  orientation  imparts  a  specific 
EcoRV digestion pattern, as described in Figure 3.15.  
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Figure 3.15 Map of EcoRV digestion  
 A, Clockwise proximal insertion. This orientation places the EcoRV recognition sites of TOPO 
and Myc-hP2Y1 in close proximity. Digestion with EcoRV produces one large and one small 
fragment. The small fragment is 25 bps long and consists of RI-RV recognition sites. The larger 
fragment includes TOPO and Myc-hP2Y1 minus the RV-RI-RV digest and is 4674 bps long. B. 
Anticlockwise distal insertion. In this orientation, the RV recognition sites of TOPO and Myc-
hP2Y1  are  spaced  out;  two  fragments  closely  corresponding  to  TOPO  and  Myc-hP2Y1  are 
generated. The 1202 bps fragment consists of Myc-hP2Y1 plus the TOPO RI-RV sites. The larger 
fragment corresponds to TOPO minus RI-RV and is 3497bps long. 
 
 
  Digestion of the purified DNA with EcoRI produced two fragments of expected 
lengths  corresponding  to  the  TOPO  vector  and  Myc-hP2Y1,  respectively.  However, 
digestion with EcoRV resulted in a single band that migrated to approximately 5000 bps. 
The same pattern was detected upon repetition of the digestion reaction. The digestions 
products are shown in Figure 3.16. It was concluded that the large band corresponded to 
the 4674bps TOPO fragment produced when the clockwise proximal Myc-hP2Y1 insert is 
digested. To further ascertain that the sequence was ligated into the TOPO vector, the 
purified DNA product was sequenced. The results corroborated the previous observations 
and confirmed that Myc-hP2Y1 insertion was clockwise. Furthermore, a HA-hP2Y11 + 
stop construct was generated using the same techniques used for Myc-hP2Y1 + stop. 
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stop codon conjugated to YFP 1-173 (Myc-hP2Y1-YFP1-173) and 2) HA-hP2Y11 minus 
stop codon fused to YFP 156-239 (HA-hP2Y11-YFP156-239), but they were not completed.  
 
 
 
                                                                      Lane 1   Lane 2  Lane 3   
Figure 3.16 Agarose gel electrophoresis of EcoRI and EcoRV digests 
Lane  1  shows  the  1KB  plus  DNA  ladder  (Invitrogen).  Lane  2  shows  the  EcoRI  digestion 
products. The large band has migrated to around 4000bps and corresponds to the TOPO segment 
(3495bps). The smaller band has migrated to around 1200bps and corresponds to Myc-hP2Y1 
(1204bps). Lane 3 shows the EcoRV digestion product. Only one band is detected. It has migrated 
to around 5000bps and corresponds to the 4674bps segment generated from digestion of proximal 
construct insertion.  
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Chapter 4 
Pharmacological Characterization of Recombinant 
1321N1-hP2Y1 and 1321N1-hP2Y11 Cell lines  
 
4.1 Introduction   
Chapter 3 described the creation of a recombinant system (CHO-K1-hP2Y11) co-
expressing the purine receptors P2Y1 and P2Y11. Two versions of this system, a clone 
expressing a high density of P2Y11 (13) and a clone expressing a low density of the 
receptor  (6),  were  generated  and  characterized  using  a  set  of  eight  nucleotides  and 
nucleotide derivatives. The aim behind this experimental setup was to determine whether 
co-expression  alters  the  signalling  profiles  of  the  individual  receptor  subtypes.  Three 
interesting signalling features were observed: 1) both clones 13 and 6 respond to the 
P2Y11 agonist BzATP; 2) the response to ADP, a P2Y1 agonist, is biphasic in clone 13 as 
opposed  to  clone  6  where  it  is  monophasic,  suggesting  that  two  distinct  receptor 
populations might contribute to the response to ADP in clone 13; and, 3) the response to 
2meSATP, a P2Y1 and P2Y11 agonist, is also biphasic in clone 13 but not in clone 6. The 
changes in the nature of the response to ADP and 2meSATP in the high versus low-
expressing clone were detected in the context of an increase in the levels of expression of 
hP2Y11.   
 
To  put  the  signalling  alterations  observed  in  the  recombinant  CHO-K1-hP2Y11 
clones 6 and 13 into perspective, the signalling properties of each of the two receptors co-
expressed in CHO-K1-hP2Y11 were studied individually through the creation of a P2Y1-
only cell line and a P2Y11-only cell line, which were characterized using the same set of 
agonists described in chapter 3. The aim behind this endeavour was to generate a suitable 
platform  for  comparing  the  agonist  profiles  of  the  P2Y1-only,  P2Y11-only  and 
P2Y1+P2Y11 systems to disentangle the components of the biphasic responses detected in 
clone 13. This could possibly help to answer the question formulated in chapter 3: Does 
the co-expression of P2Y1 and P2Y11 result in the formation of novel sites of agonist 
activity through the formation of complexes containing both receptor subtypes, leading to 
differences in agonist responses?  Chapter 4      Pharmacological Characterization of Recombinant 1321N1-hP2Y1 and 1321N1-hP2Y11 Cell 
Lines 
	 ﾠ 89	 ﾠ
4.2 Pharmacological characterization of a recombinant 1321N1-hP2Y11 
cell line  
1321N1  astrocytoma  cells  have  been  shown  to  signal  through  cholinergic, 
muscarinic and P1 receptors but have not been found to express any P2 receptors (212), 
making them an appropriate null cell line in which to characterize the individual human 
P2Y1  and  P2Y11  receptors.  For  the  purpose  of  this  study,  a  recombinant  1321N1 
astrocytoma  cell  line,  expressing  the  gene  for  the  human  P2Y11  receptor  (GenBank 
accession number AF030335), that had previously been studied in the laboratory, was 
provided by Dr. Andrea Townsend-Nicholson.  
 
4.2.1 Calcium response of 1321N1-hP2Y11 to carbachol 
  The calcium response of the 1321N1 cell line to carbachol, which is mediated by 
the endogenously expressed muscarinic M3 receptor, has been widely investigated and 
documented in the literature (213-220). In order to compare the activity of nucleotide 
agonists  in  the  recombinant  1321N1-hP2Y11  cell  line,  these  cells  were  subjected  to 
increasing concentrations of carbachol, ranging from 1mM to 100nM (log value: -3 to -7) 
at physiological temperature (37°C). Non-linear regression analysis using a comparison 
of  two  different  equations  (three-parameter  equation  versus  variable  slope,  or  four-
parameter, equation) was performed to determine the most suitable fit for the obtained 
carbachol  data.  As  Figure  4.1  shows,  the  response  to  carbachol  was  sigmoidal  and 
evolved from its minimum to its maximum over three log units of agonist concentration, 
namely 360nM to 360µM (log value: -6.5 to -3.5). The preferred mathematical fit for this 
data is the three parameter equation, which generates a sigmoidal monophasic curve with 
a Hill slope of 1. The average maximal value elicited by the carbachol agonist is 0.81 ± 
0.07 (F/F0) at 360µM carbachol. The average EC50 and pEC50 values for the carbachol 
response in the studied 1321N1-hP2Y11 cell line are 2.9 ± 0.5µM and 5.54, respectively. 
Given  the  potency  of  the  endogenous  muscarinic  response  in  1321N1-hP2Y11  cells, 
carbachol was employed as the control against which the calcium responses to the studied 
nucleotide and nucleotide derivatives in the 1321N1-hP2Y11 cell line were normalized.  
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Figure 4.1 Concentration-response curve elicited by carbachol in 1321N-hP2Y11  
 
The  calcium  response  to  increasing  concentrations  of  carbachol  was  determined  at  37°C  in 
1321N1-hP2Y11  cells.  The  results  are  expressed  as  the  average  ±  s.e.m  of  three  independent 
experiments, each performed in triplicate. The calculated EC50 value for carbachol in this cell line 
is 2.9 ± 0.5µM (pEC50 = 5.55).   
 
 
4.2.2 Functional investigation of the activity of nucleotide and nucleotide 
derivatives in 13211N-hP2Y11  
As  was  mentioned  in  the  chapter’s  introduction,  the  aim  behind  the 
pharmacological characterization of the 1321N1-hP2Y11 cell line was to determine the 
signalling profile of hP2Y11 receptor expressed in a background devoid of endogenous P2 
responses, with the aim of comparing its measured calcium responses to the distinctive 
calcium profile observed in clone 13. Hence, 1321N1-hP2Y11 was tested using the same 
set of eight nucleotides and nucleotide derivatives described in Chapter 3.  
 
The  first  set  of  ligands  tested  consisted  of  four  potent  P2Y11  agonists,  namely 
BzATP, ATPγS, ATP and αβmeATP. Figure 4.2 shows the mean calcium response of the 
1321N1-hP2Y11 cell line following the addition of BzATP, ATPγS, ATP and αβmeATP 
at 37°C. The larger errors observed at some concentrations (around 13% of the calcium 
response) are caused by the variability in the maxima of the responses obtained between 
independent  experiments.  Figure  4.3  shows  the  degree  of  error  obtained  from  a 
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representative experiment. Agonists were applied at increasing concentrations ranging 
from  100nM  to  1mM  (log  value:  -7  to  -3)  or  10nM  to  1mM  (log  value:  -8  to  -3) 
depending on the lowest concentration at which a calcium response was obtained. The 
response  curves  of  the  four  agonists  were  generated  through  non-linear  regression 
analysis using a comparison of two fits (three parameter versus variable slope, or four 
parameter, equation). As figures 4.2 and 4.3 reveal, all four tested agonists produced 
sigmoidal monophasic curves with a single EC50 value.  
 
  The concentration-response curve of BzATP, which represents the average of four 
independent  experiments,  and  that  of  ATPγS,  which  represents  the  average  of  three 
independent experiments, follow a similar pattern of calcium fluorescence.  Both curves 
progress  from  their  minimum  to  maximum  responses  over  three  log  units  of  agonist 
concentration, ranging from 100nM to 100µM agonist (log value: -7 to -4). On the other 
hand, the ATP curve is shifted to the right of the BzATP and ATPγS curves and, unlike 
these two agonists, ATP achieves its minimum to maximum response over two log units 
of  agonist  concentration,  i.e.  1µM  to  100µM  agonist  (log  value:  -6  to  -4).  The 
concentration-response curve of αβmeATP is shifted to the right of the three previously 
described  curves  (BzATP,  ATPγS  and  ATP).  It  is  distinctive  in  that  the  minimum 
response  begins  at  3.16µM  and  reaches  a  maximum  at  1mM  (log  value:  -5.5  to  -3) 
following a steep increase. 
 
Nonlinear regression analysis shows that the preferred model with which to fit the 
BzATP, ATPγS, ATP and αβmeATP data in 1321N1-hP2Y11 is the simpler model, or 
three parameter equation, which assumes a Hill slope of 1. The EC50 values for these four 
agonists are 3.1 ± 0.26µM, 3.2 ± 0.26µM, 9 ± 1.4µM and 71 ± 11.5µM, respectively. The 
maximum calcium response to BzATP, ATPγS, ATP and αβmeATP relative to the 1mM 
carbachol control is 101 ± 16%, 92 ± 13%, 87 ± 14% and 98.6 ± 12%, respectively. One-
way  ANOVA  analysis  shows  that  although  maxima  vary  between  trials  on  different 
calcium assay plates, there is no statistically significant difference between the maxima of 
the tested agonists relative to the carbachol control (p =0.90) within one experimental 
setup (same assay plate).  
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Figure 4.2 Concentration-response curves for BzATP, ATPγS, ATP and αβmeATP 
on Ca
2+ mobilization in 1321N1-hP2Y11  
 
The calcium response elicited by increasing concentrations of BzATP (■), ATPγS (▲), ATP (▼) 
and αβmeATP (◆) was determined at 37°C in 1321N1-hP2Y11 cells. The results represent the 
average ± s.e.m of three independent experiments, each performed in triplicate, and are expressed 
as a percentage of the response of 1321N1-hP2Y11 to 1mM carbachol.  
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Figure 4.3 Representative concentration-response curves for BzATP, ATPγS, ATP 
and αβmeATP on Ca
2+ mobilization in 1321N1-hP2Y11  
 
The calcium response elicited by increasing concentrations of BzATP (■), ATPγS (▲), ATP (▼) 
and αβmeATP (◆) was determined at 37°C in 1321N1-hP2Y11 cells. The results represent the 
average ± s.e.m of one independent experiment performed in triplicate, and are expressed as a 
percentage of the response of 1321N1-hP2Y11 to 1mM carbachol.  
 
 
  To  complete  the  pharmacological  study  of  the  hP2Y11  receptor  expressed  in 
1321N1  cells,  the  recombinant  cell  line  was  characterized  using  ADP,  βγmeATP, 
2meSATP  and  UTP.  Figure  4.4  presents  a  comparison  of  the  maximum  calcium 
responses evoked by the naturally occurring nucleotides ATP and ADP, the nucleotide 
derivatives BzATP and 2meSATP and the muscarinic control carbachol over a period of 
180 seconds in the studied cell line. As the graph demonstrates, the potent P2Y11 agonist 
BzATP produced the highest increase in calcium fluorescence in 1321N1-hP2Y11 cells. 
The nucleotide ADP, on the other hand, failed to induce a significant increase in calcium 
fluorescence in P2Y11-only cells as compared to the other illustrated agonists.  
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Figure  4.4  Comparison  of  the  maximum  responses  of  five  tested  agonists  as  a 
function of time in 1321N1-hP2Y11 cells  
 
The maximum responses of BzATP, ATP, 2meSATP, ADP and the muscarinic control carbachol 
over a time course of 180 seconds are shown. The maximum response to BzATP (red), ATP 
(navy) and ADP (green) was reached at 316µM (log value: -3.5) agonist whereas the maximum 
response  to  2meSATP  (purple)  occurred  at  100µM  (log  value:  -4)  agonist.  The  maximum 
response to the carbachol control was achieved at 100µM (log value: -4) agonist and is shown in 
black. The nucleotide derivative BzATP elicited the highest increase in calcium fluorescence in 
1321N1-hP2Y11  cells  whereas  the  naturally  occurring  nucleotide  ADP  produced  the  smallest 
response.  
 
 
Figure  4.5  shows  representative  calcium  curves  for  ADP,  UTP,  2meSATP  and 
βγmeATP. In contrast to previous ligands, the average response curves for this particular 
set of agonists were not displayed because the errors on the 2meSATP and βγmeATP 
curves  are  substantial  (up  to  46%)  due  to  variability  in  the  detected  maxima  of  the 
responses across experimental repeats.  
 
  ADP, UTP and 2meSATP were introduced at increasing concentrations ranging 
from 100nM to 1mM (log value: -7 to -3), while βγmeATP was added at concentrations 
ranging from 100nM to 316µM (log value: -7 to -3.5). Non-linear regression analysis 
using a comparison of two fits (three parameter versus variable slope, or four parameter, 
equation) was performed to determine the best mathematical fit for each of the studied 
ligands.  As  figure  4.5  shows,  the  calcium  responses  to  the  P2Y1 and  P2Y11  agonist 
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2meSATP and the P2Y11 agonist βγmeATP were sigmoidal monophasic and were best fit 
using  the  simpler  model,  or  three  parameter  equation.  These  curves  achieved  their 
plateaus  over  three  log  units  of  agonist  concentration,  ranging  from  1µM  to  316µM 
agonist (log value: -6 to -3.5). The calculated average (all trials included) EC50 values for 
2meSATP and βγmeATP are 10.5 ± 2.5µM and 64 ± 19µM, respectively, and the average 
maximum calcium responses (all trials included) are expressed as 108 ± 42% and 87 ± 
6% of the response to 1mM carbachol, respectively. Using unpaired t-test analysis, there 
was  no  statistically  significant  difference  between  the  average  maximal  responses 
calculated  for  2meSATP  and  βγmeATP  (p  value=0.73).  Furthermore,  comprehensive 
one-way  ANOVA  analysis  showed  no  statistically  significant  difference  between  the 
maxima of all six agonists (BzATP, ATPγS, ATP, αβmeATP, 2meSATP and βγmeATP) 
relative to 1mM carbachol (p=0.985).  
 
  In contrast, non-linear regression was unable to fit a curve to the calcium data for 
ADP and UTP. In fact, UTP failed to increase calcium fluorescence in 1321N1-hP2Y11, 
resulting in a response that did not depart from baseline calcium level. ADP, on the other 
hand,  induced  a  concentration-dependent  response  but  only  at  concentrations  above 
100µM with a maximum response at 316µM (log value: -3.5), the highest concentration 
tested. This maximum constituted 25 ± 1.6% relative to 1mM carbachol. For visualization 
purposes, the concentration-curves of UTP and ADP were represented using a dotted 
connecting line.  
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Figure 4.5 Representative concentration-response curves for ADP, UTP, 2meSATP 
and βγmeATP on Ca
2+ mobilization in 1321N1-hP2Y11  
 
The calcium response to increasing concentrations of ADP ( ), UTP ( ), 2meSATP ( ) and βγmeATP 
( ) was determined at 37°C in 1321N1-hP2Y11 cells. The results represent the average ± s.e.m of a single 
representative experiment performed in quadruplicate and are expressed as a percentage of the response of 
1321N1-hP2Y11 cells to 1mM carbachol.  
 
 
4.2.3 Antagonist studies in 1321N1-hP2Y11  
  NF 340 is a highly selective P2Y11 antagonist that has been reported to function as a 
competitive inhibitor of ATPγS (221). To investigate the inhibitory potency of this drug 
in 1321N1-hP2Y11 cells, the response to a fixed concentration of BzATP, namely 10µM 
(log value: -5), was tested in the presence of increasing concentrations of NF 340, ranging 
from 1nM to 100µM (log value: -9 to -4), at 37°C. Figure 4.6 delineates the progress of 
the  concentration-inhibition  response  exerted  by  NF  340  over  a  time  course  of  180 
seconds. As the displayed traces show, high concentrations of the antagonist, i.e. 100µM 
and 10µM (log value: -4 and -5), suppress the response of hP2Y11 to its agonist BzATP 
(10µM,  log  value:  -5)  as  compared  to  the  calcium  response  exhibited  by  the  same 
concentration of agonist in the absence of NF 340 (control shown in black on the graph). 
The calcium response to 10µM BzATP is first recovered at 1µM NF 340 (log value: -6) 
and is fully restored at NF 340 concentrations between 10nM to 0.1nM (log value: -8 to -
10).  
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Figure 4.6 NF 340 inhibits the response to 10µM BzATP in a time-dependent fashion  
 
The effect of increasing concentrations of NF 340, a P2Y11 antagonist, on the response elicited by 
10µM BzATP was assessed over time in 1321N1-hP2Y11. The log10 concentrations of NF 340 
used were: -4 (
….), -5 (
_ _), -6 (grey), -7 (red), -8 (navy), -9 (purple) and -10 (green). The calcium 
fluorescence trace elicited by the 10µM BzATP control is shown (black). The traces represent the 
mean calcium response obtained from one independent experiment performed in quadruplicate, 
divided by the baseline fluorescence measured prior to the introduction of ligand at t=10 seconds. 
The results are expressed as RFU/F0. Error bars have been omitted to permit a better visualization 
of the responses. 
 
 
  The NF 340 inhibition experiment was completed in nine different trials, each 
performed in quadruplicate. Figure 4.7 shows the mean inhibition response for NF 340 in 
1321N1-hP2Y11, obtained from six independent trials. The last three trials were omitted 
due to variability in the maxima of the calcium responses. The collected data were first 
analysed through non-linear regression analysis using a comparison of two equations (log 
(inhibition) three parameters versus log (inhibition) variable slope or four parameters) 
followed  by  Leff’s  null  method,  as  refined  by  Lazareno  and  Birdsall  (222,  223),  to 
determine the KB value. The resulting curve is monophasic sigmoidal and goes from its 
minimum to its maximum value over three log units of antagonist concentration, 10µM to 
10nM (log value: -5 to -8). The maximum response constitutes 102 ± 8% of the response 
to 1mM carbachol and is reached at 1nM NF 340 (log value: -9). One-way ANOVA 
analysis indicates that there is no statistically significant difference between the calcium 
response to the 10µM BzATP control and the responses to 10µM BzATP in the presence 
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of 10nM and 1nM NF 340 (log value: -8 and -9; p value= 0.95). The mean IC50 value for 
NF 340 in 1321N1-hP2Y11 cells is 261 ± 29.6 nM, the mean pIC50 value is 6.6 ± 0.05 and 
the KB is 156 ± 18 nM.  
 
  
 
Figure 4.7 NF 340 inhibits the response to 10µM BzATP in 1321N1-hP2Y11 cells   
 
The effect of increasing concentrations of NF 340, a P2Y11 antagonist, on the calcium response to 
10µM BzATP at 37°C in 1321N-hP2Y11 was tested. The curve represents the average ± s.e.m of 
six independent experiments, each performed in quadruplicate. The results are expressed as a 
percentage of the response to 10µM BzATP.  
 
    
4.3 Pharmacological characterization of a recombinant 1321N1-hP2Y1 
cell line 
In order to gain insights about the pharmacological signature of the P2Y1 receptor 
when  expressed  individually,  a  recombinant  1321N1-P2Y1  cell  line  was  created  and 
examined  with  the  same  set  of  agonists  employed  to  study  of  1321N-hP2Y11.  The 
construct  used  to  generate  the  recombinant  cell  line  was  provided  by  Dr.  Andrea 
Townsend-Nicholson and comprised the cDNA sequence of the human P2Y1 receptor 
cloned between the HindIII and XbaI sites of the pcDNA3 vector. A batch of 1321N1 
cells was stably transfected with the human P2Y1 cDNA construct, following which the 
stably transfected cell line was selected using the antibiotic Geneticin.  
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4.3.1 Calcium response of 1321N1-hP2Y1 to carbachol 
  The  newly  created  cell  line  was  first  assayed  using  carbachol  to  verify  the 
endogenous muscarinic response of 1321N1-hP2Y1. Increasing concentrations of agonist 
ranging from 1mM to 1nM (log value: -3 to -9) were applied at physiological temperature 
(37°C).  Non-linear  regression  analysis  using  a  comparison  of  two  different  equations 
(three  parameter  equation  versus  variable  slope,  or  four  parameter,  equation)  was 
subsequently  performed  to  determine  the  best  model  with  which  to  fit  the  obtained 
carbachol data. Figure 4.8 shows the average calcium response curve of 1321N1-hP2Y1 
cells  following  carbachol  addition.  The  data  was  best  fit  using  the  three  parameter 
equation,  resulting  in  a  sigmoidal  curve  that  progressed  from  its  minimum  to  its 
maximum over three log units of agonist concentration, ranging from 100nM to 31.6µM 
(log value: -7 to -4.5). The average maximal response elicited by carbachol is 1.38 ± 0.07 
(F/F0),  achieved  at  360µM  (log  value:  -3.5)  carbachol.  The  average  EC50  value  for 
carbachol in 1321N1-hP2Y1 is 688 ± 120nM and the average pEC50 value is 6.17.  
 
 
 
Figure 4.8 Concentration-response curve elicited by carbachol in 1321N-hP2Y1  
 
The  calcium  response  to  increasing  concentrations  of  carbachol  was  determined  at  37°C  in 
1321N1-hP2Y1  cells.  The  results  are  expressed  as  the  average  ±  s.e.m  of  three  independent 
experiments, each performed in quadruplicate.  
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4.3.2 Functional investigation of the activity of nucleotide and nucleotide 
derivatives in 13211N-hP2Y1  
  A pharmacological characterization of the P2Y1 receptor expressed in isolation in 
1321N1 cells was performed using the 1321N1-hP2Y1 cell line that was generated as 
described in section 4.2. The fluorescence data gathered for BzATP, UTP, αβmeATP and 
βγmeATP  was  mathematically  analysed  through  non-linear  regression  using  a 
comparison of two equations (three parameter equation versus variable slope, or four 
parameter, equation). Figure 4.9 shows the mean calcium response of the four agonists, 
obtained from one representative trial. No further experimental repeats were performed 
for these agonists as all ligands except UTP failed to produce a curve, indicating that 
these  nucleotide  derivatives  are  not  active  at  the  P2Y1  receptor.  Although  the  Prism 
software was able to fit a curve to the BzATP, αβmeATP and βγmeATP data according to 
the simple model, or three parameter equation, statistical analysis of these data revealed 
that  this  mathematical  fit  is  ambiguous  and  not  applicable.  For  instance,  one-way 
ANOVA  analysis  of  the  calcium  response  (n=3)  to  BzATP  shows  that  there  is  no 
statistically significant difference (p= 0.0745) between all seven concentrations of agonist 
tested (100µM to 10nM, log value: -4 to -8). Similarly, the calcium responses to the 
tested βγmeATP concentrations were not statistically significantly different (p= 0.3867) 
using one-way ANOVA analysis.  
 
Given  the  ambiguity  of  the  BzATP,  αβmeATP  and  βγmeATP  data,  it  was  not 
possible to calculate EC50 and pEC50 values for these agonists. In contrast, non-linear 
regression analysis of the UTP data resulted in a sigmoidal monophasic curve that was 
best  fit  using  the  three  parameter  equation.  The  resulting  curve  progressed  from  its 
minimum to its maximum over one log unit of agonist concentration, i.e. 100nM to 1µM 
(log value: -7 to -6) agonist. It achieved its maximum value, namely 32.6  ± 0.5% relative 
to 1mM carbachol, at 100µM (-4) UTP and had an EC50 of 382nM and a pEC50 value of 
6.41. 
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Figure  4.9  Concentration-response  curves  for  BzATP,  UTP,  αβmeATP  and 
βγmeATP in 1321N1-hP2Y1 cells 
 
The calcium response to increasing concentrations of BzATP ( ), UTP ( ), αβmeATP ( ) and 
βγmeATP ( ) was determined at 37°C in 1321N1-hP2Y1 cells. The results represent the average 
± s.e.m of one independent experiment performed in triplicate, and are expressed as a percentage 
of the response of 1321N1-hP2Y1 cells to 1mM carbachol. 
 
 
  The  second  set  of  experiments  studied  the  calcium  responses  to  agonists  with 
known activity at P2Y1, namely ADP, 2meSATP, ATP and ATPγS. Figure 4.10 displays 
a visual comparison between the maximum responses to ADP, ATP, 2meSATP, BzATP 
and the carbachol control over a time course of 180 seconds in 1321N1-hP2Y1 cells. As 
the graph shows, the muscarinic carbachol control elicited the highest increase in calcium 
fluorescence in this cell line. Among the studied purinergic receptor agonists, the potent 
P2Y1 agonist ADP evoked the highest peak in calcium fluorescence detected. The potent 
P2Y11 agonist BzATP, on the other hand, failed to produce a significant rise in calcium 
levels relative to the measured baseline fluorescence.  
 
  The mean calcium response curves for ADP, 2meSATP, ATP and ATPγS in the 
recombinant 1321N1-hP2Y1 cell line are shown in Figure 4.11. The concentrations of 
ADP and 2meSATP used went from 10µM to 10pM (log value: -5 to -11). ATP was 
added at concentrations ranging from 100µM to 0.1nM (log value: -4 to -10) whereas 
ATPγS concentrations ranged from 10µM to 0.1nM (log value: -5 to -9). The agonist data 
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was  subjected  to  non-linear  regression  analysis  using  a  comparison  of  two  equations 
(three parameter versus four parameter, or variable slope, equation) to determine the best 
fit for each agonist. The calcium curves of all four ligands achieved their plateaus over 
three log units of agonist concentration, ranging from 0.1nM to 100nM (log value: -10 to 
-7) for ADP and 2meSATP, 10nM to 10µM (log value: -8 to -5) for ATP and to 100µM 
(log value: -9 to -6) for ATPγS. 
 
 
 
Figure  4.10  Comparison  of  the  maximum  responses  of  five  tested  agonists  as  a 
function of time in 1321N1-hP2Y1 cells  
 
The maximum responses of BzATP, ATP, 2meSATP, ADP and the muscarinic control carbachol 
over a period of 180 seconds are shown. The maximum calcium response occurred at 100µM (log 
value: -4) for ATP (purple) and BzATP (green), 10µM (log value: -5) for ADP (red) and 100nM 
(log  value:  -7)  for  2meSATP  (navy).  The  maximum  response  to  the  carbachol  control  was 
achieved  at  100µM  (log  value:  -4)  agonist  and  is  shown  in  black.  The  naturally  occurring 
nucleotide  ADP  elicited  the  highest  increase  in  calcium  fluorescence  in  1321N1-hP2Y1  cells 
whereas the nucleotide derivative BzATP produced the smallest fluorescence trace.  
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Figure 4.11 Concentration-response curves for ADP, 2meSATP, ATP and ATPγS in 
1321N1-hP2Y1 cells 
 
The calcium response to increasing concentrations of ADP ( ), 2meSATP ( ), ATP ( ) and 
ATPγS ( ) was determined at 37°C in 1321N1-hP2Y1 cells. The results represent the average ± 
s.e.m  of  three  independent  experiments,  each  performed  in  triplicate,  and  are  expressed  as  a 
percentage of the response of 1321N1-hP2Y1 cells to 1mM carbachol. 
 
 
The calcium responses to ADP, 2meSATP, ATP and ATPγS were best fit using the 
simpler  model,  or  three  parameter  equation,  which  resulted  in  monophasic  sigmoidal 
curves for all four agonists. The maximum response to ADP occurred at 1µM (-6) agonist 
and constituted 47 ± 4% of the response to the 1mM carbachol control. The mean EC50 
value calculated for ADP is 5.8 ± 1nM. The nucleotide derivative 2meSATP elicited its 
maximum response, i.e. 45 ± 2.6% relative to 1mM, at 1µM (-6) agonist and has a mean 
EC50 value of 4.7 ± 1.3nM. The maximum response to ATP is 40.8 ± 0.7 of the response 
to  1mM  carbachol,  reached  at  10µM  (-5)  agonist  and  the  mean  EC50  value  for  this 
nucleotide is 151 ± 40nM. The agonist ATPγS produced its maximum response, i.e. 24.3 
± 1.7% relative to 1mM carbachol, at 100µM (-4) agonist and has a mean EC50 value of 
15.6 ± 3.6 nM. Using one-way ANOVA analysis, there was no statistically significant 
difference between the mean maximum responses, relative to 1mM carbachol control, for 
the agonists ADP, 2meSATP and ATP (p=0.1842). However, ANOVA analysis revealed 
that there is a statistically significant difference between the maximum responses to these 
three ligands compared to the maximum response elicited by ATPγS (**, p= 0.0015).  
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4.3.3 Antagonist studies in 1321N1-hP2Y1  
  Having  determined  the  agonist  profile  of  the  receptor,  an  investigation  of  its 
antagonist  profile  was  carried  out.  This  was  achieved  using  three  antagonists:  an 
established P2Y1 antagonist, MRS 2179 (151), the P2Y-selective antagonist and ecto-
nucleotidase  inhibitor  Reactive  Red  (224)  and  a  P2Y11  selective  antagonist,  NF  340 
(221). The antagonist studies were conducted in the form of IC50 inhibition curves where 
increasing concentrations of antagonist were added to a fixed concentration of agonist. 
ADP was selected as the agonist of choice for these experiments given its potency in 
activating P2Y1 and the fact that it resulted in a biphasic response in the recombinant 
CHO-K1-hP2Y11 clone 13.  
 
  The  first  ligand  to  be  investigated  was  the  P2Y1  inhibitor,  MRS  2179.  The 
antagonist was added at increasing concentrations ranging from 1mM to 1nM (log value: 
-3 to -9) to a fixed concentration of agonist, 1µM ADP (log value: -6), which corresponds 
to the concentration at which the maximum response to ADP is observed, as described in 
section 4.3.2. MRS 2179 exerted a concentration-dependent inhibitory action against the 
ADP response in 1321N1-hP2Y1. Figure 4.12 shows a representative time course of this 
inhibitory  activity  over  a  period  of  180  seconds.  As  the  traces  reveal,  higher 
concentrations  of  antagonist,  namely  1mM  and  316µM  (log  value:  -3  and  -3.5) 
completely block the response to ADP, suppressing it to baseline level. The effect of the 
antagonist on the ADP response subsides starting from 100µM MRS 2179 (-4) as the 
calcium fluorescence elicited by the agonist progressively increases. The ADP response is 
93% of the control response to 1µM ADP (measured in the absence of antagonist) at the 
lowest concentration of antagonist tested, i.e. 100nM (log value: -7) MRS 2179.  
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Figure 4.12 Time dependence of the response to ADP in the presence of MRS 2179 
in 1321N1-hP2Y1 cells 
 
The effect of increasing concentrations of MRS 2179, a P2Y1 antagonist, on the response elicited 
by 1µM ADP was assessed over time in 1321N1-hP2Y1 cells. The log10 concentrations of MRS 
2179 used were: -3 (
…), -3.5 (
_ _), -4 (grey), -4.5 (red), -5 (navy), -6 (purple) and -7 (green). The 
calcium fluorescence elicited by the 1µM ADP control is shown (
__). The traces represent the 
mean  calcium  response  obtained  from  one  independent  experiment  performed  in  triplicate, 
divided by the baseline fluorescence measured prior to the introduction of ligand at t=10 seconds. 
The results are expressed as RFU/F0. Error bars have been omitted to permit a better visualization 
of the responses.  
 
 
  The  MRS  2179  data,  obtained  from  four  independent  trials,  were  normalized 
against  the  response  to  the  1µM  ADP  (-6)  control  and  analysed  using  non-linear 
regression and Leff’s null method. A comparison of two inhibitory dose-response models, 
namely  the  log  (inhibitor)  three  parameter  equation  versus  the  log  (inhibitor)  four 
parameter, or variable slope, equation was performed. The preferred model for all four 
trials was the simpler model, or three parameter equation. Figure 4.13 shows the mean 
IC50  inhibition  curve  for  MRS  2179  in  1321N1-hP2Y1  cells.  The  depressive  action 
exerted by the antagonist on the response to 1µM ADP was concentration dependent and 
occurred over five log units of antagonist concentration, i.e. 1mM to 10nM (log value: -3 
to -8) MRS 2179. The average maximum response to ADP in the presence of MRS 2179 
was measured at 10nM (-8) antagonist. The mean IC50 value for MRS 2179 in 1321N1-
hP2Y1 cells is 22 ± 3µM, the mean pIC50 is 4.68 ± 0.07 and the KB is 124 ± 17nM.  
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Figure 4.13 MRS 2179 inhibits the response to 1µM ADP in 1321N-hP2Y1 
 
The effect of increasing concentrations of MRS 2179, a P2Y1 antagonist, on the calcium response 
to 1µM ADP was tested at 37°C in 1321N1-hP2Y1. The curve represents the average ± s.e.m of 
four independent experiments, performed in triplicate or quadruplicate. The results are expressed 
as a percentage of the response to the 1µM ADP control.  
 
 
  The next antagonist to be investigated was Reactive Red, which was added to 
1µM ADP at increasing concentrations ranging from 100µM to 10nM (log value: -4 to -
8). Figure 4.14 displays a time course of the response to 1µM ADP in the presence of 
Reactive Red. As the figure shows, Reactive Red failed to alter the response to ADP at 
concentrations between 10µM and 10nM (log value: -5 to -8) but provoked a decline in 
calcium fluorescence at the higher concentrations of Reactive Red tested, i.e 31.6µM and 
100µM  (log  value:  -4  and  -4.5).  The  data  was  further  evaluated  using  non-linear 
regression  analysis  through  a  comparison  of  two  equations  (log  (inhibitor)  three 
parameter equation versus log (inhibitor) four parameter, or variable slope, equation). 
Figure 4.15 shows the mean IC50 inhibition curve for Reactive Red in 1321N1-hP2Y1. 
Analysis revealed that both fits were ambiguous and it was not possible to calculate an 
IC50 value for the Reactive Red data in 1321N1-hP2Y1. 
 
 
-9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
log10 antagonist (M)
C
a
l
c
i
u
m
 
R
e
s
p
o
n
s
e
 
(
%
 
o
f
 
c
o
n
t
r
o
l
 
A
D
P
 
r
e
s
p
o
n
s
e
)Chapter 4      Pharmacological Characterization of Recombinant 1321N1-hP2Y1 and 1321N1-hP2Y11 Cell 
Lines 
	 ﾠ 107	 ﾠ
 
Figure 4.14 Time dependence of the response to ADP in the presence of Reactive 
Red in 1321N1-hP2Y1 cells  
 
The effect of increasing concentrations of Reactive Red, a P2Y selective inhibitor, on the calcium 
response to 1µM ADP was assessed over time in 1321N1-hP2Y1 cells. The log10 concentrations of 
Reactive Red used were: -4 (
…), -4.5 (
_ _), -5 (grey), -5.5 (red), -6 (navy), -7 (purple) and -8 
(green). The calcium fluorescence elicited by the 1µM ADP control is also shown (
__). The traces 
represent the mean calcium response obtained from one independent experiment performed in 
triplicate, divided by the baseline fluorescence measured prior to the introduction of ligand at 
t=10 seconds. The results are expressed as RFU/F0. Error bars have been omitted to permit a 
better visualization of the responses.  
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Figure  4.15  The  calcium  response  to  ADP  in  the  presence  of  Reactive  Red  in 
1321N1-P2Y1 
 
The  effect  of  increasing  concentrations  of  Reactive  Red,  a  P2Y  selective  antagonist,  on  the 
calcium response to 1µM ADP was tested at 37°C in 1321N-hP2Y1 cells. The curve represents 
the average ± s.e.m of four independent experiments, each performed in triplicate. The results are 
expressed as a percentage of the response to 1µM ADP.  
 
 
  The last ligand to be tested was the P2Y11 selective inhibitor NF 340, which was 
added to 1µM ADP at increasing concentrations ranging from 100µM to 0.1nM (log 
value: -4 to -10). Figure 4.16 shows a representative time course of the response to ADP 
in the presence of NF 340 in 1321N1-hP2Y1 cells. As the graph reveals, none of the 
tested concentrations of antagonist were able to alter the level of calcium fluorescence 
elicited  by  1µM  ADP.  Non-linear  regression  analysis  using  a  comparison  of  the  log 
(inhibitor) three parameter equation versus the log (inhibitor) four parameter, or variable 
slope, equation was also performed and the mean IC50 inhibition curve is shown in Figure 
4.17. Both models were ambiguous and failed to fit a curve to the measured data.  
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Figure 4.16 Time dependence of the calcium response to ADP in the presence of NF 
340 in 1321N1-hP2Y1 cells  
 
The effect of increasing concentrations of NF 340, a P2Y11 antagonist, on the response to 1µM 
ADP was investigated over time in 1321N1-hP2Y1 cells. The log10 concentrations of NF 340 used 
were: -4 (
…), -4.5 (
_ _), -5 (grey), -5.5 (red), -6 (navy), -7 (purple) and -8 (green). The calcium 
fluorescence elicited by the 1µM ADP control is also shown (
__). The traces represent the mean 
calcium response obtained from one independent experiment performed in triplicate, divided by 
the baseline fluorescence measured prior to the introduction of ligand at t=10 seconds. The results 
are expressed as RFU/F0. Error bars have been omitted to permit a better visualization of the 
responses. 	 ﾠ
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Figure 4.17 NF 340 does not inhibit the response to 1µM ADP in 1321N1-P2Y1  
 
The effect of increasing concentrations of NF 340, a P2Y11 antagonist, on the calcium response to 
1µM ADP was tested at 37°C in 1321N-hP2Y1. The curve represents the average ± s.e.m of four 
independent experiments, each performed in triplicate. The results are expressed as a percentage 
of the response to the 1µM ADP control. One-way ANOVA analysis shows that none of the 
increasing concentrations of NF 340 has an effect on the response to 1µM ADP.  
 
 
4.4 Conclusion  
  In  this  chapter,  two  distinct  systems,  1321N1-hP2Y1 and  1321N1-hP2Y11,  were 
characterized. Table 4.1 shows the average EC50 and pEC50 values measured for eight 
different nucleotides and nucleotide derivatives and carbachol in both cell lines. 1321N1-
hP2Y1 cells were activated by five out of eight tested nucleotide analogues, namely ADP, 
2meSATP, ATPγS, ATP and UTP, but did not respond to the P2Y11 agonists BzATP, 
αβmeATP and βγmeATP. The rank order of agonist potency in 1321N1-hP2Y1 is:  
 
2meSATP (8.33) ≈ ADP (8.24) > ATPγS (7.81) > ATP (6.82)> UTP (6.41) > carbachol 
(6.17). 
 
1321N1-hP2Y11  cells  responded  to  six  out  of  eight  tested  ligands,  including 
BzATP, αβmeATP, βγmeATP, ATP, ATPγS and 2meSATP. ADP and UTP, on the other 
hand,  failed  to  elicit  a  response  in  these cells.  The  rank  order  of  agonist  potency  in 
1321N1-hP2Y11 is: 
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Carbachol (5.54) ≈  BzATP (5.51) ≈ ATPγS (5.50) > ATP (5.05) ≈  2mesATP (4.98) > 
βγmeATP (4.19) ≈  αβmeATP (4.15) 
   
  To  formulate  a  comparative  rank  order  of  agonist  potencies  in  1321N1-hP2Y1 
versus 1321N1-hP2Y11, the mean EC50 value of each agonist was divided by the mean 
EC50 value for 2meSATP in each cell line (ratios shown in Table 4.2). 2meSATP was 
chosen as the control ligand against which agonist potencies were normalized because it 
activates both P2Y1 and P2Y11 receptors and was found to elicit a biphasic response in 
clone 13.  
 
 
Agonist 
EC50 
(nM + s.e.m.) 
pEC50 
1321N1-P2Y1  1321N1-P2Y11  1321N1-P2Y1  1321N1-P2Y11 
ADP   5.8 ± 1.0  ND  8.24  ND 
ATP  151 ± 40  9000 ± 1400  6.82  5.05 
UTP  382  ND  6.41  ND 
2meSATP   4.7 ± 1.3  10500 ± 2500  8.33  4.98 
αβmeATP  ND  70800 ± 11500  ND  4.15 
βγmeATP  ND  64000 ± 19000  ND  4.19 
ATPγS  15.6 ± 3.6    3200 ± 260  7.81  5.50 
BzATP  ND    3100 ± 260  ND  5.51 
Carbachol  672 ± 154    2900 ± 500  6.17  5.54 
Table 4.1 The calcium response elicited by nucleotide analogues and carbachol in 
1321N1-hP2Y11 and 1321N1-hP2Y1 cells 
 
The EC50 and pEC50 values of a set of seven nucleotide analogues and carbachol were determined 
in 1321N1-hP2Y1 and 1321N1-hP2Y11 cells. The results are expressed as the mean EC50 and the 
mean pEC50 of three independent experiments, each performed in triplicate. The ND sign (not 
determined) refers to agonists that failed to elicit a significant calcium response and for which it 
was not possible to determine an EC50 or pEC50 value.  
 
    
The rank order of agonist potencies in 1321N1-hP2Y1 cells using the mean EC50 of 
2meSATP as a reference is  
2meSATP (1) > ADP (1.23) > ATPγS (3.32) > ATP (32) > UTP (81) > 
carbachol (142) 
  where 2meSATP = 1.0, >1 = less potency and <1 = greater potency than the 
reference ligand. The rank order of agonist potencies in 1321N1-hP2Y11  cells using 
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Carbachol (0.28) > BzATP (0.3) = ATPγS (0.3) > ATP (0.86) > 2meSATP (1) 
> βγmeATP (6.1) > αβmeATP (6.74) 
  where 2meSATP = 1.0, >1 = less potency and <1 = greater potency than the 
reference ligand. 
 
 
Agonists  
Ratio 
 
1321N1-P2Y1              1321N1- P2Y11 
ADP  1.23  ND 
ATP  32  0.86 
UTP  81  ND 
2meSATP  1  1 
αβmeATP  ND  6.74 
βγmeATP  ND  6.1 
ATPγS  3.32  0.3 
BzATP  ND  0.3 
carbachol  142  0.28 
Table 4.2 Comparison of agonist potencies of the calcium response in 1321N1-hP2Y1 
and 1321N1-hP2Y11  
 
The ratio of the mean EC50 of each of the tested agonists was divided by the mean EC50 of 
2meSATP in both 1321N1-hP2Y1 and 1321N1-hP2Y11. 2meSATP was chosen as the reference 
agonist because it acts on both P2Y1 and P2Y11 receptors thus allowing a comparison of potencies 
in  the  two  cell  lines.  The  ND  sign  (not  determined)  refers  to  agonists  that  failed  to  elicit  a 
significant calcium response and for which it was not possible to determine a ratio.  
 
 
  Figures 4.18 and 4.19 offer a visual comparison between the calcium response 
curves  for  the  eight  nucleotides  and  nucleotide  derivatives  tested  in  1321N1-hP2Y1 
versus  1321N1-hP2Y11.  As  the  graphs  show,  the  calcium  responses  of  the  agonists 
achieved higher maxima relative to carbachol control in 1321N1-hP2Y11 cells as opposed 
to 1321N1-hP2Y1 cells and one-way ANOVA analysis confirms that they are statistically 
significant different (****; p < 0.0001). In contrast, calcium response curves in 1321N1-
hP2Y1 cells were shifted to the left as compared to 1321N1-hP2Y11, signifying that the 
agonists were more potent in the Y1-only as opposed to the Y11-only cells.  
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Figure 4.18 Visualization of differences in agonist responses in 1321N1-hP2Y11 and 
1321N1-hP2Y1  
The calcium responses of 1321N1-hP2Y1  and 1321N1-hP2Y11  to  each  of  the  eight  tested  agonists  are 
shown on a single graph to allow comparison of the functional responses in each recombinant cell line. A) 
BzATP; B) ATPγS; C) ATP; D) αβmeATP; E) ADP; F) UTP; G) 2meSATP and H) βγmeATP.     
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Figure 4.19 Comparison of agonist responses in 1321N1-hP2Y1 and 1321N1-hP2Y11   
 
The calcium responses of 1321N1-hP2Y1 and 1321N-hP2Y11 to two distinct sets of agonists are 
shown on two different graphs to allow comparison of the functional responses in the Y1-only cell 
line  versus  the  Y11-only  cell  line.  A.  BzATP,  ATPγS,  ATP  and  αβmeATP;  B.  ADP,  UTP, 
2meSATP and βγmeATP.  
 
   
-10 -9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
log10 agonist (M)
C
a
l
c
i
u
m
 
R
e
s
p
o
n
s
e
 
(
p
e
r
c
e
n
t
 
o
f
 
c
a
r
b
a
c
h
o
l
 
c
o
n
t
r
o
l
)
BzATP Y1
BzATP Y11
ATP Y1
ATP Y11
ATPγS Y1
ATPγS Y11
αβmeATP Y1
αβmeATP Y11
-11 -10 -9 -8 -7 -6 -5 -4 -3
0
30
60
90
120
150
180
log10 agonist (M)
C
a
l
c
i
u
m
 
R
e
s
p
o
n
s
e
 
(
p
e
r
c
e
n
t
 
o
f
 
c
a
r
b
a
c
h
o
l
 
c
o
n
t
r
o
l
)
ADP Y1
ADP Y11
2meSATP Y1
2meSATP Y11
UTP Y1
UTP Y11
βγmeATP Y1
βγmeATP Y11Chapter 4      Pharmacological Characterization of Recombinant 1321N1-hP2Y1 and 1321N1-hP2Y11 Cell 
Lines 
	 ﾠ 115	 ﾠ
In  conclusion,  the  detailed  pharmacological  investigation  of  1321N1-hP2Y1  and 
1321N1-hP2Y11  reveals  that  ADP  activates  1321N1-hP2Y1  cells  only  while  BzATP 
activates 1321N1-hP2Y11 cells only when the receptor subtypes are expressed in a null 
system. In contrast, 2meSATP acts at both hP2Y1 and hP2Y11 but has greater potency at 
the  hP2Y1  receptor  as  compared  to  hP2Y1.  Finally,  ATP  and  ATPγS  activate  both 
receptors with a similar order of potency.  
 
  Inhibition  studies  were  subsequently  performed  in  both  cell  lines  to  identify 
antagonists for each receptor. For instance, the calcium response of 1321N1-hP2Y1  cells 
to ADP was tested in the presence of three ligands, the P2Y1 antagonist MRS 2179, the 
P2Y11 antagonist NF 340 and Reactive Red. As was expected, MRS 2179 competitively 
inhibited  the  ADP  response  in  these  cells  whereas  NF  340  failed  to  antagonise  it. 
Reactive  Red  reduced  this  response  at  concentrations  above  10µM  only.  In  1321N1-
hP2Y11 cells, NF 340 inhibited the calcium response to BzATP, thus confirming that it is 
an  antagonist  of  P2Y11.  Data  published  by  King  and  Townsend-Nicholson  state  that 
reactive Red is another competitive inhibitor of this receptor while MRS 2179 does not 
inhibit  it (174).  Table  4.3  displays  the  IC50  and  pIC50  values  for  the  three  described 
antagonists in 1321N1-hP2Y1 versus 1321N1-hP2Y11 cells. The results presented in this 
chapter will be of assistance in analysing the biphasic response to ADP and 2meSATP in 
clone 13 described in chapter 3.  
 
 
Antagonist 
IC50 
(µM + s.e.m.) 
1321N1-P2Y1    1321N1-P2Y11 
pIC50 
 
1321N1-P2Y1    1321N1-P2Y11 
MRS 2179  17.4 ± 3.6  ND  4.8  ND 
Reactive Red  ND  ND  ND  ND 
NF 340  ND  0.28 ± 0.05  ND  6.62 
Table 4.3 The activity of antagonists in 1321N1-hP2Y1 versus 1321N1-hP2Y11 cells  
 
This table shows the IC50 and pIC50 values for three antagonists in hP2Y1-only versus hP2Y11-
only cells. The P2Y1  antagonist, MRS 2179, behaves as a competitive inhibitor of hP2Y1  in 
1321N1-hP2Y1  cells  but  does  not  affect  hP2Y11  activity  in  1321N1-hP2Y11  cells.  The  P2Y11 
antagonist NF 340 is a competitive inhibitor of hP2Y11 but does not alter hP2Y1 signalling. The 
P2Y  selective  antagonist  Reactive  Red  inhibits  the  calcium  response  at  higher  ligand 
concentrations only in 1321N1-hP2Y1 cells but is a full inhibitor of hP2Y11 (as described in the 
literature). The ND sign (not determined) refers to antagonists that failed to inhibit the calcium 
response and for which it was not possible to determine IC50 and pIC50 values.  
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Chapter 5 
Antagonist Experiments in CHO-K1-hP2Y11 Clone 13 
 
5.1 Introduction  
The combined findings from Chapters 3 and 4 illustrate how the calcium responses 
of hP2Y1 and hP2Y11 differ in a one receptor only system versus a co-expressing system. 
The detection of biphasic calcium responses in the P2Y1+P2Y11 system suggests that co-
expression could reconfigure the individual binding affinities of these two purinoceptors, 
thus creating novel sites of agonist and antagonist sensitivity. To verify this hypothesis 
and  determine  whether  the  biphasic  effect  is  due  to  agonist  binding  to  two  separate 
populations of receptors with different ADP properties as opposed to two separate sites of 
the same receptor, a series of antagonist studies were performed in clone 13.  
 
5.2 MRS 2179 Schild experiments in CHO-K1-hP2Y11 clone 13 
“An  alternative  method  of  estimating  antagonistic  power  is  to  determine  the 
concentration of B, which alters by a selected proportion (e.g. tenfold) the concentration 
of A needed to produce a selected effect’’ (225). In an article entitled “Why the Schild 
method is better than Schild realised”, David Colquhoun explains that the ‘beauty’ of the 
Schild experiment is that “the agonist does not appear at all. The nature of the agonist, its 
concentration, affinity and efficacy are all irrelevant.” Thus, the rightward shift of the 
concentration-response  curve  caused  by  antagonist  addition  should  be  the  same, 
independently of the nature of the agonist or amplitude of the response (206). In light of 
these theoretical predictions, the biphasic concentration-response curve for ADP in clone 
13 was tested in the presence of MRS 2179, NF 340 and Reactive Red to determine 
whether  any  of  these  ligands  would  shift  this  response  to  the  right.  ADP  signalling 
constituted the main focus of these Schild experiments because this P2Y1 selective ligand 
induced a biphasic response in clone 13, indicating the possible existence a novel site of 
agonist activity in the high-expressing clone.  
 
5.2.1 Schild analysis of MRS 2179 activity at the ADP response  
  Concentration-response  curves  for  increasing  concentrations  of  ADP  were 
generated in the absence and presence of 1µM, 10µM, 100µM and 316µM (log value: -6, 
-5, -4 and -3.5) MRS 2179. The high and low affinity sites were divided into separate Chapter 5  Antagonist Experiments in CHO-K1-hP2Y11 Clone 13 
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curves with fixed upper and lower limits, analysed individually using global non-linear 
regression and summed together to generate the average Schild curves shown in Figure 
5.1.  The  control  ADP  curve  was  biphasic  and  progressed  from  its  minimum  to  its 
maximum over four log units of agonist concentration (10nM to 100µM; log value: -8 to -
4). The high affinity site occurred between 10nM to 1µM ADP (log value: -8 to -6), while 
the low affinity site went from 1µM to 100µM (log value: -6 to -4). The maximum 
response to ADP was observed at 100µM and constituted 92 ± 3% of the UTP control. 
Similarly,  the  ADP  response  in  the  presence  of  1µM  MRS  2179  was  biphasic.  Its 
maximum occurred at 100µM agonist and constituted 90.8 ± 5% of the UTP control.  
 
 
 
Figure 5.1 The effect of MRS 2179 on the calcium response to ADP in CHO-K1-
hP2Y11 clone 13  
 
The response of CHO-K1-hP2Y11 cells to increasing concentrations of ADP was tested in the 
absence (●) and presence of four different concentrations of the P2Y1 antagonist MRS 2179: -3.5 
( ), -4 (○), -5 ( ) and -6 ( ). The results represent the average ± s.e.m of four independent 
experiments each performed in triplicate and are expressed as a percentage of the response to 
100µM UTP. Increasing concentrations of MRS 2179 caused a rightward shift of the ADP curves 
without affecting the maximum calcium response of the agonist, thus converting the biphasic 
response into a monophasic response in the presence of higher concentrations of MRS 2179.   
   
 
  The addition of 10µM MRS 2179 altered the biphasic response to ADP. In fact, it 
was not possible to fit a curve to the data corresponding to the high affinity site although 
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the calcium response at the low affinity site was retained. The resulting average curve 
was monophasic sigmoidal and progressed from its minimum to its maximum over three 
log  units  of  agonist  concentration,  i.e.  100nM  to  100µM  (log  value:  -7  to  -4).  Its 
maximum response constituted 89 ± 4% of the UTP control at 100µM ADP. The addition 
of 100µM and 316µM MRS 2179 also supressed agonist activity at the high affinity site 
and shifted the ADP response to the right of the previous curves. Both data sets generated 
a monophasic response that progressed from its minimum to its maximum over two log 
units of agonist concentration, i.e. 1µM to 100µM (log value: -6 to -4), corresponding to 
the high affinity site of the control biphasic curve. The average maximum response was 
83 ± 3.5% and 81 ± 3.4% of the UTP control at 100µM ADP, respectively, and was not 
statistically significantly different from that of previous curves (p value = 0.2737).  
 
  The average EC50 values of the ADP curves in the absence and presence of MRS 
2179 are listed in Table 5.1. Agonist potencies at the high and low affinity sites of the 
control ADP curve were statistically significantly different (**; p value = 0.0069). ADP 
exhibited the same potency at the high affinity sites of the ADP and ADP + 1µM MRS 
2179 curves (p value = 0.2993) and this site disappeared in the presence of 10, 100 and 
316µM  MRS  2179.  Furthermore,  the  ADP  response  at  the  low  affinity  sites  of  the 
biphasic curves was similar to the monophasic ADP response in the presence of higher 
antagonist concentrations (p value = 0.0546), confirming that MRS 2179 does not inhibit 
the low affinity site of the response.  
 
 
Antagonist Concentration  EC50-1 
(µM + S.E.M.) 
EC50-2 
(µM + S.E.M.) 
Fraction  
ADP  0.028 ± 0.01  16.7 ± 3.3  0.55 ± 0.20 
ADP + 1µM MRS 2179  0.18 ± 1.3    1.7 ± 0.7  0.62 ± 0.07 
ADP + 10µM MRS 2179  ND    1.8 ± 0.6  ND 
ADP + 100µM MRS 2179  ND    4.8 ± 1.6  ND 
Table  5.1  The  EC50  shift  of  the  calcium  response  to  ADP  in  the  presence  of  increasing 
concentrations of MRS 2179 in CHO-K1-hP2Y11 clone 13 
 
The EC50 values for ADP concentration-response curves in the absence and presence of three 
different dilutions of MRS 2179 were calculated in CHO-K1-hP2Y11 clone 13. The fractions of 
the biphasic curves, showing the contribution of the high affinity site to the response, are also 
shown.  The  results  represent  the  average  ±  s.e.m  of  four  independent  experiments,  each 
performed in triplicate. ND (not determined) refers to replicates for which a value could not be 
determined. Chapter 5  Antagonist Experiments in CHO-K1-hP2Y11 Clone 13 
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  To determine the nature of the antagonism exerted by MRS 2179 against ADP, the 
Schild curves were globally fit using the Gaddum/Schild EC50 shift equation. Figure 5.2 
shows the rightward shift of the ADP curves in the absence and presence of increasing 
concentrations of MRS 2179 in clone 13. The mean Schild slope of the curves, which 
measures  how  well  the  rightward  shifts  concord  with  the  “prediction  of  competitive 
antagonism” (Prism Software Help), was 0.8 ± 0.08. The mean KB value for MRS 2179 
was 0.5 ± 0.2µM and the mean pA2 was 6.4 ± 0.2. To further ascertain the extent of the 
shift produced by MRS 2179 against ADP, the dose ratios for antagonist concentrations 
316  µM,  100µM,  10µM  and  1µM  (log  values:-3.5,  -4,  -5  and  -6)  were  manually 
calculated and plotted using linear regression analysis. The data formed a straight line 
with a mean slope of 0.87 ± 0.13, and the Schild plot is shown in figure 5.3. These results 
suggest that the antagonism exerted by MRS 2179 against ADP is competitive.  
 
 
 
Figure 5.2 EC50 Shift of the MRS 2179 and ADP Schild in CHO-K1-hP2Y11 clone 13  
 
The EC50 shift of the calcium response to ADP in the presence of MRS 2179 was analyzed using 
the Gaddum equation in CHO-K1-hP2Y11 clone 13. The log10 concentrations of MRS 2179 used 
were: -3.5 ( ), -4 (○), -5 ( ) and -6 ( ). The results represent the average ± s.e.m of four 
independent experiments each performed in triplicate and are expressed as a percentage of the 
response to 100µM UTP.  
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Figure 5.3 Schild plot for MRS 2179 against ADP in clone 13    
 
The dose ratios for MRS 2179 concentrations 316 µM, 100µM, 10µM and 1µM (log values:-3.5, -
4, -5 and -6) tested against ADP were calculated manually and analysed using linear regression. 
The plotted values fell into a straight line with a slope of 0.87 ± 0.13, indicating that MRS 2179 is 
a competitive antagonist of ADP.  The results represent the average ± s.e.m of four independent 
experiments, each performed in triplicate. The 95% confidence interval of the fit is represented by 
dotted lines. 
 
 
5.2.2 Schild analysis of MRS 2179 activity at the 2meSATP response 
  To  determine  the  effect  of  MRS  2179  on  the  biphasic  response  to  2meSATP, 
concentration-response curves were generated in the absence and presence of increasing 
antagonist concentrations, ranging from 1µM to 100µM (log value: -6 to -4). The data 
were analysed as per section 5.2.1. and the average Schild curves are shown in Figure 5.4. 
The control 2meSATP response was biphasic and progressed from its minimum to its 
maximum over four log units of agonist concentration, i.e. 10nM to 100µM (log value: -8 
to -4), for all trials. The high affinity site ranged from 100nM to 1µM (log value: -8 to -6) 
while the low affinity response occured from 1µM to 100µM (log value: -6 to -4) agonist. 
The maximum ADP response occured at 100µM (log value: -4) and constituted 94 ± 4% 
of response to 100µM UTP control. The 2meSATP response in the presence of 1µM 
MRS 2179 (log value: -6) was also biphasic. 
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Figure 5.4 The effect of MRS 2179 on the calcium response to 2meSATP in CHO-
K1-hP2Y11 clone 13  
 
The  response  of  CHO-K1-hP2Y11  cells  to  increasing  concentrations  of  the  P2Y1  and  P2Y11 
agonist 2meSATP was tested in the absence (●) and presence of three different concentrations of 
MRS  2179:  -4  ( ),  -5  ( )  and  -6  ( ).  The  results  represent  the  average  ±  s.e.m  of  six 
independent experiments each performed in triplicate and are expressed as a percentage of the 
response to 100µM UTP.  
 
 
The addition of 10µM MRS 2179 althered the biphasic response to 2meSATP in 
clone 13. Non-linear regression failed to fit the data corresponding to the low affinity site. 
The resulting curve was monophasic sigmoidal with a maximum response of 95.8 ± 4.8%  
relative to the UTP control at 100µM 2meSATP. The highest concentration of antagonist 
tested, i.e. 100µM MRS 2179, also inhibted the low affinity site of the biphasic cruve and 
resulted in a monophasic ADP response with a maximum of 102.7 ± 5% relative to the 
UTP control at 100µM 2meSATP.  
 
  The  EC50  values  for  2meSATP  in  the  presence  and  absence  of  MRS  2179  are 
shown in Table 5.2. The 2meSATP potencies were distinct at the high versus low affinity 
sites of the control 2meSATP (**; p value = 0.0014) and 2meSATP + 1µM MRS 2179 
curves (*; p value = 0.0171). The agonist elicited the same response at the high affinity 
portions of both curves (p value = 0.21) and this site disappeared in the presence of 
higher antagonist concentrations. Furthermore, the 2meSATP potency at the low affinity 
site of the biphasic curves was the same as its potency in the presence of 10 and 100µM 
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MRS 2179  (p value = 0.0699), indicating that the antagonist did no inhibit the low 
affinity site.   
 
 
Antagonist Concentration  EC50-1 
(µM + S.E.M.) 
EC50-2 
(µM + S.E.M.) 
Fraction  
2meSATP  0.12 ± 0.05  4.5 ± 0.9  0.46 ± 0.06 
2meSATP + 1µM MRS 2179  0.3 ± 1.2  8.9 ± 3.2  0.69 ± 0.09 
2meSATP + 10µM MRS 2179  ND  2.4 ± 0.7  ND 
2meSATP + 100µM MRS 2179  ND  4.2 ± 0.8  ND 
Table 5.2 The EC50 shift of the calcium response to 2meSATP in the presence of 
increasing concentrations of MRS 2179 in CHO-K1-hP2Y11 clone 13 
 
The EC50 values for 2meSATP concentration-response curves in the absence and presence of 
three different dilutions of MRS 2179 were calculated in CHO-K1-hP2Y11 clone 13. The fractions 
of the biphasic curves, showing the contribution of the high affinity site to the response, are also 
shown.  The  results  represent  the  average  ±  s.e.m  of  four  independent  experiments,  each 
performed in triplicate. ND (not determined) refers to replicates for which a value could not be 
determined. 
 
 
  The Schild data were analyzed using the Gaddum/Schild EC50 shift equation to 
investigate the nature of the antagonism exerted by MRS 2179 against 2meSATP in clone 
13 cells. As Figure 5.5 shows, the addition of increasing concentrations of antagonist 
provoked  a  rightward  shift  of  the  2meSATP  curves  without  affecting  the  maximum 
response. The mean Schild slope of the curves was 0.87 ± 0.07. The mean KB value for 
MRS 2179 against 2meSATP was 21.5 ± 12.6µM and the mean pA2 value was 5.4 ± 0.5. 
The dose ratios for antagonist concentrations 100µM, 10µM and 1µM (log values:-3.5, -4, 
-5 and -6) were manually calculated and plotted using linear regression analysis. The data 
formed a straight line with a mean slope of 1 ± 0.3, and the average Schild plot is shown 
in Figure 5.6 A. The large error bars (up to 39%) observed for all three points are due to 
the variability within the different experimental trials. To offer a more accurate depiction 
of the dose ratios, a representative Schild plot calculated from one individual repeat is 
displayed in Figure 5.6 B. As the graph shows, the points formed a straight line with a 
slope of 1. Gaddum and Schild plot analysis suggest that the antagonism exhibited by 
MRS  2179  against  the  2meSATP  response  is  competitive.  Furthermore,  MRS  2179 
antagonised the high-affinity site of the curve only, indicating that the receptor acting at 
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Figure 5.5 EC50 Shift of the MRS 2179 and 2meSATP Schild in CHO-K1-hP2Y11 
clone 13  
 
The EC50 shift of the calcium response to 2meSATP as a function of increasing concentrations of 
MRS 2179 was analyzed using the Gaddum equation in CHO-K1-hP2Y11 clone 13. The log10 
concentrations of MRS 2179 used were: -4 ( ), -5 ( ) and -6 ( ). The results represent the 
average ± s.e.m of six independent experiments each performed in triplicate and are expressed as 
a percentage of the response to 100µM UTP.  
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A.          B.  
 
 
Figure 5.6 Schild plot for MRS 2179 against 2meSATP in clone 13    
 
A. Average Schild plot for MRS 2179 against 2meSATP in clone 13. The concentration ratios for 
MRS 2179 concentrations 100µM, 10µM and 1µM (log values: -4, -5 and -6), were calculated 
manually and analysed using linear regression. The results represent the average ± s.e.m of six 
individual experiments, each performed in triplicate. The 95% confidence interval of the fit is 
represented by doted lines. The large error bars observed for the data points are due to variability 
within the experimental repeats. B. Representative Schild plot for MRS 2179 against 2meSATP 
in clone 13 obtained from one of the six individual experiments used to obtain the average plot 
shown in A. The dose ratios for MRS 2179 concentrations 100µM, 10µM and 1µM (log values: -
4, -5 and -6), were calculated manually and analysed using linear regression. The results were 
calculated from one independent experiment performed in triplicate. The 95% confidence interval 
of the fit is represented by doted lines.  
 
 
5.3 NF 340 Schild analysis in CHO-K1-hP2Y11 clone 13 
To determine the effect of a P2Y11 antagonist on the calcium response in clone 13, 
ADP  concentration-response  curves  were  generated  in  the  presence  and  absence  of 
different dilutions of NF 340. Data were analysed using global non-linear regression with 
a  comparison  of  two  equations  (biphasic  equation  versus  variable  slope  or  four 
parameters equations) and the average concentration-response curves are shown in Figure 
5.7.  All  the  curves  (control,  ADP+1µM,  ADP+10µM  and  ADP+100µM  NF  340) 
progressed  from  their  minimum  to  their  maximum  over  four  log  units  of  agonist 
concentration, ranging from 100nM to 100µM (log value: -8 to - 4) and were best fit 
using the biphasic model. Table 5.3 lists the EC50 values of the Schild curves.  Using one-
way ANOVA analysis, there was a statistically significant difference between the EC50-1 
and  EC50-2  values  of  all  the  biphasic  ADP  curves  (**,  p  value  =  0.0075).  The 
Gaddum/Schild EC50 shift equation failed to fit the ADP+NF 340 data and yielded a 
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Schild slope of 0.0018, indicating that antagonist addition did not alter the potency of the 
ADP response in clone 13 cells. Global non-linear regression and Gaddum analysis of the 
ADP+NF 340 data thus reveal that the P2Y11 antagonist NF 340 does not inhibit the 
biphasic response to ADP in clone 13. 
 
 
 
Figure 5.7 The effect of NF 340 on the calcium response to ADP in CHO-K1-hP2Y11 
clone 13  
 
The response of CHO-K1-hP2Y11 cells to increasing concentrations of the P2Y1 agonist ADP was 
tested in the absence (●) and presence of three different concentrations of the P2Y11 antagonist 
NF 340: -4 ( ),-5 ( ) and -6 ( ). The results represent the average ± s.e.m of one independent 
experiment performed in triplicate and are expressed as a percentage of the response to 100µM 
UTP.  
 
 
Antagonist Concentration  EC50-1 
(µM) 
EC50-2 
(µM) 
ADP  0.15  44 
ADP + 1µM NF 340  0.08    370 
ADP + 10µM NF 340  0.09  41 
ADP + 100µM NF 340  0.1  159 
Table  5.3  The  EC50  shift  of  the  calcium  response  to  ADP  in  the  presence  of 
increasing concentrations of NF 340 in CHO-K1-hP2Y11 clone 13 
 
The EC50 values for ADP concentration-response curves in the absence and presence of three 
different dilutions of NF 340 were calculated in CHO-K1-hP2Y11 clone 13. Antagonist addition 
did not affect the potency of the high affinity and low affinity site of the ADP response. The 
shown EC50 values were obtained from one experiment performed in triplicate.  
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5.4 Reactive Red Schild against ADP in CHO-K1-hP2Y11 clone 13 
  Having studied the effect of a P2Y1 and a P2Y11 antagonist on agonist activity in 
clone  13,  it  was  of  interest  to  examine  whether  a  P2Y-selective  (P2Y1  and  P2Y11) 
antagonist would affect the ADP response in this clone. Thus, concentration-response 
curves for ADP were generated in the absence and presence of 1µM, 10µM and 100µM 
Reactive Red (log value: -6 to -4). The data were analysed as per section 5.2.1. The 
fluorescence  quenching  caused  by  the  encounter  between  the  antagonist  and  the 
fluorophore dye was first addressed. This was achieved by calculating the baseline level 
of calcium fluorescence (F0; average baseline fluorescence between t = 0 to 9.2 seconds) 
present in the cells prior to the addition of 100µM ADP at t = 10 seconds in the absence 
and presence of antagonist. The ADP + Reactive Red data sets were then normalized 
against the maximum ADP response of each individual curve to eliminate any possible 
interference with the results. Figure 5.8 shows the average ADP concentration response 
curves  in  the  absence  and  presence  of  Reactive  Red.  Both  the  control  ADP  and 
ADP+1µM responses progressed from their minimum to their maximum over four log 
units of agonist concentration ranging from 10nM to 100µM (log value: -8 to -4) and 
were best fit using the biphasic equation. In contrast, the ADP+10µM Reactive Red curve 
spanned three log units of agonist concentration ranging from 100nM to 100µM (log 
value: -7 to -4) and was sigmoidal monophasic. Finally, it was not possible to fit the 
ADP+100µM Reactive Red data since this antagonist concentration completely inhibited 
the ADP response.  
 
  Table 5.4 displays the ADP potencies in the absence and presence of Reactive Red. 
The agonist displayed distinct potencies at the high versus low affinity sites of both the 
control ADP (**; p value = 0.0026) and ADP+1µM Reactive Red (*; p value = 0.0492) 
curves. There was no statistically significant difference between the ADP potency at the 
high affinity site of the biphasic curves (p value = 0.14) and this site vanished in the 
presence of higher antagonist concentrations. Further mathematical analysis revealed no 
statistically significant difference between the ADP potency at the low affinity site of the 
biphasic curves and its potency at the monophasic ADP + 10µM Reactive Red curve. 
Finally, the highest concentration of antagonist used, i.e. 100µM, completely inhibited the 
response to ADP, indicating that Reactive Red was able to antagonise both sites of the 
biphasic ADP response.  
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Figure 5.8 The effect of Reactive Red on the calcium response to ADP in CHO-K1-
hP2Y11 clone 13  
 
The response of CHO-K1-hP2Y11 cells to increasing concentrations of ADP was tested in the 
absence and presence of different concentrations of Reactive Red. A. Quenching of the baseline 
calcium fluorescence as a function of Reactive Red concentration in CHO-K1-hP2Y11 clone 13.  
The level of basal calcium fluorescence (F0) observed in CHO-K1-hP2Y11 clone 13 cells prior to 
the addition of the maximum concentration of agonist tested, 100µM ADP (log value: -4), was 
calculated in the absence (0) and presence of increasing concentrations (1µM, 10µM and 100µM; 
log values: -6, -5 and -4) of Reactive Red. The results represent the average of 5 independent 
experiments each performed in triplicate and were normalized against the control F0. B. Reactive 
Red Schild against ADP in CHO-K1-hP2Y11 clone 13. The log10 concentrations of Reactive Red 
used against ADP were: (0) (●), -4 ( ), -5 ( ) and -6 ( ). The results represent the average ± 
s.e.m of five representative experiments performed in triplicate and were normalized against the 
maximum ADP response of each individual curve to eliminate the quenching effect caused by the 
antagonist.  
    
 
Antagonist Concentration  EC50-1 
(µM + S.E.M.) 
EC50-2 
(µM + S.E.M.) 
ADP  0.13 ± 0.02  8.2 ± 3.7 
ADP + 1µM Reactive Red  0.1 ± 0.02  7.1 ± 3 
ADP + 10µM Reactive Red  ND    5.81± 0.7 
ADP + 100µM Reactive Red  ND  ND 
Table  5.4  The  EC50  shift  of  the  calcium  response  to  ADP  in  the  presence  of 
increasing concentrations of Reactive Red in CHO-K1-hP2Y11 clone 13 
 
The EC50 values for ADP concentration-response curves in the absence and presence of three 
different dilutions of Reactive Red were calculated in CHO-K1-hP2Y11 clone 13. The results 
represent the average ± s.e.m of five independent experiments each performed in triplicate. The 
ND sign (not  determined)  refers  to  replicates  for  which  no  significant  calcium  response  was 
detected.  
 
 
  To quantify the extent of the shift exerted by Reactive Red against the ADP curves 
in clone 13, the Schild data were analysed using the Gaddum/Schild EC50 shift equation. 
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As  Figure  5.9  shows,  the  addition  of  increasing  dilutions  of  Reactive  Red  caused  a 
rightward of the ADP sensitivity in clone 13 cells. The average Schild slope of the curves 
was 0.8 ± 0.18. The mean KB value was 1.1 ± 0.2µM and the mean pA2 value was 6 ± 0.1 
in  clone  13  cells.  The  concentration  ratios  corresponding  to  the  concentrations  of 
antagonist used were calculated and they formed a line with a slope of 1, shown in Figure 
5.10.  
 
 
Figure 5.9 EC50 Shift of the Reactive Red and ADP Schild in CHO-K1-hP2Y11 clone 
13  
 
The EC50 shift of the calcium response to ADP as a function of increasing concentrations of 
Reactive Red was analyzed using the Gaddum equation in CHO-K1-hP2Y11 clone 13. The log10 
concentrations of Reactive Red used were: -4 ( ), -5 ( ) and -6 ( ). The analysis shows that 
increasing concentrations of antagonist caused a rightward shift of the response to ADP relative to 
the control response in the absence of antagonist (●). The results represent the average of five 
independent experiments each performed in triplicate and were normalized against the maximum 
ADP response to correct for the observed quenching effect.  
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Figure 5.10 Schild plot for Reactive Red against ADP in clone 13    
 
The dose ratios for Reactive Red concentrations tested against ADP, namely 100µM, 10µM and 
1µM (log values: -4, -5 and -6), were calculated manually and analysed using linear regression. 
The plotted values formed a straight line with a slope of 1. The results represent the average ± 
s.e.m of five independent experiments, each performed in triplicate. The 95% confidence interval 
of the fit is represented by dotted lines.  
 
 
5.5 MRS 2179 inhibition curves in CHO-K1-hP2Y11 clone 13 
  For an in-depth understanding of antagonist activity at the high versus low affinity 
sites of the curve, the biphasic responses to ADP and 2meSATP were divided into their 
constituent components. Two distinct agonist concentrations, one of which activates the 
high affinity site of the curve while the other stimulates the low affinity site, were used. 
The response to these ADP and 2meSATP concentrations was tested in the presence of 
increasing concentrations of MRS 2179, NF 340 and Reactive Red to examine antagonist 
action  against  each  site  individually.  Inhibition  experiments  were  also  performed  for 
BzATP in clone 13 to determine which antagonists would inhibit hP2Y11 activity in the 
co-expressing system.  
 
5.5.1 The calcium response to 100nM ADP in the presence of increasing 
concentrations of MRS 2179 
The calcium response to 100nM (log value: -7) ADP was tested in the absence and 
presence of increasing concentrations of MRS 2179 ranging from 10nM to 100µM (log 
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value: -8 to -4) in clone 13 cells. Non linear regression analysis using a comparison of 
two  equations  (log(inhibitor)  vs.  response  (three  parameters)  versus  log(inhibitor)  vs. 
response  --  variable  slope  (four  parameters))  was  then  performed  and  the  average 
inhibition curves are shown in Figure 5.11. The data were best fit using the simple model 
or three parameters equation and produced a monophasic sigmoidal curve with a Hill 
slope of -1, indicating that the agonist and inhibitor competed for a single population of 
binding sites. The antagonist exerted its inhibitory effect in a concentration-dependent 
fashion over three log units of concentration, ranging from 316nM to 100µM (log value: -
6.5 to -4). The response to 100nM ADP control constituted 49.8 ± 2.7% of the response 
to 100µM UTP control. The highest concentration of antagonist tested or 100µM MRS 
2179 reduced the calcium response to 5 ± 2.4% of the UTP control and this value was 
statistically significant different from the ADP control (p value < 0.0001). The agonist 
response returned to control level at 316nM MRS 2179 as confirmed by statistical tests. 
The maximum response to 100nM ADP occured in the presence of 10nM MRS 2179 (log 
value: -8) and was higher than the control ADP response (*; p value = 0.0235). The mean 
IC50 value for MRS 2179 in clone 13 was 1.8 ± 0.5µM and the mean pIC50 value was 5.7. 
 
 
 
Figure 5.11 MRS 2179 inhibits the response to 100nM ADP in CHO-K1-hP2Y11 
clone 13 
 
The  effect  of  increasing  concentrations  of  the  P2Y1  antagonist  MRS  2179  on  the  calcium 
response to 100nM ADP was tested at 37°C in CHO-K1-hP2Y11 clone 13. The results represent 
the average ± s.e.m of six independent experiments each performed in quadruplicate and are 
expressed as a percentage of the response to 100µM UTP.  
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5.5.2 The calcium response to 100µM ADP in the presence of increasing 
concentrations of MRS 2179 
  The  response  to  100µM  ADP  (log  value:  -4)  was  tested  in  the  presence  of 
increasing concentrations of MRS 2179, ranging from 10nM to 100µM (log value: -8 to -
4). As Figure 5.12 shows, the calcium fluoresence evoked by agonist addition was high 
and did not return to baseline for any antagonist concentration used, indicating that MRS 
2179 does not inhibit the response to 100µM ADP in clone 13.  
 
 
 
Figure 5.12 MRS 2179 does not affect the response to 100µM ADP in CHO-K1-
hP2Y11 clone 13 
 
The effect of increasing concentrations of MRS 2179 on the calcium response to 100µM ADP 
(log value: -4) was tested at 37°C in CHO-K1-hP2Y11 clone 13. The results represent the average 
± s.e.m of three independent experiments each performed in quadruplicate and are expressed as a 
percentage of the response to 100µM UTP.  
 
 
5.5.3  The  calcium  response  to  100nM  2meSATP  in  the  presence  of 
increasing concentrations of MRS 2179 
  The previous experiments examined the effect of MRS 2179 on the the bipahsic 
ADP  response  in  clone  13.  The  high  affinity  site  of  the  biphasic  2meSATP  curve, 
corresponding to 100nM 2meSATP (log value: -7), was also challenged using the same 
dilutions  of  MRS  2179.  Non-linear  regression  analysis  using  a  comparison  of  two 
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equations  (log(inhibitor)  vs.  response  (three  parameters)  versus  log(inhibitor)  vs. 
response  --  variable  slope  (four  parameters))  was  then  performed  and  the  average 
inhibition curve is shown in Figure 5.13. The data were best fit using the three parameters 
model  which  produced  a  monophasic  sigmoidal  curve  with  a  Hillslope  of  -1.  The 
antagonist exerted its inhibitory action over three log units of concentration, ranging from 
316nM to 100µM (log value: -6.5 to -4).  The control response to 100nM 2meSATP was 
56 ± 2% of the control UTP response. The highest concentration of antagonist tested, 
100µM 2meSATP (log value: -4), reduced the calcium response to 100nM 2meSATP to 
9.6 ± 1.8% of the UTP control. Low concentrations of antagonist, i.e. 316nM, 100nM and 
10nM (log value: -6.5, -7 and -8), had no detectable effect on the response to 100nM 
2mesATP, as confirmed by statistical analysis (p value = 0.9183). The average IC50 value 
for MRS 2179 against 100nM 2meSATP was 2.3 ± 0.5µM and the mean pIC50 value was 
5.6. 
 
 
Figure  5.13  MRS  2179  inhibits  the  response  to  100nM  2meSATP  in  CHO-K1-
hP2Y11 clone 13 
 
The  effect  of  increasing  concentrations  of  MRS  2179  on  the  calcium  response  to  100nM 
2meSATP was tested at 37°C in CHO-K1-hP2Y11 clone 13. The results represent the average ± 
s.e.m of three independent experiments each performed in quadruplicate and are expressed as a 
percentage of the response to 100µM UTP.  
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5.5.4  The  calcium  response  to  100µM  2meSATP  in  the  presence  of 
increasing concentrations of MRS 2179 
  The  response  of  clone  13  cells  to  100µM  2meSATP  was  investigated  in  the 
presence of increasing dilutions of MRS 2179 and the resulting inhibition curve is shown 
in Figure 5.14. According to non-linear regression analysis using a comparison of two 
equations  (log(inhibitor)  vs.  response  (three  parameters)  versus  log(inhibitor)  vs. 
response -- variable slope (four parameters)), the MRS 2179 versus 100µM 2meSATP 
curve  preferred  the  simple  model.  However,  one-way  ANOVA  analysis  showed  no 
statistically significant difference between the calcium responses to 100µM 2meSATP in 
the presence of all concentrations of antagonist used (p value = 0.076). This indicates that 
MRS 2179 does not inhibit the response to 100µM 2meSATP in clone 13 cells.  
 
 
 
Figure 5.14 MRS 2179 does not affect the response to 100µM 2meSATP in CHO-K1-
hP2Y11 clone 13 
 
The  effect  of  increasing  concentrations  of  MRS  2179  on  the  calcium  response  to  100µM 
2meSATP (log value: -4) was tested at 37°C in CHO-K1-hP2Y11 clone 13. The results represent 
the average ± s.e.m of three independent experiments each performed in quadruplicate and are 
expressed as a percentage of the response to 100µM UTP.  
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5.5.5  The  calcium  response  to  10µM  BzATP  in  the  presence  of 
increasing concentrations of MRS 2179 
  To determine whether MRS 2179 would alter the calcium response to BzATP in 
clone 13, the cells were pre-incubated with increasing antagonist dilutions, ranging from 
10nM to 100µM MRS 2179 (log value: -8 to -4). The mean inhibition curve for MRS 
2179 against 10µM BzATP is shown in Figure 5.15. As the graph reveals, the Prism 
software was unable to fit a curve to the analysed data and it was represented with a line 
for visualization purposes. Using one-way ANOVA analysis, there was no statistically 
significant difference between the response to 10µM BzATP in the absence and presence 
of increasing concentrations of MRS 2179 (p value = 0.225). These results demonstrate 
that MRS 2179 is not an antagonist of BzATP in clone 13 cells.  
 
 
 
Figure 5.15 MRS 2179 does not affect the response to 10µM BzATP in CHO-K1-
hP2Y11 clone 13 
 
The effect of increasing concentrations of MRS 2179 on the calcium response to 10µM BzATP 
(log value: -5) was tested at 37°C in CHO-K1-hP2Y11 clone 13. The results represent the average 
± s.e.m of three independent experiments each performed in quadruplicate and are expressed as a 
percentage of the response to the 10µM BzATP control. 
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5.6 NF 340 Inhibition Curves in CHO-K1-hP2Y11 Clone 13 
  To  determine  whether  NF  340  would  affect  the  ADP,  2meSATP  and  BzATP 
responses, inhibition experiments using increasing concentrations of antagonist versus a 
fixed concentration of agonist were carried out in CHO-K1-hP2Y11 clone 13.  
 
5.6.1 The calcium response to 100nM ADP in the presence of increasing 
concentrations of NF 340 
  The response of clone 13 cells to 100nM ADP (log value: -7) was assayed in the 
presence of serial concentrations of NF 340, ranging from 100nM to 100µM (log value: -
8 to -4). Figure 5.16 shows the average inhibition curve for NF 340 versus 100nM ADP 
in clone 13. Using Prism analysis, the inhibition data were best fit using the simple model 
or three parameters equation. However, mathematical analysis showed no statistically 
significant difference between the control 100nM ADP response (which amounted to 31 
± 7.3% of the response to 100µM UTP control) and the agonist response measured in the 
presence of different antagonist concentrations (p value = 0.5745). In summary, NF 340 
did not antagonize the response to 100nM ADP in clone 13 cells.  
 
 
Figure 5.16 NF 340 does not affect the response to 100nM ADP in CHO-K1-hP2Y11 
clone 13 
 
The effect of increasing concentrations of NF 340 on the calcium response to 100nM ADP (log 
value: -7) was tested at 37°C in CHO-K1-hP2Y11 clone 13. The results represent the average ± 
s.e.m of three independent experiments each performed in quadruplicate and are expressed as a 
percentage of the response to 100µM UTP.  
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5.6.2 The calcium response to 100µM ADP in the presence of increasing 
concentrations of NF 340 
  The low affinity site of the biphasic ADP response was then investigated using the 
same concentrations of NF 340. Prism software failed to fit a curve to the inhibition data 
shown in Figure 5.17. One-way ANOVA analysis revealed no statistically significant 
difference between the control 100µM ADP response and the response to 100µM ADP in 
the presence of antagonist (p value = 0.2568), indicating that NF 340 did not modify the 
calcium response to 100µM ADP. For visualisation purposes, the data were joined using a 
connecting line.  The large error bars (up to 24%) observed for some data points resulted 
from the variability in the measured calcium response across the experimental repeats.  
 
 
 
Figure 5.17 NF 340 does not affect the response to 100µM ADP in CHO-K1-hP2Y11 
clone 13 
 
The effect of increasing concentrations of NF 340 on the calcium response to 100µM ADP (log 
value: -4) was tested at 37°C in CHO-K1-hP2Y11 clone 13. The addition of NF 340 did not alter 
the calcium response to ADP. The results represent the average ± s.e.m of three independent 
experiments each performed in quadruplicate and are expressed as a percentage of the response to 
100µM UTP.  
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5.6.3 The calcium response to 100nM 2meSATP in the presence of 
increasing concentrations of NF 340 
  To investigate the antagonist profile of the bottom portion of the 2meSATP curve, 
100nM 2meSATP (log value: -6) was added to clone 13 cells pre-incubated with inhibitor 
concentrations ranging from 10nM to 100µM NF 340. As Figure 5.18 shows, there was 
no statistically significant difference between the control 100nM 2meSATP response and 
the agonist response in the presence of increasing concentrations of antagonist (p value = 
0.8358). The large error bars (up to 16%) detected for some data points arose from the 
variability  in  the  measured  calcium  response  to  100nM  2meSATP  across  the 
experimental trials.  
 
 
 
Figure 5.18 NF 340 does not affect the response to 100nM 2meSATP in CHO-K1-
hP2Y11 clone 13 
 
The effect of increasing concentrations of NF 340 on the calcium response to 100nM 2meSATP 
(log value: -7) was tested at 37°C in CHO-K1-hP2Y11 clone 13. The results represent the average 
± s.e.m of one independent experiment performed in triplicate and are expressed as a percentage 
of the response to the 100nM 2meSATP control. 
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with increasing dilutions of NF 340, ranging from 100nM to 100µM (log value: -8 to -4). 
Using  one-way  ANOVA  analysis,  there  was  no  statistically  significant  difference 
between the control 100µM 2meSATP response and the agonist response in the presence 
of  antagonist  (p  value  =  0.0824),  confirming  that  NF  340  does  not  antagonize  the 
response to 100µM 2meSATP in clone 13 cells. The results are shown in Figure 5.19. For 
visualization purposes, the 100µM 2meSATP and NF 340 inhibition data points were 
joined using a connecting line.  
 
 
 
Figure 5.19 NF 340 does not affect the response to 100µM 2meSATP in CHO-K1-
hP2Y11 clone 13 
 
The effect of increasing concentrations of NF 340 on the calcium response to 100µM 2meSATP 
(log value: -4) was tested at 37°C in CHO-K1-hP2Y11 clone 13. The results represent the average 
±  s.e.m of four independent experiments each performed in triplicate and are expressed as a 
percentage of the response to the 100µM 2meSATP control. 
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ANOVA analysis confirmed the absence of a statistically significant difference between 
the control BzATP and the BzATP response in the presence of antagonist (p value = 
0.6905), indicating that NF 340 is not a competitive inhibitor of the BzATP response in 
clone 13 cells. 
 
 
 
Figure 5.20 NF 340 does not affect the response to 10µM BzATP in CHO-K1-hP2Y11 
clone 13 
 
The effect of increasing concentrations of NF 340 on the calcium response to 10µM BzATP (log 
value: -5) was tested at 37°C in CHO-K1-hP2Y11 clone 13. The results represent the average ± 
s.e.m of three independent experiments each performed in quadruplicate and are expressed as a 
percentage of the response to the 10µM BzATP control. 
 
 
5.7 Reactive Red Inhibition Curves in CHO-K1-hP2Y11 Clone 13 
  The  last  set  of  inhibition  experiments  explored  the  effect  of  Reactive  Red, 
reported to antagonize both hP2Y1 and hP2Y11, on the response to these agonists in clone 
13.  
 
5.7.1 The calcium response to 100nM ADP in the presence of increasing 
concentrations of Reactive Red 
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to -4). Fluorescence quenching due to Reactive Red was first analysed. For this purpose, 
the  baseline  level  of  calcium  fluorescence  (F0;  average  fluorescence  for  t  =  0  to  9.2 
seconds) present in the cells prior to agonist addition at t = 10 seconds in the absence and 
presence of antagonist was calculated and is shown in Figure 5.21A. Using one-way 
ANOVA analysis there was no statistically significant difference between the control F0 
values and the F0 values of the cells pre-incubated with antagonist concentrations 100nM 
to 1µM (p value = 0.3059). However, there was a statistically significant difference in 
baseline fluorescence (F0) between the control and the cells treated with 3.16µM Reactive 
Red (log value: -5.5)  (*; p value = 0.0208), 10µM Reactive Red (log value: -5) (*; p 
value  =  0.01),  and  100µM  Reactive  (log  value:  -4)  (****;  p  value  <  0.0001).  These 
results indicate that while antagonist concentrations 10nM to 1µM (log value: -8 to -6) 
did not interfere with the dye, antagonist concentrations 3.16µM to 100µM gradually 
provoked the quenching of the calcium fluorescence (log value: -5.5 to -4).  
 
  Having analysed the fluorescence quenching caused by Reactive Red, the calcium 
response  to  100nM  ADP  over  time  was  analysed  in  the  absence  and  presence  of 
antagonist. Graph 5.21 B. shows a representative time course of the 100nM ADP versus 
Reactive  Red  inhibition  curve  in  clone  13  cells.  As  the  traces  show,  Reactive  Red 
concentrations  ranging  from  100µM  to  3.16µM  caused  a  progressive  decrease  of  the 
calcium response to 100nM ADP leading to a complete suppression of the response at 
10µM (-5) and 100µM (-4) antagonist. The calcium response was fully restored to control 
level starting from 1µM Reactive Red and concentrations ranging from 316nM to 100nM 
(log value: -6.5 to -8) had no effect on the ADP sensitivity. 
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A.           B.  
 
Figure 5.21 Time dependence of the response to 100nM ADP in the presence of 
increasing concentrations of Reactive Red in CHO-K1-hP2Y11 clone 13 
 
The calcium response to 100nM (log value: -7) ADP was measured over time in the presence of 
increasing concentrations of Reactive Red in CHO-K1-hP2Y11 clone 13 cells. A. Quenching of 
the  baseline  calcium  fluorescence  as  a  function  of  Reactive  Red  concentration  in  CHO-K1-
hP2Y11 clone 13.  The level of basal calcium fluorescence (F0) observed in clone 13 cells prior to 
the addition of 100nM ADP (log value: -7) was analyzed in the absence (0) and presence of the 
increasing  dilutions  of  Reactive  Red.  The  results  represent  the  average  of  three  independent 
experiments  each  performed  in  quadruplicate  and  were  normalized  against  the  (0)  control  F0 
value.  B.  Time  course  of  the  Reactive  Red  and  100nM  ADP  inhibition  curve.  The  log10 
concentrations of Reactive Red used were: -4 (
__), -5 (
_ _), -5.5 (
__), -6 (
__), -6.5 (
__), -7 (
__) and -8 
(
__). The calcium fluorescence elicited by the 100nM ADP control is also shown (
…). The traces 
represent the mean calcium response obtained from one independent experiment performed in 
quadruplicate, divided by the baseline fluorescence measured prior to the introduction of ligand at 
t=10 seconds. The results are expressed as RFU/F0. Error bars have been omitted to ensure a 
better visualization of the curves.  
 
 
  To correct for the fluorescence quenching caused by Reactive Red, the F/F0 values 
of each dataset were transformed against their own maximum response to 100nM ADP. 
Non-linear regression analysis using a comparison of two equations (log(inhibitor) vs. 
response  (three  parameters)  versus  log(inhibitor)  vs.  response  --  variable  slope  (four 
parameters))  was performed and the average inhibition curve for Reactive Red versus 
100nM ADP is shown in Figure 5.22. The antagonist exerted its inhibitory effect over 
two log units of concentration, ranging from 1µM to 100µM (log value: -6 to -4). The 
data  were  best  fit  using  the  three  parameters  equation  and  produced  a  monophasic 
sigmoidal curve with a Hill slope of -1. The mean IC50 value for Reactive Red against 
100nM ADP was 2.9 ± 0.8µM and the mean pIC50 value was 5.5. 
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Figure 5.22 Reactive Red inhibits the response to 100nM ADP in CHO-K1-hP2Y11 
clone 13 
 
The effect of increasing concentrations of Reactive Red on the calcium response to 100nM ADP 
(log value: -7) was tested at 37°C in CHO-K1-hP2Y11 clone 13. The results represent the average 
± s.e.m of three independent experiments each performed in quadruplicate and are expressed as a 
percentage  of  the  maximum  response  of  each  individual  inhibition  curve  to  correct  for 
fluorescence quenching.  
 
 
5.7.2 The calcium response to 100µM ADP in the presence of increasing 
concentrations of Reactive Red  
Reactive Red was tested against 100µM ADP (log value: -4) to determine whether it 
would affect the low affinity site of the biphasic ADP curve. The fluorescence quenching 
provoked by Reactive Red was evaluated as described in section 5.7.1 and the calculated 
F0  values  are  shown  in  Figure  5.23.  Mathematical  analysis  revealed  a  statistically 
significant  difference  between  the  baseline  fluorescence  of  cells  treated  with  1µM  to 
100µM (log value: -6 to -4) Reactive Red versus the control F0 (****; p value < 0.0001), 
indicating  that  these  antagonist  concentrations  caused  fluorescence  quenching.  Figure 
5.23 shows a representative time course of the inhibition curve of Reactive Red against 
100µM ADP. As the traces indicate, antagonist concentrations ranging from 10nM to 
3.16µM (log value: -8 to -5.5) did not alter the calcium response of clone 13 cells to 
100µM ADP as compared to the control. In contrast, 10µM Reactive Red reduced the 
response of the cells to 100µM ADP while the highest concentrations of antagonist tested, 
i.e. 100µM Reactive Red, completely supressed it.  
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A.     B.  
 
Figure 5.23 Time dependence of the response to 100µM ADP in the presence of 
increasing concentrations of Reactive Red in CHO-K1-hP2Y11 clone 13 
 
The calcium response to 100µM (log value: -4) ADP was measured over time in the presence of 
increasing concentrations of Reactive Red in CHO-K1-hP2Y11 clone 13 cells. A. Quenching of 
the  baseline  calcium  fluorescence  as  a  function  of  Reactive  Red  concentration  in  CHO-K1-
hP2Y11 clone 13. The level of basal calcium fluorescence (F0) observed in CHO-K1-hP2Y11 clone 
13 cells prior to the addition of 100µM ADP (log value: -4) was analysed in the absence (0) and 
presence of increasing concentrations of Reactive Red. The results represent the average of three 
independent experiments each performed in quadruplicate and were normalized against the (0) 
control F0 value. B. Time course of the Reactive Red and 100µM ADP inhibition curve. The log10 
concentrations of Reactive Red used were: -4 (
__), -5 (
_ _), -5.5 (
__), -6 (
__), -6.5 (
__), -7 (
__) and -8 
(
__). The calcium fluorescence elicited by the 100µM ADP control is also shown (
…). The traces 
represent the mean calcium response obtained from one independent experiment performed in 
quadruplicate, divided by the baseline fluorescence measured prior to the introduction of ligand at 
t=10 seconds. The results are expressed as RFU/F0. Error bars have been omitted to ensure a 
better visualization of the curves.  
 
 
The F/F0 values of the inhibition curves were transformed against their respective 
maximum responses to 100µM ADP to correct for fluorescence quenching. Figure 5.24 
shows the average inhibition curve for Reactive Red against 100µM ADP. The preferred 
fit  for  the  analysed  data  was  the  simple  model  or  three  parameters  equations,  which 
yielded a sigmoidal curve with a Hill slope of -1. The average IC50 value for Reactive 
Red versus 100µM ADP was 32 ± 18µM while the average pIC50 value was 4.55 ± 0.25. 
This experiment shows that Reactive Red inhibited the agonist response at maximum 
concentrations (10µM to 100µM) only.   
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Figure 5.24 Reactive Red inhibits the response to 100µM ADP in CHO-K1-hP2Y11 
clone 13 
 
The effect of increasing concentrations of Reactive Red on the calcium response to 100µM ADP 
(log  value:  -4)  was  tested  at  37°C  in  CHO-K1-hP2Y11  clone  13.  These  results  represent  the 
average  ±  s.e.m  of  three  independent  experiments  each  performed  in  quadruplicate  and  are 
expressed as a percentage of the maximum response of each individual inhibition curve to correct 
for fluorescence quenching.  
 
 
5.7.3  The  calcium  response  to  100nM  2meSATP  in  the  presence  of 
increasing concentrations of Reactive Red 
  The  biphasic  calcium  response  to  2meSATP  was  studied  using  the  same 
concentrations of Reactive Red to investigate whether the antagonist would affect the 
high and low affinity sites of the curve. Increasing antagonist concentrations, ranging 
from 10nM to 100µM (log value: -8 to -4), were first applied to 100nM 2meSATP (log 
value: -7) in clone 13 cells. The fluorescence quenching provoked by antagonist addition 
was analysed as per section 5.7.1 and the baseline fluorescence of control cells versus 
cells  containing  10nM  to  100µM  Reactive  Red  is  shown  in  Figure  5.25A.  One-way 
ANOVA analysis revealed a statistically significant difference between the control basal 
fluorescence and the baseline fluorescence of cells pre-incubated with 100µM antagonist 
(log value: -4) only, indicating that the maximum concentration of Reactive Red resulted 
in fluorescence quenching. Figure 5.25 B. displays a representative time course of the 
Reactive  Red  versus  100nM  2meSATP  inhibition  curve  in  clone  13.  As  the  traces 
indicate, antagonist concentrations ranging from 1µM to 100µM (log value: -6 to -4) 
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resulted  in  a  concentration  dependent  decrease  in  the  calcium  response  to  100nM 
2meSATP  in  clone  13  cells  while  the  maximum  concentration  of  Reactive  Red,  i.e. 
100µM,  completely  blocked  this  response.  Lower  antagonist  concentrations,  namely 
10nM to 316nM, did not alter the response to 100nM 2meSATP as compared to the 
control.  
 
 
A.            B.  
 
Figure 5.25 Time dependence of the response to 100nM 2meSATP in the presence of 
increasing concentrations of Reactive Red in CHO-K1-hP2Y11 clone 13 
 
The  calcium  response  to  100nM  (log  value:  -7)  2meSATP  was  measured  over  time  in  the 
presence of increasing concentrations of Reactive Red in CHO-K1-hP2Y11  clone 13 cells. A. 
Quenching of the basal level of calcium fluorescence as a function of Reactive Red concentration 
in CHO-K1-hP2Y11 clone 13. The level of basal calcium fluorescence (F0) observed in CHO-K1-
hP2Y11 clone 13 cells prior to the addition of 100nM 2meSATP (log value: -7) was analyzed in 
the absence (0) and presence of increasing concentrations of Reactive Red. The results represent 
the  average  of  three  independent  experiments  each  performed  in  quadruplicate  and  were 
normalized against the (0) control F0 value. B. Reactive Red against 100nM 2meSATP inhibition 
curves in CHO-K1-hP2Y11 clone 13. The calcium response to 100nM (log value: -7) 2meSATP 
was  measured  over  time  in  the  presence  of  increasing  concentrations  of  the  P2Y-selective 
antagonist Reactive Red in CHO-K1-hP2Y11 clone 13 cells. The log10 concentrations of Reactive 
Red  used  were:  -4  (
__),  -5  (
_  _),  -5.5  (
__),  -6  (
__),  -6.5  (
__),  -7  (
__)  and  -8  (
__).  The  calcium 
fluorescence elicited by the 100nM 2meSATP control is also shown (
…). The traces represent the 
mean calcium response obtained from one independent experiment performed in quadruplicate, 
divided by the baseline fluorescence measured prior to the introduction of ligand at t=10 seconds. 
The results are expressed as RFU/F0. Error bars have been omitted to ensure a better visualization 
of the curves.  
 
 
  To  eliminate  the  quenching  effect  of  Reactive  Red,  the  inhibition  data  were 
transformed against the maximum response to 100nM 2meSATP then analysed using 
non-linear regression as per section 5.7.1. Figure 5.26 shows the average inhibition curve 
for Reactive Red versus 100nM 2meSATP in clone 13. Two out of the three trials were 
best fit using the four parameters equation, while one trial was fit using the simple model 
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or three parameters equation. The average Hill slope for Reactive Red versus 100nM 
2meSATP was -1.7 ± 0.3, indicating that Reactive Red and 2meSATP might have been 
competing for a heterogeneous population of receptors. The mean IC50 value for Reactive 
Red against 100nM 2meSATP was 22 ± 17µM and the mean pIC50 value was 4.97.  
 
 
Figure 5.26 Reactive Red inhibits the response to 100nM 2meSATP in CHO-K1-
hP2Y11 clone 13 
 
The calcium response of clone 13 cells to 100nM 2meSATP (log value: -7) was studied in the 
absence and presence of Reactive Red at physiological temperature. The results represent the 
average ± s.e.m of three independent experiments each performed in triplicate or quadruplicate 
and are expressed as a percentage of the maximum response to 100nM 2meSATP to eliminate 
fluorescence quenching.   
 
 
  The large error bars detected for some concentrations (up to 58%) were caused by 
the  variability  of  the  responses  obtained  in  the  independent  experimental  trials.  A 
representative inhibition curve from one independent trial is shown in Figure 5.27 for 
clarity purposes. The corresponding data were best fit using the four parameters equation, 
which produced a sigmoidal monophasic curve with a Hill slope of -1.88. In summary, 
this experiment shows that Reactive Red inhibits the response to 100nM 2meSATP in 
clone 13 and might be acting at a heterogeneous population of receptors.  
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Figure  5.27  Representative  inhibition  curve  for  Reactive  Red  versus  100nM 
2meSATP in CHO-K1-hP2Y11 clone 13 
 
The  response  to  100nM  2meSATP  (log  value:  -4)  was  tested  in  the  presence  of  increasing 
concentrations of Reactive Red, ranging from 10nM to 100µM (log value: -8 to -4), at 37°C in 
clone  13  cells.  The  results  represent  the  average  ±  s.e.m  of  one  independent  experiment 
performed in triplicate, and are expressed as a percentage of the maximum response to 100nM 
2meSATP to correct for fluorescence quenching.  
 
 
5.7.4 The calcium response to 100µM 2meSATP in the presence of 
increasing concentrations of Reactive Red 
  The response to 100µM 2meSATP (log value: -4) was tested in the presence of 
increasing concentrations of Reactive Red, ranging from 10nM to 100µM (log value: -8 
to -4), in clone 13. To assess fluorescence quenching due to Reactive Red, the baseline 
fluorescence (F0) of the control wells and the cells pre-incubated with different antagonist 
dilutions  was  calculated  and  is  shown  in  figure  5.28A.  One-way  ANOVA  analysis 
revealed  a  statistically  significant  difference  between  the  control  F0  and  the  baseline 
fluorescence detected in the presence of the maximum concentration of antagonist tested, 
100µM Reactive Red (****; p value < 0.0001), indicating that this concentration exerted 
a quenching effect. Figure 5.28 B. displays a representative time course of the Reactive 
Red  and  100µM  2meSATP  inhibition  curve  in  clone  13  cells.  Reactive  Red 
concentrations 10nM to 10µM (log value: -8 to -5) did not alter the agonist response. In 
contrast,  the  maximum  concentration  of  antagonist  tested,  namely  100µM  2meSATP, 
completely suppressed the response to the agonist.  
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A.           B.  
 
Figure 5.28 Time dependence of the response to 100µM 2meSATP in the presence of 
increasing concentrations of Reactive Red in CHO-K1-hP2Y11 clone 13 
 
The  effect  of  increasing  concentrations  of  Reactive  Red  on  the  calcium  response  to  100µM 
2meSATP (log value: -4) was tested at 37°C in CHO-K1-hP2Y11 clone 13. A. Quenching of the 
baseline calcium fluorescence as a function of Reactive Red concentration in CHO-K1-hP2Y11 
clone 13. The level of basal calcium fluorescence (F0) observed in CHO-K1-hP2Y11 clone 13 
cells prior to the addition of 100µM 2meSATP (log value: -4) was analyzed in the absence (0) and 
presence of increasing concentrations of Reactive Red. The results represent the average of three 
independent experiments each performed in quadruplicate and were normalized against the (0) 
control F0 value. B. Reactive Red against 100µM 2meSATP inhibition curves in CHO-K1-hP2Y11 
clone 13.The calcium response to 100µM (log value: -4) 2meSATP was measured over time in 
the presence of increasing concentrations of the P2Y-selective antagonist Reactive Red in CHO-
K1-hP2Y11 clone 13 cells. The log10 concentrations of Reactive Red used were: -4 (
__), -5 (
_ _), -
5.5 (
__), -6 (
__), -6.5 (
__), -7 (
__) and -8 (
__). The calcium fluorescence elicited by the 100µM 
2meSATP control is also shown (
…). The traces represent the mean calcium response obtained 
from one independent experiment performed in quadruplicate.   
 
 
  The  quenching  effect  of  the  antagonist  was  corrected  by  transforming  the 
inhibition  datasets  against  the  maximum  response  to  100µM  2meSATP.  Non-linear 
regression  was  performed  as  per  section  5.7.1  and  the  average  inhibition  curve  for 
Reactive Red against 100µM 2meSATP is shown in Figure 5.29. The Prism software was 
unable to fit a curve to the inhibition data, for which it was not possible to calculate an 
IC50 value, and the points were represented with a connecting line.  
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Figure 5.29 Reactive Red inhibits the response to 100µM 2meSATP in CHO-K1-
hP2Y11 clone 13 
 
The response of clone 13 cells to 100µM 2meSATP (log value: -4) in the presence of increasing 
concentrations of Reactive Red was measured at 37°C. These results represent the average ± 
s.e.m of three independent experiments each performed in quadruplicate and are expressed as a 
percentage of the maximum response to 100µM 2meSATP to correct for fluorescence quenching.  
 
 
5.8 Conclusion 
  This  chapter  focused  on  antagonist  action  against  ADP,  2meSATP  and  BzATP 
responses in the high-expressing CHO-K1-hP2Y11 clone 13. The used antagonists were 1) 
MRS 2179, 2) NF 340 and 3) Reactive Red. The antagonist experiments were divided 
into  two  distinct  experimental  setups.  The  inhibitors  were  first  tested  using  Schild 
experiments  following  which  inhibition  experiments  were  conducted.  The  objective 
behind this design was to investigate the components of the biphasic ADP and 2meSATP 
curves in clone 13 to determine whether tested antagonists would affect the high versus 
low affinity sites of the curves differently. This could help identify the population(s) of 
receptors involved in these sites.  
 
  Four Schild experiments were performed in clone 13: 1) ADP and MRS 2179, 2) 
2meSATP and MRS 2179, 3) ADP and NF 340 and 4) ADP and Reactive Red. MRS 
2179 resulted in a rightward shift of the ADP and 2meSATP responses and appeared to 
affect the high affinity site of the curve only. NF 340 did not alter the response of clone 
13  to  ADP.  Reactive  Red  completely  supressed  the  biphasic  ADP  response,  thus 
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inhibiting both sites of this response. The KB and pA2 values of MRS 2179, NF 340 and 
Reactive Red obtained from the Schild experiments are displayed in Table 5.5.  
 
 
Schild  KB 
(µM ± s.e.m) 
pA2 
ADP + MRS 2179  0.5 ± 0.2  6.4 ± 0.2 
2mesATP + MRS 2179  22 ± 13  5.4 ± 0.5 
ADP + NF 340  ND  ND 
ADP + Reactive Red  1.1 ± 0.2  6 ± 0.1 
Table 5.5 The KB and IC50 values measured from Schild experiments in CHO-K1-
hP2Y11 clone 13 
 
The  KB  and  IC50  values  obtained  from  five  Schild  experiments  conducted  in  clone  13  are 
displayed in this table. MRS 2179 was found to be a competitive inhibitor of the biphasic ADP 
and 2meSATP responses in clone 13. Reactive Red competitively inhibited the biphasic ADP 
response. NF 340, on the other hand, did not alter the sensitivity of clone 13 cells to ADP. The 
ND sign (not determined) refers to antagonists that failed to inhibit the calcium response and for 
which it was not possible to determine KB and pA2 values.  
  
 
  Inhibition experiments were then performed to examine antagonist action against 
the high versus low affinity sites of the biphasic ADP and 2meSATP curves individually 
as well as against the monophasic BzATP response. Eleven inhibition experiments were 
conducted and are shown in Table 5.6, which displays the IC50 values measured for each 
experiment.  MRS  2179  competitively  inhibited  the  response  to  100nM  ADP,  which 
corresponds to the high affinity site of the ADP curve, but did not affect the response to 
100µM ADP, which corresponds to agonist activity at the low affinity site of the curve. 
Similarly, MRS 2179 antagonized the high affinity site of the 2meSATP curve but did not 
affect the low affinity site of the curve. NF 340, which is reported to antagonize hP2Y11 
activity,  did  not  affect  the  biphasic  response  to  ADP  and  2meSATP  in  clone  13. 
Surprisingly, NF 340 did not alter the response of clone 13 to BzATP either. Reactive 
Red antagonized the response to 100nM ADP but only reduced the response to 100µM 
ADP at maximum concentrations of antagonist. Moreover, it inhibited the response to 
100nM 2meSATP but only suppressed the agonist response of the low affinity site at 
maximum antagonist concentrations.  
 
  These experiments reveal that MRS 2179, NF 340 and Reactive Red exhibited 
different effects at the high affinity versus low affinity sites of the biphasic ADP and 
2meSATP curves in clone 13. This difference might be due to the presence of two distinct 
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receptor  population  with  two  separate  binding  sites.  In  summary,  the  Schild  and 
inhibition experiments performed in this chapter demonstrate that:  
 
 
Inhibition Curve  IC50 
(µM ± s.e.m) 
100nM ADP + MRS 2179  1.8 ± 0.5 
100µM ADP + MRS 2179  None 
100nM 2meSATP + MRS 2179  2.3 ± 0.5 
100µM 2meSATP + MRS 2179  None  
10µM BzATP + MRS 2179  None 
100nM ADP + NF 340  None 
100µM ADP + NF 340  None 
100nM 2meSATP + NF 340  None 
100µM 2meSATP + NF 340  None 
10µM BzATP + NF 340  None 
100nM ADP + Reactive Red  2.9 ± 0.8 
100µM ADP + Reactive Red  32 ± 18 
100nM 2meSATP + Reactive Red  22 ± 17 
100µM 2meSATP + Reactive Red  None 
Table 5.6 The IC50 values of MRS 2179, NF 340 and Reactive Red in CHO-K1-
hP2Y11 clone 13 
 
The IC50 values of the inhibition curves for MRS 2179, NF 340 and Reactive Red in clone 13 are 
shown  in  this  table.  MRS  2179  inhibited  the  calcium  response  to  100nM  ADP  and  100nM 
2meSATP in clone 13 cells. NF 340 had no effect on the calcium response to ADP, 2meSATP 
and BzATP in clone 13 while Reactive Red altered the calcium response to 100nM ADP, 100µM 
ADP and 100nM 2meSATP.  
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Chapter 6 
Discussion  
 
6.1 Introduction  
The P2Y1 and P2Y11 receptors are closely related purinergic receptors that have 
been found to regulate the relaxation of smooth muscle cells (SMCs) in the taenia coli 
(174). Co-immunoprecipitation experiments have demonstrated that these receptors form 
a heteromer in HEK-293T cells and that dimerization induces the co-internalization of 
hP2Y11, which does not internalize on its own following receptor activation (55). This 
discovery is exciting as it suggests that P2Y1 and P2Y11 oligomers might exist in the 
plasma membrane of SMCs and partake in their relaxation, implying that the P2Y1:P2Y11 
dimer  could  be  a  potential  target  for  anti-obesity  drugs.  To  better  understand  the 
interaction between these receptors, recombinant models co-expressing P2Y1 and hP2Y11 
were  established  in  CHO-K1  cells  and  comprised  endogenous  P2Y1  and  transfected 
hP2Y11. Two different CHO-K1-hP2Y11 clones: 1) a clone expressing a low density of 
hP2Y11 and 2) a clone expressing a high density of hP2Y11, were subsequently selected 
and  investigated.  The  rationale  behind  this  endeavour  was  to  generate  two  distinct 
receptor landscapes to mimic possible purinoceptor microenvironments in the SMCs of 
taenia  coli  cells,  where  the  relative  expression  levels  of  P2Y1  and  P2Y11  remain 
unknown. Pharmacological characterization of the two cell lines might reveal whether a 
change in the density of one receptor could affect the signalling of its partner receptor. 
Additionally, two control cell lines expressing one receptor each, namely 1321N1-hP2Y1 
and  1321N1-hP2Y11,  were  created  and  characterized  for  comparison  with  the  co-
expressing P2Y1 and hP2Y11 systems.  
 
6.2  The  effect  of  co-expression  on  the  BzATP  response  in  CHO-K1-
hP2Y11 clones 6 and 13 
 
6.2.1  The  density  of  hP2Y11  receptors  affects  the  magnitude  of  the 
response to BzATP in clones 6 and 13 
To  determine  whether  the  density  of  transfected  hP2Y11  affects  the  calcium 
response  of  the  clones  to  BzATP,  a  potent  hP2Y11  agonist,  the  time  course  of  the 
response to 100µM BzATP was analysed in the high-expressing clone 13 versus the low-
expressing clone 6. As Figure 3.11 shows, the increase in calcium fluorescence was three Chapter 6   Discussion 
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times higher in clone 13 than clone 6, as reflected by the large difference in the area 
under the curves (226,872). These results imply that as the levels of hP2Y11 expression 
are increased, the exposure to a fixed concentration of BzATP increases as seen in clone 
13. This could be due to the presence of a bigger population of hP2Y11 receptors at the 
plasma membrane of this clone, resulting in more agonist binding and the activation of a 
larger reserve of Gq/11 proteins. This, in turn, could cause more calcium release from 
intracellular stores, inducing a higher peak of calcium fluorescence in clone 13 versus 6.  
 
6.2.2  BzATP  is  more  potent  in  CHO-K1-hP2Y11  clones  6  and  13  as 
compared to 1321N1-hP2Y11 
Despite the difference in the magnitude of the response in clones 13 and 6, BzATP 
displayed a similar potency at hP2Y11 in the two clones, as demonstrated by the absence 
of  a  statistically  significant  difference  between  BzATP  potency  in  clones  13  (1.27  ± 
0.15µM) and 6 (0.98 ± 0.12 µM)	 ﾠ(ratio: 1.28; p value= 0.19). This indicates that an 
increase  in  P2Y11  concentration  does  not  necessarily  correlate  with  an  increase  in 
monomeric P2Y11, therefore the EC50 remains unchanged.  
 
Comparison  with  assays  conducted  in  the  control  1321N1-hP2Y1  and  1321N-
hP2Y11  cells  shows  that  BzATP  does  not  stimulate  the  hP2Y1  receptor.  However,  it 
activates the hP2Y11 receptor expressed in 1321N1-hP2Y11 cells with a potency of 3.1 ± 
0.26µM, which is statistically significantly different from this agonist’s potency in clones 
13 and 6 (**; p value = 0.0028; **; p value = 0.0012, respectively). The BzATP potency 
calculated in the studied 1321N1-hP2Y11 cells agrees with a previously published EC50 
value for BzATP, namely 4.37 ± 1.65µM, obtained from calcium experiments in 1321N1-
hP2Y11  cells  (174)  (p  value  =  0.2939).  This  published  value  is  also  statistically 
significantly different from the BzATP potency in clones 13 and 6 (**, p value = 0.0094). 
In  1321N1-hP2Y11,  the  BzATP  curve  had  a  Hill  slope  of  1,  indicating  that  agonist 
binding occurred at a single binding site. In clones 13 and 6 however, the Hill slopes were 
1.59 ± 0.23 and 1.28 ± 0.07. These values are greater than 1, which suggests possible 
positive  cooperativity  in  agonist  binding  to  the  receptor  or  the  presence  of  multiple 
binding sites.  
 
These results show that, while BzATP is more potent in the clones as compared to 
the  control  1321N1-hP2Y11  cells,  different  levels  of  hP2Y11  expression  in  CHO-K1-
hP2Y11  clones  13  versus  6  do  not  affect  BzATP  potency,  indicating  that  potency  is Chapter 6   Discussion 
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independent of receptor density in the co-expressing cell lines. The different potency in 
clones 13 and 6 versus the control could result from distinct active receptor states of 
hP2Y11 in the clones versus 1321N1-hP2Y11 cells (226). These states could arise from 
conformational changes of hP2Y11 due to physical interaction or functional crosstalk with 
P2Y1 in the clones, leading to positive cooperativity and increased affinity of hP2Y11 for 
BzATP. In conclusion, crosstalk could stabilize hP2Y11 in a conformation with increased 
affinity for BzATP in the clones as compared to the control cells (227).  
 
6.3 The effect of co-expression on the calcium response to ATP, ATPγS 
and UTP in clones 13 and 6 
 
6.3.1  Co-expression  does  not  alter  the  potency  of  ATP  at  hP2Y11  in 
clones 6 and 13 
ATP has been reported to activate P2Y1, P2Y2 and P2Y11 (210) receptors, all of 
which are expressed in CHO-K1-hP2Y11 clones 13 and 6 (178, 208). The response to 
ATP was tested in the clones and was monophasic sigmoidal in both cases. There was no 
statistically significant difference in ATP potency in clones 13 versus 6 (47 ± 20nM	 ﾠand 
33 ± 6nM, respectively; p value = 0.54). The Hill slope of the ATP curve was 0.75 ± 0.13 
in clone 6, suggesting the existence of multiple binding sites (210, 228), and 1.1 ± 0.3 in 
clone 13. Closer inspection of the individual Hill slopes in clone 13 (0.61, 0.95 and 1.7) 
shows that two out of three trials point to positive cooperativity in agonist binding. This 
suggests the presence of multiple receptor sites for ATP in clones 13 and 6, consistent 
with the expression of P2Y1, P2Y2 and hP2Y11 in these clones.  
 
The  ATP  response  in  1321N1-hP2Y11  and  1321N1-hP2Y1  was  sigmoidal 
monophasic with a Hill slope of 1 in both cell lines. This response was more potent in 
1321N1-hP2Y1 versus 1321N1-hP2Y11 cells (151 ± 40nM and 9 ± 1.4µM, respectively; 
**; p value = 0.0028), suggesting that hP2Y1 has greater affinity for ATP than hP2Y11. 
ATP was more potent in clones 13 and 6 as compared to 1321N1-hP2Y11 (**; p value = 
0.0027 for both clones) and 1321N1-hP2Y1 (*; p value = 0.0356). 
 
The obtained values were compared with ATP potencies published in the literature. 
One of the first studies to describe an ATP response in CHO-K1 cells (EC50 = 2.3 ± 
0.5µM)  associated  this  response  with  the  activation  of  an  endogenous  P2Y2  receptor 
(208). Another published value detected from calcium measurements in 1321N1-hP2Y2 Chapter 6   Discussion 
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cells    (176nM)  (229)  agreed  with  the  ATP  potency  in  clones  13  and  6,  further 
highlighting the contribution of P2Y2 to the ATP response. ATP potencies calculated 
from  recent  experiments  in  CHO-K1  cells  using  first  and  second  generation  calcium 
assay  kits,  i.e.  62.6nM  and  72.6nM,  (230)  also  matched  the  values  measured  in  the 
clones,  indicating  that  ATP  potency  in  CHO-K1  cells  is  not  affected  by  hP2Y11 
expression and density. Studies conducted by Communi et al. and Qi et al. in 1321N1-
hP2Y11  and  CHO-K1-hP2Y11 cells  revealed  that  ATP  promotes  IP3  but  also  cAMP 
generation in both cell lines (176-178, 211), which confirms the activation of hP2Y11 by 
ATP. Interestingly,  these  studies  also  found  that  ATP  was  more  potent  in  CHO-K1-
hP2Y11 versus 1321N1-hP2Y11 cells (178), in agreement with the results observed in this 
project. In summary, analysis of the results and comparison with the literature show that 
the ATP response in clones 13 and 6 is most likely mediated by three receptors, namely 
endogenous  haP2Y1  and  haP2Y2  receptors  and  transfected  hP2Y11  receptors.  This 
response is monophasic sigmoidal with a single EC50 value, implying that the potencies 
of ATP at all three receptors overlap.  
 
6.3.2 Co-expression does not alter the potency of ATPγS at hP2Y11 in 
clones 6 and 13  
ATPγS, like ATP, has been reported to activate P2Y1, P2Y2 and P2Y11 receptors 
(210). The ATPγS response in clones 13 and 6 was monophasic sigmoidal with a single 
EC50 value. There was no statistically significant difference in ATPγS potency in clones 
13 versus 6 (274 ± 48nM and 260 ± 39nM, respectively; p value = 0.54), indicating that 
the density of transfected hP2Y11 does not alter the calcium response to ATPγS in the 
clones. The Hill slopes of the ATP curves were 1.16 ± 0.13 in clone 6 and 1.3 ± 0.1 in 
clone 13, suggesting the existence of multiple binding sites or positive cooperativity of 
the response. The ATPγS potency in 1321N1-hP2Y11 and 1321N1-hP2Y1 cells (3.2 ± 
0.26µM and 15.6 ± 3.6nM, respectively) was statistically significantly different from its 
potency in the clones. In fact, ATPγS was more potent in clones 13 and 6 versus 1321N1-
hP2Y11 cells (***, p value = 0.0004 and ***, p value = 0.0003, respectively) and less 
potent in clones 13 and 6 versus 1321N1-hP2Y1 cells (**, p value = 0.0058 and **, p 
value = 0.0033, respectively).  
 
These results indicate that clones 13 and 6 display an ATPγS profile specific to 
them  and  distinct  from  that  of  individual  hP2Y1  and  hP2Y11  receptors.  The  ATPγS 
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and hP2Y11) and possesses a single EC50 value, indicating that the agonist’s potencies at 
the multiple binding sites overlap. The marked discrepancy in ATPγS potency between 
1321N1-hP2Y11  and  1321N1-hP2Y1  cells  versus  clones  13  and  6  could  arise  from 
differences in receptor subtypes among distinct species (human versus hamster), varying 
expression levels of receptors in the studied cells or the co-expression of haP2Y1 and 
hP2Y11, leading to enhanced P2Y11 affinity and reduced P2Y1 affinity of for ATPγS.  
 
6.3.3 The UTP response assumes a hP2Y2-like character in clones 6 and 
13  
  UTP is a potent agonist of the P2Y2 receptor (210) but has also been reported to 
activate hP2Y11 (153). The UTP response was tested in CHO-K1-hP2Y11 clones 13 and 6, 
resulting in monophasic sigmoidal curves with a single EC50 value each (89 ± 22nM and 
67 ± 22nM, respectively). These values were not statistically significantly different (p 
value = 0.5221), signifying that the levels of hP2Y11 expression do not alter the calcium 
response to UTP in the clones. The Hill slope of the UTP curve was 1.98 ± 0.6 in clone 6 
and 1.2 ± 0.2 in clone 13, implying the presence of multiple binding sites to UTP or 
positive cooperativity.  The UTP response was also investigated in the 1321N1-hP2Y11 
and 1321N1-hP2Y1 controls. UTP failed to induce a calcium response in 1321N1-hP2Y11 
cells,  which  contradicts  previous  findings  published  in  the  literature  (153).  However, 
UTP produced a sigmoidal monophasic response in 1321N1-hP2Y1 cells (EC50 value= 
382nM), indicating that this agonist activates hP2Y1 receptors.  
 
   The UTP response observed in the various cell lines was compared with potencies 
reported in the literature. One of the first descriptions of UTP activity at P2Y2 in CHO-K1 
cells found a potency (2.8 ± 0.6µM) (208) that is different from the UTP potency detected 
in clones 13 and 6. A recent study in 1321N1-hP2Y2 cells described a UTP potency of 
73nM, in agreement with the values measured in the clones, thus highlighting the P2Y2 
component of the UTP response. The literature was ambivalent regarding UTP action at 
hP2Y11 receptors. For instance, White et al., as wells as previous assays performed in this 
laboratory, detected a UTP response in 1321N1-hP2Y11 cells (153). In contrast, Morrow 
et  al.  failed  to  reproduce  a  UTP  response  in  1321N1-hP2Y11  cells  although  the  two 
laboratories (White and Morrow) utilized the same cell line handed from one laboratory 
to the other (229). This finding agrees with the lack of UTP action in 1321N1-hP2Y11 
cells observed in the present study. According to Morrow et al., a possible explanation for 
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non-nucleotide agent acting at a non-purinergic receptor, thus triggering the observed 
calcium response (229).  
 
  In  summary,  the  UTP  response  in  CHO-K1-hP2Y11  clones  13  and  6  was 
monophasic, hP2Y2-like and independent of the levels of expression of hP2Y11 receptors. 
Hill  slope  analysis  suggested  the  presence  of  multiple  binding  sites  or  positive 
cooperativity. In fact, UTP not only activated P2Y2, but also acted at P2Y1, as confirmed 
by the UTP response observed in 1321N1-hP2Y1 cells.  
 
6.4  Co-expression  reduces  the  affinity  of  hP2Y11  for  αβmeATP  and 
βγmeATP in clones 6 and 13 
  The ATP derivatives αβmeATP and βγmeATP failed to produce a calcium response 
with a clear maximum in clones 13 and 6, and it was not possible to fit a curve to the data 
generated by these agonists. Control 1321N1-hP2Y1 cells did not respond to αβmeATP 
and βγmeATP, indicating that these derivatives do not activate the hP2Y1 receptor. In 
contrast,  both  agonists  elicited  a  full  monophasic  calcium  response  in  the  control 
1321N1-hP2Y11  cells,  in  agreement  with  previous  experiments  performed  in  the 
laboratory using 1321N1-hP2Y11 cells. The discrepancy in the behaviour of αβmeATP 
and  βγmeATP  in  clones  13  and  6  versus  1321N1-hP2Y11  cells  suggests  that  co-
expression could modify the binding properties of hP2Y11 through possible interactions 
with P2Y1 and/or P2Y2, thus producing hP2Y11 active states with a lower affinity for 
these methylene phosphate ligands.  
 
6.5 Co-expression modifies the rank order of agonist potency in clones 6 
and 13 
  The order of agonist potency in the studied cell lines (clone 6, clone 13, 1321N1-
hP2Y11  and  1321N1-hP2Y1)  were  compared  to  determine  whether  co-expression  and 
different levels of hP2Y11 receptor expression affected agonist responses in clones 6 and 
13. In the control 1321N1-hP2Y11 cells, the order of agonist potency using 2meSATP as a 
reference was:  
 
BzATP (0.3) ≈ ATPγS (0.3) > ATP (0.86) > 2meSATP (1) > βγmeATP (6.1) > 
αβmeATP (6.74). 
 Chapter 6   Discussion 
	 ﾠ 	 ﾠ 158	 ﾠ
It is consistent with the order of agonist potency previously reported for the hP2Y11 
receptor  by  Communi  et  al.  (177).    In  the  control  hP2Y1  cells,  the  order  of  agonist 
potency using 2meSATP as a reference was:  
 
2meSATP (1) > ADP (1.23) > ATPγS (3.32) > ATP (32) > UTP (81) 
 
It matches the order of agonist potency reported by Schachter et al. and Filtz et al. 
(2meSATP>  ADP>  ATPγS>  ATP)  for  the  hP2Y1  receptor  (231,  232).  However,  it 
disagrees with the order identified by Palmer et al. (ADP> 2meSATP> ATP) in which 
ADP had a higher potency in 1321N1-hP2Y1 cells relative to 2meSATP (157). In the 
CHO-K1-hP2Y11  clones,  the  rank  order  of  potency  of  the  tested  agonists  relative  to 
2meSATP was:  
 
Clone 6:  2meSATP (1) > ATP (1.57) > ADP (1.67) > UTP (3.2) > ATPγS (12) > 
BzATP (47)  
 
Clone 13: 2meSATP1 (1) > ATP (2.2) > UTP (4.2) > ADP1 (5.2) > ATPγS (13) > 
BzATP (60) > ADP2 (604) ≈ 2meSATP2 (639)  
 
  Comparison of these results shows that co-expression does not modify the rank 
order of potency of 2meSATP in the co-expressing CHO-K1-hP2Y11 clones 13 and 6 
versus 1321N1-hP2Y1 cells. However, higher levels of hP2Y11 expression introduce a 
novel site of 2meSATP responsiveness in clone 13 that is 639 times less potent than the 
original  site.  In  contrast,  co-expression  reduces  the  potency  of  hP2Y1  for  ADP, 
decreasing it from second most potent agonist in 1321N1-hP2Y1 cells to third and fifth in 
clones 6 and 13. The increased levels of hP2Y11 expression in clone 13 also introduce a 
second site of ADP responsiveness with lower agonist affinity. Furthermore, ATP is more 
potent in clones 13 and 6 as opposed to the 1321N1-hP2Y1 and 1321N1-hP2Y11 cells, 
indicating that the P2Y1-P2Y2-P2Y11 co-expressing system has a higher affinity for ATP 
as compared to P2Y1- or P2Y11-only cells. This agrees with previously published findings 
by Qi et al. who detected an enhanced ATP response in CHO-K1-hP2Y11 versus 1321N1-
hP2Y11 cells, explained by the presence of a larger hP2Y11 receptor reserve or increased 
coupling of the receptor with the Gq/11 pathway in CHO-K1-hP2Y11 (178).  
 Chapter 6   Discussion 
	 ﾠ 	 ﾠ 159	 ﾠ
  Comparison of the order of agonist potencies in CHO-K1-hP2Y11 clones 13 and 6, 
1321N1-hP2Y1 and 1321N1-hP2Y11 reveals that the agonist profile of clones 13 and 6 is 
a hybrid of P2Y1 and hP2Y11 signalling. In fact, co-expression seems to: 
 
1-  Increase the affinity of hP2Y11 for BzATP, ATP, ATPγS and reduce its affinity of 
for αβmeATP and βγmeATP 
2-  Decrease the affinity of P2Y1 for ATPγS and ADP and enhance its affinity for 
ATP  
3-  Create novel sites of ADP and 2meSATP affinity with lower agonist potencies  
 
Co-expression thus produces active P2Y1 and hP2Y11 receptor states with altered 
agonist affinities, leading to a unique pharmacological profile distinct from that of the 
individual receptors.  
 
6.6 Co-expression alters the affinity of NF 340 to hP2Y11 in clones 6 and 
13 
  To determine the effect of co-expression on the antagonist profile of hP2Y11, the 
response of clones 13 and 6 to 10µM BzATP was tested in the presence of increasing 
concentrations of NF 340, which inhibits hP2Y11 activity with 520-fold selectivity over 
other purinoceptors (221). NF 340 failed to inhibit the calcium response to BzATP in 
both clones 13 (Figure 5.20) and 6 (data not shown). In contrast, NF 340 antagonised the 
response  to  10µM  BzATP  in  the  control  1321N1-hP2Y11  cells,  showing  that  this 
compound was active. The average pIC50 value for this antagonist in 1321N1-hP2Y11 
cells (6.62 ± 0.09) agreed with the previously published pIC50 value for this antagonist, 
i.e.  6.43  (221).  NF  340  did  not  affect  the  response  of  1321N1-hP2Y1  cells  to  ADP, 
revealing that it is not an inhibitor of the P2Y1 receptor. Furthermore, NF 340 did not 
inhibit the biphasic response to ADP and 2meSATP in clone 13. As the inhibition and 
Schild experiments were conducted in all cell lines using the same vial of NF 340 within 
the same period of time, it can be concluded that NF 340 is unable to inhibit the hP2Y11 
receptor when this receptor is co-expressed in the recombinant CHO-K1-hP2Y11 clones. 
Thus, co-expression modifies the antagonist profile of hP2Y11 regardless of its level of 
expression in the clones. Loss of NF 340 antagonism could result from a modification of 
the binding pocket of the receptor that alters its affinity for antagonist binding.  
 Chapter 6   Discussion 
	 ﾠ 	 ﾠ 160	 ﾠ
6.7 The high-affinity site of the response to ADP in CHO-K1-hP2Y11 
clone 13 is endogenous P2Y1 receptor-mediated  
 
6.7.1  The  high-affinity  site  of  the  biphasic  response  in  clone  13  has 
reduced affinity for ADP   
  In-depth analysis of the calcium response to BzATP, ATP and ATPγS in CHO-K1-
hP2Y11 clones 13 and 6 shows that different levels of hP2Y11 expression do not alter the 
calcium  response  of  the  clones  to  these  agonists.  However,  co-expression  seems  to 
enhance the affinity of hP2Y11 for these ligands in the clones as compared to 1321N1-
hP2Y11 cells. In contrast, ADP and 2meSATP triggered an additional layer of complexity 
in clone 13. ADP, a potent P2Y1 agonist (158, 231, 233, 234), engendered a biphasic 
response with two distinct potencies in this clone, as compared to a monophasic response 
in clone 6. Mathematical analysis revealed a statistically significant difference between 
the ADP potency at the high-affinity site (110 ± 6nM) versus the low-affinity site (12.7 ± 
1.8µM) of the curve in clone 13 (**; p value = 0.002), signifying that two distinct binding 
sites are involved in the biphasic ADP response.  
 
  The  ADP  potencies  at  the  high  and  low  affinity  sites  of  the  biphasic  ADP 
response in clone 13 were statistically significantly different from the ADP potency in 
clone 6 (*; p value = 0.0246 and**; p value = 0.002, respectively). In the control 1321N1-
hP2Y11 cells, the ADP response attained 40% of the control carbachol response only and 
did not produce a measurable EC50 value, indicating that hP2Y11 does not fully respond to 
ADP. In contrast, ADP evoked a marked response in 1321N1-hP2Y1 cells, the potency of 
which (5.6 ± 1nM) matched the ADP potency in clone 6 (p value = 0.1989), indicating 
that human and hamster P2Y1 have a similar affinity for ADP at low levels of hP2Y11 
expression.  The  ADP  potency  in  1321N1-hP2Y1  cells  was  statistically  significantly 
different from the ADP potency at the high and low affinity sites of the biphasic ADP 
response in clone 13 (****; p value < 0.0001 and **; p value = 0.002, respectively). 
These  comparison  indicate  that  higher  levels  of  hP2Y11  expression  influence  the 
sensitivity of CHO-K1-hP2Y11 cells to ADP, reducing the affinity of endogenous P2Y1 
for ADP and producing a novel site of ADP responsiveness as seen in clone 13.   
 
Comparison with the literature shows that the ADP response in untransfected CHO-
K1 cells based on intracellular calcium measurements is monophasic (EC50 value= 69 ± 
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content only without activating the cAMP pathway. Similarly, Qi et al. found that ADP 
increased calcium fluorescence in CHO-hP2Y11 cells but failed to elicit a cAMP response 
with a clear maximum (178, 211).  Since the transfected receptor did not fully respond to 
the agonist, it was not possible to calculate an EC50 value for ADP in this cell line (178, 
211). In contrast, the ADP potencies in different 1321N1-hP2Y1 cell lines, i.e. 10nM 
(157) and 18.3nM (235), agreed with those observed in clone 6 and 1321N1-hP2Y1 cells 
(p value = 0.3788). The ADP potency in these cell lines is thus consistent with published 
values and the ADP response in clone 6 can be attributed to the P2Y1 receptor. On the 
other hand, the ADP potency at the low and high affinity sites of the biphasic ADP 
response in clone 13 differs from the ADP potency in clone 6, 1321N1-hP2Y1 cells and 
published values.  
 
A  plausible  explanation  for  the  observed  results  is  that  high  levels  of  hP2Y11 
expression  in  CHO-K1-hP2Y11  cells  provoke  a  conformational  change  in  P2Y1  that 
reduces its affinity for ADP and they generate a novel site of ADP affinity distinct from 
P2Y1 and hP2Y11. This low affinity site is a function of hP2Y11 but assumes a P2Y1-like 
character given its responsiveness to the P2Y1 agonist ADP. Since hP2Y11 ‘density’ is the 
only known variable in clones 6 and 13, it can be hypothesized that the increased levels 
of hP2Y11 expression in clone 13 might trigger a physical interaction between the P2Y1 
and hP2Y11 receptors, responsible for the formation of this novel site with altered binding 
and agonist properties.  
 
6.7.2 The high-affinity site of the ADP response is inhibited by MRS 
2179  
  To confirm that the high affinity site of the biphasic ADP curve in clone 13 is 
endogenous P2Y1, the response to increasing concentrations of ADP was tested in the 
presence of four different concentrations of MRS 2179, a well-described P2Y1 antagonist 
(170,  236-238).  Increasing  antagonist  concentrations  shifted  the  ADP  response  to  the 
right  and  gradually  abolished  the  biphasic  response.  The  ADP  potencies  at  the  high 
affinity  site  of  the  control  ADP  and  ADP+1µM  MRS  2179  curves  were  similar  but 
differed  from  the  ADP  potency  at  the  low-affinity  site  of  the  curves.  The  higher 
concentrations of MRS 2179, i.e. 10 and 100µM, shifted the ADP sensitivity of the high-
affinity  site  to  the  right,  resulting  in  a  monophasic  response  with  the  same  ADP 
sensitivity  as  the  low-affinity  site  of  the  response.  The  order  of  ADP  potency  at  the 
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ADP (EC50-1) ≈ ADP (EC50-1) + 1µM MRS 2179 > ADP (EC50-2) ≈ ADP (EC50-2) + 
1µM MRS 2179 ≈ ADP +10µM MRS 2179 ≈ ADP + 100µM MRS 2179 
   
These results show that MRS 2179 inhibits the high affinity site of the biphasic 
ADP response without affecting its low-affinity site. This suggests that the orthosteric 
binding sites at the high versus low affinity sites of the biphasic curve are distinct. The 
mean KB (500 ± 200nM) and pA2  (6.4 ± 0.2) values for MRS 2179 in clone 13 agreed 
with previously published KB, i.e. 102nM (238, 239) and 177nM (151, 210), and pA2 
values,  i.e.  6.55  ±  0.05  (170),  for  this  antagonist  at  hP2Y1.  Furthermore,  increasing 
concentrations of MRS 2179 competitively antagonized the response to 100nM ADP in 
clone 13, in agreement with its inhibitory action against ADP in 1321N1-hP2Y1 cells and 
published data (236).  
 
The biphasic ADP response in clone 13 was also tested in the presence of Reactive 
Red, previously reported to antagonize P2Y receptors (174, 224, 240). The addition of 
10µM Reactive Red shifted the biphasic ADP response to the right, converting it to a 
monophasic one, while the maximum antagonist concentration completely abolished it 
(Figure 5.8). This suggests that Reactive Red blocked the ADP response at both sites of 
the curve in a non-competitive fashion, in agreement with the mode of action previously 
reported  for  this  antagonist  (224).  Furthermore,  increasing  concentrations  of  Reactive 
Red inhibited the response to 100nM ADP in a concentration-dependent fashion. This 
concords  with  previously  published  data  showing  that  Reactive  Red  inhibited  the 
relaxations  mediated  by  a  P2Y1-like  receptor  in  the  guinea  pig  taenia  coli  (224).  In 
contrast, the hP2Y11 antagonist NF 340 did not affect the ADP sensitivity of the high 
affinity site of the ADP curve in clone 13. In summary, these antagonist experiments 
show that the high-affinity site of the biphasic ADP curve in clone 13 is inhibited by 
MRS  2179  and  Reactive  Red,  both  previously  reported  to  antagonize  P2Y1-mediated 
calcium responses, but is unaffected by NF 340, a hP2Y11 inhibitor. Consequently, it can 
be  hypothesized  that  the  high-affinity  site  of  the  ADP  response  in  clone  13  exhibits 
marked P2Y1-like properties and most probably consists of P2Y1 receptors.  
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6.8  The  high  affinity  site  of  the  response  to  2meSATP  in  CHO-K1-
hP2Y11 clone 13 is endogenous P2Y1  
 
6.8.1 The high-affinity site of biphasic 2meSATP curve in clone 13 has 
P2Y1-like character 
Similarly to ADP, the ATP derivative 2meSATP also evoked a complex biphasic 
response in clone 13 as opposed to a monophasic response in clone 6. The 2meSATP 
potencies at the high versus low affinity sites of the biphasic curve in clone 13 were 
statistically significantly different (****; p value < 0.0001). Unlike the ADP sensitivity of 
endogenous P2Y1 in clone 13, which was altered by higher levels of hP2Y11 expression in 
this clone compared to clone 6, the 2meSATP potency at the high-affinity site of the 
biphasic response in clone 13 was the same as its potency in clone 6 (p value = 0.9482). 
In  contrast,  the  agonist  potency  of  the  low  affinity  site  was  statistically  significantly 
different from that of clone 6 (****; p value < 0.0001). These results suggest that the 
same population of receptors is active at the high-affinity site of clone 13 and in clone 6 
while a distinct population of receptors is acting at the low-affinity site of clone 13.  
 
  Comparison with the 2meSATP response in control 1321N1-hP2Y11 and 1321N1-
hP2Y1 cells shows that the 2meSATP potency of the high-affinity site of the response in 
clone 13 was similar to its potency in 1321N1-hP2Y1 cells (p value = 0.1654), suggesting 
that P2Y1 could be responsible for the calcium response of this site. On the other hand, 
the agonist potency of the low affinity site of the biphasic 2meSATP curve in clone 13 
was  similar  to  its  potency  in  1321N1-hP2Y11  cells  (p  value  =  0.319),  implying  that 
hP2Y11 or an hP2Y11-like binding site might be operating at this site. Various mentions of 
2meSATP action at purinoceptors were found in the literature. A pharmacological study 
in CHO-K1 cells described a partial 2meSATP response at a P2U receptor (now known 
as P2Y2) (208) while the detailed analysis of adenosine triphosphate action in 1321N1-
hP2Y1 cells found a 2meSATP potency of 116nM (157). A third paper reported a mean 
2mesATP potency of 1.36nM in hP2Y1-expressing cells (235), in agreement with the 
potency found in 1321N1-hP2Y1 cells in the present study. 2meSATP assays in CHO-
K1-hP2Y11 cells detected an increase in both IP3 and cAMP content following agonist 
addition, although the concentration-response curve was monophasic (177, 178). This 
finding reveals that 2meSATP stimulates hP2Y11 in recombinant cell lines expressing this 
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curve and that the appearance of a second site of 2meSATP affinity is a function of 
hP2Y11 density. Taken together, these results indicate that the high affinity component of 
the 2meSATP response in clone 13 most likely corresponds to P2Y1 while its low affinity 
component corresponds to P2Y11. The two distinct populations of receptors mediating the 
biphasic  response  to  2meSATP  in  this  clone  thus  correlate  to  two  known  and 
characterized  receptors  (P2Y1  and  hP2Y11),  unlike  the  low  affinity  site  of  the  ADP 
response, which harbours an unknown component with novel properties and might be a 
P2Y1+P2Y11 hybrid.  
 
6.8.2 The high affinity site of the biphasic 2meSATP curve is inhibited 
by MRS 2179 
  The  biphasic  response  to  2meSATP  was  tested  in  the  presence  of  the  same 
antagonists used for ADP. The P2Y1 antagonist MRS 2179 provoked a parallel rightward 
shift of the biphasic 2meSATP response, converting the biphasic curve into a monophasic 
one. The antagonist inhibited the high-affinity site of the curve only without affecting the 
low-affinity site, thus indicating that the high and low affinity sites possess different 
sensitivities for MRS 2179. Increasing concentrations of MRS 2179 and Reactive Red 
inhibited  the  calcium  response  to  100nM  2meSATP  in  a  concentration-dependent 
fashion, further confirming that these antagonists inhibit the receptors active at the high 
affinity site of the 2meSATP response. In contrast, NF 340 failed to alter the calcium 
response to 100nM 2meSATP in this clone, implying that this antagonist has no effect on 
the high affinity site of the curve. In summary, the receptors present at the high affinity 
site of the biphasic 2meSATP curve in clone 13 are inhibited by MRS 2179 and Reactive 
Red but not by NF 340. Moreover, the 2meSATP potency at these receptors is similar to 
the  2meSATP  potency  at  hP2Y1.  Thus,  these  receptors  assume  P2Y1-like  affinities, 
indicating that the high affinity site of the biphasic 2meSATP in clone 13 most likely 
consists of endogenous P2Y1.  
 
6.9 Pharmacological evidence for P2Y1 and hP2Y11 interactions   
 
6.9.1 The low-affinity site of the response to ADP and 2meSATP in clone 
13 has P2Y1 and hP2Y11-like characteristics 
  Agonist experiments in clones 13 versus 6 revealed that the low affinity site of the 
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potency of ADP at this site is unique and does not match its potency at the P2Y1 receptor 
and  other  purinoceptors  expressed  in  the  recombinant  CHO-K1  cells.  The  2meSATP 
potency at this site, however, matches its potency at the human P2Y11 receptor. Schild 
plots and inhibition experiments in clone 13 showed that the P2Y1 antagonist MRS 2179 
does  not  antagonise  the  low  affinity  site  of  the  biphasic  curves,  as  opposed  to  its 
inhibitory action against the P2Y1-like high-affinity site. The hP2Y11 antagonist NF 340 
also failed to alter the calcium response of these low-affinity sites. Hence, the low affinity 
site  of  the  biphasic  curves  exhibits  P2Y1-like  agonist  affinity  characterized  by  ADP 
responsiveness but a distinct antagonist profile from both P2Y1 and hP2Y11. In contrast to 
MRS 2179 and NF 340, 10µM to 100µM Reactive Red abolished the calcium response of 
the low-affinity site of the biphasic ADP and 2meSATP, in agreement with previous 
reports of Reactive Red antagonism at P2Y1 (224) and P2Y11 (174, 224) receptors. In 
fact,  antagonist  experiments  in  the  guinea  pig  taenia  coli  revealed  that  Reactive  Red 
depressed αβmeATP relaxations mediated by a P2Y11-like receptor in a non-competitive 
fashion and with less potency than against the P2Y1-like receptor (224). This effect is 
comparable to its action at the low-affinity site of the biphasic ADP and 2meSATP curves 
where it suppressed agonist response non-competitively and exhibited less potency than 
at the high-affinity site (19, 224).  
 
  In summary, higher levels of hP2Y11 expression provoke the formation of a novel 
orthosteric site with a distinct pharmacology in clone 13. This low affinity site responds 
to  ADP  similarly  to  P2Y1,  possesses  the  same  2meSATP  potency  as  hP2Y11,  lacks 
affinity for both the P2Y1 antagonist MRS 2179 and the P2Y11 inhibitor NF 340 and is 
inhibited by Reactive Red in an antagonistic fashion similar to its action against P2Y11 in 
the guinea pig. In the case of the biphasic ADP response, the low-affinity site appears to 
be a hybrid of endogenous P2Y1 and transfected hP2Y11 with unique agonist/antagonist 
affinities (P2Y1+P2Y11). The low-affinity site of the biphasic 2meSATP curve showcases 
pharmacological properties similar to those of hP2Y11 in clones 6 and 13 and most likely 
corresponds to hP2Y11.  
 
6.9.2 The low-affinity site of the response to ADP and 2meSATP results 
from the interaction between P2Y1 and hP2Y11 in clone 13 
  Agonist and antagonist experiments in clones 6 and 13 show that co-expression of 
P2Y1 and hP2Y11 affects the pharmacological profile of endogenous P2Y1 and transfected 
hP2Y11. Thus, both low and high levels of hP2Y11 expression, represented by clone 6 and Chapter 6   Discussion 
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13, increased the affinity of hP2Y11 for BzATP, ATP, ATPγS and decreased its affinity 
for αβmeATP and βγmeATP. Moreover, they decreased the affinity of P2Y1 for ATPγS 
and caused the loss of NF 340 antagonism at the human P2Y11 receptor. Higher levels of 
hP2Y11  expression  introduced  an  additional  layer  of  complexity  to  the  co-expressing 
P2Y1-hP2Y11  system,  resulting  in  novel  sites  of  ADP  and  2meSATP  potency  and 
decreased  affinity  of  P2Y1  for  ADP.  The  low  affinity  sites  of  the  biphasic  curves 
displayed a lower potency for ADP and 2meSATP than their high-affinity sites and were 
blocked  by  Reactive  Red  only.  These  findings  indicate  that  P2Y1  and  hP2Y11  might 
interact when co-expressed in CHO-K1-hP2Y11 clones 6 and 13. This crosstalk could 
provoke conformational changes in the ligand binding pockets of the receptors leading to 
altered active receptor states with novel agonist and antagonist affinities. It could also 
explain the positive cooperativity for ATP, ATPγS and UTP binding observed in the 
CHO-K1-hP2Y11 clones whereby P2Y1 activation would enhance the binding of these 
agonists to hP2Y11 in the clones as compared to 1321N1-hP2Y11 cells. Co-expression of 
the two receptors and subsequent communication also abolishes the affinity of NF 340 for 
hP2Y11 thus modifying the pattern of allosteric modulation of this receptor. Receptor co-
expression could also alter the coupling of P2Y1 and hP2Y11 to cognate Gq/11 proteins, 
resulting in further changes in the calcium response.  
 
  A plausible explanation for the altered properties of clone 13 may be that high 
hP2Y11 reserves at the cellular membrane of clone 13 force increased oligomerisation 
with P2Y1, leading to the formation of a second site of agonist sensitivity with novel 
pharmacological properties. An emergent feature of this site is its responsiveness to ADP, 
which  normally  exhibits  no  activity  at  individual  hP2Y11  receptors  while  a  second 
characteristic is the absence of MRS 2179 and NF 340 antagonism at this site. Studies 
performed  by  Ecke  et  al.  have  previously  reported  the  existence  of  a  P2Y1:hP2Y11 
oligomer resulting from direct physical interaction between P2Y1 and P2Y11 in HEK-293 
cells  (55).  This  oligomer  was  characterized  using  BzATP,  MRS  2179  and  the  P2Y11 
antagonist NF 157, revealing that NF 157 was not able to inhibit the BzATP response in 
co-expressing cells, which concurs with the loss of NF 340 antagonism in clone 13. The 
researchers  concluded  that  the  P2Y1:hP2Y11  oligomer  possesses  a  distinct 
pharmacological profile from its constitutive receptors, a notion increasingly supported 
by recent evidence (55). These discoveries support the conclusion that endogenous P2Y1 
and transfected hP2Y11 form a hetero-oligomer at high levels of hP2Y11 expression in 
CHO-K1-hP2Y11  clone  13  cells.  Furthermore,  the  current  findings  suggest  that  ADP, Chapter 6   Discussion 
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2meSATP and Reactive Red bind to this P2Y1:P2Y11 oligomer active at the low affinity 
site of the biphasic responses, while MRS 2179 and NF 340 do not bind to it. 
 
  Two scenarios can be envisaged. According to the first, the biphasic response to 
ADP and 2meSATP is mediated by two distinct populations of binding sites: 1) P2Y1 at 
the  high-potency  site  of  the  curves  and  2)  P2Y1:hP2Y11  at  the  low-potency  site. 
According to the second, the entire biphasic ADP response of clone 13 could be mediated 
by the P2Y1:hP2Y11 heteromer. In this scenario, the P2Y1 component of the heteromer 
would account for the high affinity site of the curve while hP2Y11 would mediate the low 
affinity response to ADP. This mechanism fits into the two state dimer receptor model 
described by Casadó et al. (241), according to which conformational modifications in one 
protomer of the dimer are transmitted to the partner protomer, indicating that the two 
subunits of the receptor dimer can interact, leading to negative or positive cooperativity 
(241). 
 
6.10  Predictive  analysis  of  the  binding  pocket  and  conformational 
rearrangements involved in P2Y1 and hP2Y11 interaction  
  The modified agonist and antagonist potencies observed in the co-expressing CHO-
K1-hP2Y11  clones  signify  that  purinoceptor  “cross-talk”  provoked  conformational 
reorganizations of the P2Y1 and hP2Y11 receptor structures. This raises questions as to 
what  domains  or  amino  acid  residues  of  the  receptors  might  have  contributed  to  the 
altered affinities of the orthosteric sites for certain ligands. Modelling and mutagenesis 
studies of P2Y1 and hP2Y11 have uncovered the residues implicated in agonist and/or 
antagonist recognition and docking. For instance, studies of the human P2Y11 receptor 
reveal that its binding pocket resides between TM2 and TM7 and is constrained by the 
residues Leu
82 (TM2), Phe
109 (TM3), Leu
113 (TM3), Pro
311 
(TM7) and Ala
313 (TM7) (242, 
243). Amino acids involved in ligand binding in this receptor comprise Arg
106 (TM3), 
Phe
109 (TM3), Ser
206 (TM5), Arg
268 (TM6), Arg
307 (TM6) and Met
310 (TM7) (242, 243). 
Residues necessary for ligand recognition include Arg
106 (TM3), Tyr
261 (TM6), Arg
268 
(TM6), Arg
307 (TM6), Ala
313 (TM7) and Glu
186 (EL2) (242, 243). The positively charged 
arginine  residues  play  a  critical  role  in  stabilizing  bound  ATP  through  electrostatic 
interactions  with  its  triphosphate  moiety  while  Ser
206  engages  in  hydrogen  bonding 
interaction  with  Pγ  (242,  243).  In  light  of  these  structural  configurations,  a  plausible 
explanation for the increased affinity of hP2Y11 for ATP and its derivatives BzATP and 
ATPγS is that interaction with P2Y1 could shift the residues of the binding cleft away Chapter 6   Discussion 
	 ﾠ 	 ﾠ 168	 ﾠ
from TM7. This could in turn permit tighter binding and interaction of the arginine and 
serine residues of the ligand cavity with the triphosphate moiety of ATP, BzATP and 
ATPγS,  resulting  in  greater  stability  of  ligand  binding  to  hP2Y11  and  greater  agonist 
potency. This modification of the binding pocket could also account for the lost affinity 
of NF 340 for hP2Y11. Furthermore, a study by Qi et al. found that mutating Arg
268 
increases the potency of hP2Y11 for ADP (211). This indicates that this basic residue 
plays  an  important  role  in  distinguishing  between  nucleotide  diphosphates  and 
triphosphates and accounts for the preference of ATP over ADP in hP2Y11 receptors (211, 
242). Since the key feature of clone 13 is the appearance of a P2Y1-hP2Y11 heteromer 
with decreased potency for ADP, a potent agonist of P2Y1 with no activity at monomeric 
hP2Y11,  the  responsiveness  of  heteromeric  hP2Y11  to  ADP  could  result  from  a 
conformational change that shields or displaces Arg
268 away from the receptor’s binding 
pocket, rendering hP2Y11 more responsive to ADP. 
 
  The computational modelling and mutagenesis studies of the P2Y1 receptor have 
shown  that  the  amino  acid  residues  involved  in  agonist  binding  also  contribute  to 
antagonist binding. Although the results originate from experiments at human P2Y1, they 
were extrapolated to hamster P2Y1 for the purpose of this discussion. According to the 
devised  model,  the  “receptor  architecture”  conducive  to  ATP  docking  was  also 
energetically favourable for MRS 2179 (242). The amino acid residues crucial for agonist 
stabilization include Arg
128 (TM3), Thr
222 (TM5), Lys
280 (TM6) and Arg
310 (TM7) while 
residues involved in agonist recognition comprise Gln
307 (TM7) and Ser
314 (TM7). Thr
222 
and  Lys
280  are  particularly  important  for  binding  of  the  adenosine  moiety  (151). 
Furthermore, a high degree of coordination of the β-phosphate is crucial for binding of 
adenosine phosphates to hP2Y1, which explains the greater potency of ADP versus ATP 
at  this  receptor  (151).  Residues  implicated  in  antagonist  binding  are:  Arg
128  (TM3), 
Arg
310 (TM7) and Tyr
136 (TM3), while His
132 (TM3), Tyr
136 (TM3) and Thr
222 (TM5) 
also fulfilled a modulatory function. P2Y1-related changes observed in clone 13 included 
1) reduced ADP potency at the high affinity site of the curve mediated by endogenous 
P2Y1 and 2) loss of MRS 2179 activity at the P2Y1:hP2Y11 oligomer. Given that ADP 
and MRS 2179 binding requires Arg
128, Arg
310 and Thr
222, it can be hypothesized that 
interaction with hP2Y11 caused the rearrangement of these residues into a conformation 
less energetically favourable for ADP and MRS 2179 by decreasing the coordination of 
the  β-phosphate  upon  binding.  These  modifications  could  have  also  resulted  in  the 
impaired  interaction  of  the  5’  and  3’-monophosphate  groups  of  MRS  2179  with  the Chapter 6   Discussion 
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positively charged residues of the binding pocket. Given the importance of this step for 
antagonist docking and stabilization, this alteration could explain the absence of MRS 
2179 action at the heteromer.  
 
  Crystallization and modelling studies have identified a role for TM4, TM5 and the 
intracellular  loop  connecting  TM3  and  TM4  in  dimeric  interactions  (28,  79)  and 
suggested a number of dimerization interfaces with contacts between TM4-TM4, TM4-
TM6 and TM5-TM6 (77). A closer inspection of the location of the residues involved in 
agonist  and  antagonist  binding  in  P2Y1  and  hP2Y11  reveals  that  many  of  the  crucial 
amino  acids  are  situated  in  TMs  3,  5  and  6  in  both  receptors.  This  implies  that  the 
transmembranes  containing  the  residues  important  for  ligand  binding  could  also  be 
involved in the interaction and dimerization between P2Y1 and hP2Y11. Conformational 
rearrangements due to cross-talk and oligomerisation could shift the location of these 
residues  within  the  plane  of  the  receptors,  thus  altering  the  docking  and  binding  of 
agonists and antagonists.  
   
6.11 Conclusions  
The  experiments  conducted  in  this  project  have  provided  a  detailed 
pharmacological profile of two recombinant cell lines: a low-expressing CHO-K1-hP2Y11 
clone 6 and a high-expressing CHO-K1-hP2Y11 clone 13. Two distinct scenarios arise 
from the obtained results. At low levels of hP2Y11 expression, co-expression was found 
to alter the affinity of BzATP, ATPγS, ATP, UTP, αβmeATP, βγmeATP and NF 340 for 
hP2Y11  in  CHO-K1-hP2Y11  clones  as  compared  to  1321N1-hP2Y11.    High  levels  of 
hP2Y11 expression produced biphasic responses to ADP and 2meSATP, characterized by 
the appearance of a low-affinity site with unique ligand potencies and selectivities. These 
results provide convincing proof of some form of interaction between P2Y1 and hP2Y11 
in the co-expressing clones 6 and 13. They also suggest that the extent and dynamics of 
this interaction are different at low levels of hP2Y11 expression as compared to higher 
levels,  suggesting  that  different  modes  of  interaction  might  be  implicated  in  clone  6 
versus  13.  Hence,  while  evidence  points  to  possible  oligomerisation  and  physical 
communication between P2Y1 and hP2Y11 in clone 13, the nature of receptor cross-talk in 
clone 6 is more elusive. In fact, it seems that clone 6 constitutes an intermediary state 
between individual receptor pharmacology as detected in the control 1321N-hP2Y1 and 
1321N1-hP2Y11 cell lines and oligomeric receptor interaction in clone 13.  
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The  literature  suggests  that  receptor  interaction  could  be  functional/indirect  or 
physical/direct. Consequently, it can be argued that the crosstalk between endogenous 
P2Y1 and hP2Y11 is functional in clone 6 and might arise from signalling crosstalk as 
illustrated  by  the  example  of  the  mGlu1a  and  GABAB  receptors  (see  Introduction).  
Increasing the density of the hP2Y11 receptor reserve at the cellular membrane, as in the 
case of clone 13, seems to push this communication further, resulting in direct physical 
contact between the two receptors and the formation of a P2Y1:hP2Y11 complex with a 
unique signalling profile. According to Durroux (64), there are two distinct models of 
receptor dimerization. In the first model, receptors fluctuate between two dimeric states, 
the R∼R state in which protomers are independent from one another and the R–R state in 
which  protomers  can  interact.  In  the  second  model,  receptors  oscillate  between  a 
monomeric state and a dimeric state in which protomers are able to interact (241). The 
interaction between P2Y1 and P2Y11 as illustrated by the behaviours of clone 6 and 13 
could fall into the second model of dimerization expounded by Durroux. Taken together, 
these observations lead to the following conclusion: 1) P2Y1 and hP2Y11 are proteins 
that  display  a  propensity  to  interact  when  co-expressed.  This  interaction  can  be 
functional at lower receptor reserves or physical at higher receptor densities. 
 
For these interactions to occur, it is necessary that the communicating partners be 
recruited  to  common  compartments  permitting  receptor  organization  and  association. 
Cells  have  resolved  this  spatio-temporal  dilemma  by  confining  signalling  proteins 
including  GPCRs  to  membrane  microdomains  such  as  lipid  rafts  (244).  The  current 
GPCR literature argues that cells have accomplished an additional organisational feat by 
pooling GPCRs into receptor mosaics, defined as macromolecular assemblies of more 
than two receptors that interact directly to form various arrangements (87, 89, 94-96, 
245).  These  topologies  are  regulated  by  conformational  and  allosteric  interactions 
between members of these specialized signalling hubs (89, 245). Experimental evidence 
has suggested that P2Y receptors, including P2Y1, localize to cholesterol-rich signalling 
microdomains or lipid rafts (55, 246, 247). This indicates that P2Y1 and hP2Y11 receptors 
(and  possibly  hP2Y2)  might  localise  to  specific  membrane  microdomains  in  the 
recombinant  CHO-K1-hP2Y11  clones  6  and  13,  thus  enabling  functional  cross-talk, 
cooperativity,  allosteric  regulation,  and  oligomerisation  between  the  two  receptors,  as 
detected in the clones. Interestingly, these recent findings suggest that while P2Y1 and 
hP2Y11 can form heteromers, they might even exist in macromolecular assemblies with 
other GPCRs such as P2Y2. These assemblies or receptor mosaics may possess different Chapter 6   Discussion 
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properties to receptor heteromers, thus explaining the absence of hP2Y11 internalization in 
CHO-K1-hP2Y11 clone 13, as opposed to the P2Y1-induced internalization of hP2Y11 
observed by Ecke et al. in recombinant 1321N1 cells (55). The receptor mosaic might 
exert spatial and functional restraints on its receptor components, causing them to behave 
differently to monomers or heteromers.  
 
Seeing as receptor dimerization confers novel signalling profiles to the heteromers, 
Franco  et  al.  have  advanced  the  notion  of  ‘dimer  fingerprint’,  defined  as  a  specific 
pharmacological, biochemical or functional property exhibited by the receptor heteromer 
(248). This notion was applied to the distinct pharmacological entity observed at the low-
affinity site of the biphasic ADP and 2meSATP responses in CHO-K1-hP2Y11 clone 13, 
leading  to  the  following  conclusion:  2)  The  P2Y1:hP2Y11  heteromer  occurring  in 
CHO-K1-hP2Y11 clone 13 possesses a unique dimer fingerprint. It responds to ADP, 
unlike individual hP2Y11 receptors, but is not antagonized by MRS 2179 or NF 340, 
in contrast to individual P2Y1 or hP2Y11 receptors, respectively. 
 
Another interesting feature of calcium signaling in the high-expressing CHO-K1-
hP2Y11  clone  13  is  that  the  biphasic  2meSATP  and  ADP  curves  integrate  P2Y1  and 
hP2Y11 activity into a single signalling event. The significance of this observation lies in 
that P2Y1 and P2Y11 have been reported to mediate the rapid and slow relaxation of 
smooth muscle cells, respectively (174). Consequently, studies conducted in the guinea 
pig taenia coli have investigated these relaxations separately, activating and inhibiting 
each individually. The present study reveals that in certain instances, the components of 
the two phases of SMC relaxation can merge into a single continuous calcium occurrence 
with two distinct plateaus. Moreover, these two components can interact to form one 
signalling entity or P2Y1:hP2Y11 heteromer with a unique pharmacology. Two agonists, 
namely ADP and 2meSATP, were able to activate these two components simultaneously, 
while Reactive Red was able to block them simultaneously. It was also possible to inhibit 
the P2Y1 component of the biphasic response separately from the heteromeric component 
using MRS 2179. However, it was not possible to target the oligomeric phase separately 
from the P2Y1 phase using any of the antagonists tested in this study, as neither MRS 
2179  nor  NF  340  were  active  against  the  low-affinity  site.  Furthermore,  it  was  not 
possible to inhibit the hP2Y11 receptor as it displayed no affinity for NF 340 in the co-
expressing clones 6 and 13. These observations of great pharmacological potential draw a 
bridge  between  the  findings  of  this  study  and  the  inspiration  behind  it,  namely  the Chapter 6   Discussion 
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investigation of P2Y1 and P2Y11 interactions to develop a drug that could target SMC 
relaxation in the stomach. This drug, if implemented, could function as a chemical gastric 
band  in  obese  patients,  thus  replacing  the  invasive  bariatric  surgery  or  harmful  anti-
obesity drugs such as orlistat. They draw a roadmap for future pharmacological testing 
delineated  by  the  following  conclusion:  3)  Co-expression  often  alters  the 
agonist/antagonist profile of purinoceptors and produces oligomeric receptors with 
novel  pharmacologic  properties.  This  signalling  diversification  highlights  the 
necessity to enlarge the current ligand repertoire by testing and developing novel 
drugs specific to monophasic and oligomeric populations of receptors that occur in 
the cellular membrane. 
 
This agrees with the conclusion drawn by Franco et al. in a review entitled “G-
protein-coupled  receptor  heteromers:  function  and  ligand  pharmacology”  (248).  The 
researchers argue that the major shortcoming of the current drug industry lies in its failure 
to recognize the inherent complexity of receptor signalling in favour of the old-fashioned 
reductionist approach focusing on individual receptors characterized in single-transfected 
cells where oligomerisation does not occur. This simplification skews the real effect of 
drugs at receptors by ignoring the increasing evidence that receptors tend to interact or 
oligomerize  in  real  organisms,  thus  altering  or  abolishing  the  affinities  of  ligands  at 
targeted receptors. Franco et al. thus advise pharmaceutical companies to test potential 
drugs against therapeutically relevant heteromers, such as opioid or cannabinoid receptor 
heteromers for pain or dopamine/adenosine receptor heteromers for Parkinson’s disease 
(248). P2Y1 and P2Y11 can be added to this endeavour given their participation in a wide 
range of metabolic pathways and functions. In conclusion, the novel paradigm of receptor 
oligomerisation  acknowledging  the  complexity  of  receptor  behaviour  at  cellular 
membranes echoes the insight formulated by Martin Rodbell in his Nobel Prize lecture 
exactly twenty years ago, according to which “receptor-coupled signalling processes in 
general now seem more Bhudda-like in their structures, both in their stationary setting 
and the multi-component structures which appear to interact in a flickering fashion, more 
in keeping with the ephemeral relationship between action and inaction, between life and 
death”(249). 
 
6.12 Future Work 
  The main objective behind this project was to study the interaction between P2Y1 
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stomach, to develop an anti-obesity drug that could block this relaxation. Characterization 
of  calcium  responses  in  clones  6  and  13  suggests  the  existence  of  a  P2Y1:P2Y11 
heteromer with unique signalling properties. cAMP assays constitute a logical follow-up 
on these experiments and could discriminate between ligand activity at hP2Y11 versus 
P2Y1.  Increased  cAMP  production  would  confirm  the  involvement  of  hP2Y11  in  the 
biphasic responses, although lack of cAMP increase would not disprove it. In fact, the 
coupling of dimers to G-proteins seems to be asymmetric with a 2:1 stoichiometry (250), 
implying that heteromerisation could decouple one protomer from its cognate G-protein. 
cAMP  assays  might  thus  offer  insights  into  the  G-protein  stoichiometry  of  the 
P2Y1:hP2Y11 dimer.  
 
  Furthermore,  radioligand  binding  assays  could  be  performed  to  identify  a 
“binding  fingerprint”  for  this  dimer  using  suitable  radioligands.  Possible  candidates 
include radioactive ADP such as [2-
3H] ADP (251) or [
14C] ADP (252, 253), previously 
employed  to  study  ADP  binding  to  platelet  membranes  (KD  =  0.35,  1  and  0.5  µM, 
respectively).  In  fact,  deeming  the  current  functional  assays  non-suitable  for  dimers, 
Casadó et al. have proposed a novel procedure for determining ligand affinities at the 
high- and low- affinity sites of biphasic responses using radioligand binding assays. This 
procedure  reflects  communication  within  the  dimer  with  a  “cooperativity  index”  and 
provides  accurate  KD  and  B50  (concentration  providing  half  saturation)  values  for 
agonists, useful for elucidating the rank order of potency of ligands at dimers (241). Most 
importantly, it can elucidate a specific property of the receptor or its dimer fingerprint 
(248).  For instance, radioligand binding assays in cotransfected cells and rat striatum 
have  revealed  a  main  biochemical  characteristic  of  the  A1R:A2AR  heteromer,  i.e.  the 
ability of A2A activation to reduce the agonist affinity of A1 receptors, thus providing a 
switch mechanism by which low and high concentrations of adenosine can respectively 
inhibit and stimulate glutamate release (254). Another example is the antagonistic A2A:D2 
interaction whereby the stimulation of A2A receptors reduces the affinity of dopamine D2 
agonist binding (46, 255).  
 
    As described in Chapter 3, unsuccessful attempts to quantify the level of hP2Y11 
expression in clone 13 versus 6 were made using reverse transcription of mRNA followed 
by  PCR  experiments.  Since  mRNA  levels  do  not  necessarily  correlate  with  receptor 
density at the plasma membrane, more suitable techniques including ligand binding or 
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used to study the colocalization of P2Y1 and hP2Y11 in clones 6 and 13. Additionally, 
lipid raft markers can be employed to determine if the two receptors are pooled to lipid 
rafts, which would facilitate receptor-receptor interaction. It might also be interesting to 
quantify hP2Y11 densities in the intermediary clones between 6 and 13 to measure the 
lowest density of hP2Y11 required to generate biphasic responses.  
 
    Together  with  functional  assays,  biochemical  and  biophysical  methods  are 
commonly employed tools for investigating GPCR oligomerisation. The existence of a 
P2Y1:P2Y11 oligomer has already been demonstrated (242). Since the nature of the low 
affinity site observed in the biphasic responses in clone 13 is unknown, molecular assays 
may allow clear identification of the P2Y1:P2Y11 entity as a functional heteromer in this 
clone. For  instance,  co-immunoprecipitation  studies  could  be  implemented  using  the 
constructs from Chapter 3 although caution should be warranted in interpreting these 
results due to artifactual aggregation of receptors. Biophysical techniques such as FRET 
and  BiFC,  which  overcome  this  problem,  offer  a  better  platform  for  studying 
heteromerisation. BiFC has been previously used to identify GPCR oligomers such as 
A2A:D2 (93) and can be performed to monitor P2Y1 and hP2Y11 interactions in clone 13. 
It might also provide insight on the subcellular localisation of the oligomer, revealing 
whether it occurs in the plasma membrane or forms in the endoplasmic reticulum during 
receptor biogenesis. If P2Y1 and hP2Y11 are located in a receptor mosaic, they can homo- 
or hetero-oligomerize with other protomers such as endogenous P2Y2. Previous research 
has  shown  that  P2Y2  forms  constitutive  homo-oligomer  in  non-hematopoietic  and 
hematopoietic cells (256). It has also been reported to oligomerise with A1 receptors both 
in cotransfected HEK293T cells (257) and in situ on the surface of neurons in various 
brain  regions  (258),  generating  a  unique  complex  in  which  P2Y2  activation  inhibits 
agonist binding to the A1 receptor (257). Seeing as P2Y2 partakes in the calcium response 
to some of the agonists tested in this project (such as ATP and ATPγS) and that Hill 
coefficients suggest positive cooperativity in these responses, it might be interesting to 
investigate whether P2Y2 interacts or occurs in a receptor mosaic with any of the other 
purinoceptors  in  the  clones.  Possible  interactions  include:  P2Y1:P2Y1,  P2Y1:hP2Y11, 
hP2Y11:hP2Y11, P2Y1:P2Y2, P2Y2:hP2Y11, P2Y2:P2Y2, as previously identified (256), or 
even  P2Y1:P2Y2:hP2Y11.  Multicolour  BiFC,  which  allows  the  visualisation  of  two 
distinct GPCR-GPCR interactions simultaneously (259), can be employed to study these 
multiple associations using different pairs of tags, such as Cerulean C Terminal Fragment 
(-CC)/Cerulean  N  Terminal  Fragment  (-CN),  Cerulean  C  Terminal  Fragment  (-Chapter 6   Discussion 
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CC)/Venus N Terminal (-VN) Fragment or Venus C Terminal Fragment (-VC)/Venus N 
Terminal  Fragment  (-VN),  to  identify  different  dimers  in  parallel  (93,  260).  In 
conjunction with BiFC, which is irreversible nature, FRET or BRET assays can be used 
to study the formation and dissociation of the P2Y1:hP2Y11 oligomer (259), determine if 
agonist addition (for example, ADP or 2meSATP) increases or decreases oligomerisation, 
and assess the interaction affinities between purinoceptors in the receptor mosaic.  
 
    It does not suffice to demonstrate that P2Y1 and hP2Y11 oligomerise; it is also 
important to determine the sites at which this interaction occurs. The structural study of 
GPCRs has been traditionally hampered by the difficulty of crystallizing them. However, 
promising advances such as protein engineering, lipidic cubic phase-based crystallization 
and  microfocus  synchrotron  beamlines  are  producing  a  “GPCR  structural  revolution’ 
(261).  Consequently,  the  crystal  structure  of  P2Y1,  P2Y11  and  P2Y1:P2Y11  might  be 
resolved  in  the  near  future,  permitting  structural  investigation  of  the  conformational 
changes involved in oligomerisation using techniques such as NMR or Atomic Force 
Microscopy.  
 
    Alternatively, computational homology modelling, site-directed mutagenesis and 
BiFC can be combined to study this interaction. Computer simulations using methods 
such as coarse-grained modelling might shed light on the oligomer’s binding pocket and 
the  transmembrane  interfaces  implicated  in  dimerization.  Based  on  these  predictions, 
hP2Y11 residues that participate in heteromerisation or ligand binding can be modified 
using site-directed mutagenesis. New recombinant CHO-K1 cell lines expressing low and 
high levels of mutants can be developed and characterized to study the effect of mutations 
on the biphasic responses. Additional studies include development of BiFC-tagged hP2Y1 
and hP2Y11 mutants transfected into null cells to test the interaction interfaces identified 
for  both  receptors  using  computational  studies.  The  results  from  full-length  sequence 
experiments  can  be  verified  in  a  sub-study  where  the  individual  domains/helices  of 
interest in each receptor are mutated, tagged using complimentary fluorescent epitopes 
and  tested  to  refine  the  map  of  residues  involved  in  heteromerisation.  Finally,  the 
oligomer’s coupling to G-proteins can be studied with multicolour BiFC using different 
tags for Gαs, Gq/11, hP2Y1 and hP2Y11 to prevent interference and ensure correct binding 
of the components.   
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    An oligomer detected in a recombinant system is accepted if it exists in native 
tissue, implying that the P2Y1:P2Y11 heteromer is pharmacologically significant only if it 
occurs in tissue that endogenously expresses both receptors. It is thus important to study 
this oligomer in guinea pig taenia coli smooth muscle cells and eventually in human 
smooth muscle cells of the stomach. The relative densities of the two receptors in smooth 
muscle cells can be evaluated using ligand binding assays or fluorescence correlation 
spectroscopy to determine if receptor levels in native cells match those of clones 6, 13 or 
are specific to the tissue. Receptor densities can also be studied in different compartments 
of  the  plasma  membrane  to  check  if  microenvironments  of  varying  P2Y1  and  P2Y11 
densities containing different levels of oligomers versus monomers exist. Additionally, 
co-localisation studies can be performed to define the location of the receptors in the 
plasma membrane (lipid rafts, etc.) Furthermore, the oligomerisation and sub-localisation 
(endoplasmic reticulum, plasma membrane, etc.) of these two purinoceptors in native 
tissue  can  be  tested  using  biochemical  and  biophysical  studies  such  as 
coimmunoprecipitation and FRET or BRET. These experiments can be further extended 
to investigate the existence of a receptor mosaic mediating multiple interactions between 
purinoceptors in native tissue. Quantitative PCR (qPCR) and sequencing would first be 
performed to define the receptor subtypes present in the cells, followed by co-localisation 
studies to confirm that they are closely located. FRET or BRET can then be performed to 
test if the various receptors interact to form higher-order networks.  
 
    These biophysical studies investigating the presence of the signalling complex 
should be coupled to functional studies in native tissue to check if endogenous P2Y1 and 
P2Y11 exhibit the same ligand affinities as in clone 13. If biphasic responses to ADP and 
2meSATP are detected in the native tissue, it might be worthwhile to perform specifically 
tailored functional and organ bath studies to elucidate the real effect of the low affinity 
site  in  a  physiological  context  such  as  the  relaxation  of  gut  smooth  muscle.  These 
experiments would determine the relevance of the biphasic response to this phenomenon 
and consequently to a potential anti-obesity or ‘thin’ pill.  
 
    Additionally,  it  might  be  interesting  to  investigate  whether  P2Y1  and  P2Y11 
interact with M3 receptors in smooth muscle cells. M3 receptors cause contraction of these 
cells and counteract the fast and slow relaxations mediated by P2Y1 and P2Y11. The fine-
tuning  of  stomach  relaxation  and  contraction  could  involve  cross-talk  between  the 
purinoceptors and M3 receptors, a feature that might be relevant for anti-obesity studies. Chapter 6   Discussion 
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Consequently, co-localisation, FRET, BRET and functional experiments could be applied 
to  test  this  hypothesis  and  determine  if  M3  receptors  might  affect  P2Y1  and  hP2Y11 
interactions,  as  a  feedback  mechanism  employed  by  the  cells  to  control  purinoceptor 
activity for instance.  
 
 
    If the P2Y1:P2Y11 heteromer proves relevant to gut smooth muscle relaxation in 
the  native  context,  drug  screening  for  agonists  and  antagonists  should  follow  the 
pharmacological  and  biophysical  studies.  An  initial  selection  of  compounds  can  be 
achieved using supercomputer simulations of the oligomer, followed by functional assays 
to test the activity of the selected ligands in recombinant or native tissue. An interesting 
approach adopted recently is to design dual compounds that target the receptor partners in 
a heteromer (248). For instance, dual molecules composed of a xanthine and a dopamine 
analogue  connected  by  a  spacer  of  differing  lengths  are  being  developed  against 
adenosine-dopamine heteromers in the context of Parkinson’s disease (248, 262). These 
drug  design  endeavours  might  contribute  to  the  discovery  of  a  selective  and  potent 
P2Y1:P2Y11 antagonist, thus paving the way for the development of the anti-obesity drug. 
This compound could be delivered as a pill, an inhaler, transdermal adhesive patch or 
using advanced therapeutic systems such as inorganic or metal nanoparticles, micelles or 
carbon  nanotubes  (263).  Alternatively,  cutting-edge  technologies,  which  offer  new 
platforms for multi-dimensional tissue screening aimed at identifying drug targets and 
assessing  their  specificity  and  mode  of  action  (264),  could  prove  more  useful  than 
conventional cell-based assays in predicting targets (265). For instance, 3D tissue models 
of  SMCs  can  be  developed,  using  platforms  such  as  OCELLO  or  organ-on-chip 
technologies, for pre-clinical phenotypic screening of huge libraries of compounds and 
the selection of targets depending on their affinity and selectivity.  
 
    Finally, to exploit the entire potential of this study, the functional and physical 
characterization of P2Y1:P2Y11 oligomers should be extended to other tissues of the body. 
Since these two receptors are ubiquitous and involved in many diseases, qPCR can be 
used to determine tissues in which they are co-expressed. This could uncover new roles 
for the oligomer, revealing its possible contribution to other disorder and its relevance as 
a drug target against these conditions.  
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    In summary, the functional study of clones 6 and 13, which co-express P2Y1 and 
hP2Y11,  indicates  that  they  show  characteristics  distinct  from  those  of  the  individual 
receptors, as proven by using different ligands. It was hypothesized that these properties 
result from the oligomerisation of P2Y1 and transfected hP2Y11. To further investigate 
this finding, several techniques can be employed to test oligomerisation in recombinant 
and native tissue, identify the interaction interfaces and screen for novel agonists and 
antagonists of this dimer. These endeavours could contribute to the development of an 
anti-obesity drug as a safer chemical alternative to gastric banding. It could also reveal 
alternative disorder conditions to which the oligomer contributes, thus offering additional 
ground for pharmaceutical research.  
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Appendix 1 
 
List of Ligands  
 
1-  ATPγS 
Chemical Name: Adenosine-5'-(γ-thio)-triphosphate tetralithium salt 
 
 
2-  BzATP  
Chemical Name: 2'(3')-O-(4-Benzoylbenzoyl)adenosine-5'-triphosphate tri(triethylammonium) salt 
 
 
 
3-  2meSATP 
Chemical Name: 2-Methylthioadenosine-5'-triphosphate tetrasodium salt 
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4-  αβmeATP  
Chemical name: α,β-Methyleneadenosine 5′-triphosphate lithium salt 
 
 
5-  βγmeATP:  
Chemical name: β,γ-Methyleneadenosine 5′-triphosphate disodium salt 
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6-  UTP: 
Chemical name: 2-Thiouridine 5'-triphosphate tetrasodium salt
 
 
7-  MRS 2179 :  
Chemical Name: 2'-Deoxy-N6-methyladenosine 3',5'-bisphosphate tetrasodium salt 
 
 
 
8- NF 340: 
Chemical Name: 4,4'-(Carbonylbis(imino-3,1-(4-methyl-phenylene)carbonylimino))bis(naphthalene-2,6-
disulfonic acid) tetrasodium salt 
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9- Reactive Red :  
Molecular Formula: C19H10Cl2N6Na2O7S2 
 
 
 
The structures of ADP and ATP are shown in Figure 1- in the Chapter I (introduction).  
 